









































































































































VEGFR‐1. However,  the  biological  significance  of  VEGF  interaction with  VEGFR‐1  remains 
elusive. One of our previous studies in dogs unveiled an unexpected cardioprotective activity of 
VEGF‐A, which was already evident at 48 hours after the induction of a myocardial infarction 
and was even more marked at 4 weeks. Multiple  recent evidences  suggested  that VEGF‐B, a 
VEGFR‐1  exclusive  ligand,  could  be  selectively  active  in  the  myocardium.  However  the 
available data did not define clearly  the cardiac benefits of VEGF‐B. Therefore,  in  the present 
study we wanted to investigate and compare the cardioprotective role of both VEGF‐A (and in 
particular  its 165 aminoacid  isoform) and VEGF‐B  (167 aminoacid  isoform)  in a  rat model of 
myocardial  infarction  through  intracardiac  injection  of  the  respective  genes.  For  the  efficient 
and  prolonged  expression  of  these  factors, we  exploited  viral  vectors  based  on  the Adeno‐
Associated Virus  (AAV),  as  an  efficient  tool  for  in  vivo  gene  transfer.  By  analyzing  cardiac 
function by echocardiography, we observed that the prolonged expression of both VEGF factors 
induced a marked  improvement  in cardiac contractility, preserving viable cardiac  tissue, and 
preventing left ventricular remodeling over time. In addition, we performed histopatho‐ logical 
studies  on  a  subset  of  representative  samples.  Consistent with  the  functional  outcome, we 
observed a more potent cardioprotection using the VEGFR‐1 selective ligand, VEGF‐B, despite 
its  inability  to  induce  angiogenesis. We  then  tried  to  dissect  the molecular mechanisms  by 
which VEGF‐B might act on cardiomyocytes both in vitro and in vivo.  We found that the action 
of VEGF‐B was mainly mediated by the upregulation of VEGFR‐1 and that stimulation of this 
receptor  exerted positive  inotropic  and  anti‐apoptotic  effects on  cardiomyocytes.  In  addition, 
VEGF‐B  elicited  a gene  expression pattern  reminiscent  to  the  one  observed  in  compensatory 
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heart  hypertrophy,  both  in  cultured  cardiomyocytes  and  in  infarcted  hearts.  We  further 
expanded  our  investigation  on  the  cardio  protection  conferred  by  VEGF‐B167  in  a  pacing‐
induced hear failure model  in canines. Interestingly,  the findings obtained  in  this model were 
similar and totally in keeping with the observations done in the myocardial ischemic model in 
rats,  again  showing  that  VEGF‐B167  exerted  cardio  protective  effects  in  the  absence  of 


































million people.  In  the United States, nearly  2400  individuals die of CVD  every day, with  an 
average of 1 death every 37 seconds. It is predicted that, by 2030, almost 23.6 million people will 
die  from  CVDs,  which  will  then  remain  as  the  single  leading  causes  of  death 
(www.who.int/mediacentre/factsheets/fs317/en/index.html). 
The  incidence  rate  of  CVDs  is  higher  in Western  countries  than  in  developing  countries, 
irrespective  of  industrialization,  rapid  progress  in  medical  technologies,  advancements  in 
research  and  development  of  early  prognostic  methods  or  treatments.  Current  estimates 
indicate  that CVDs  incidence  is about 50%  in developed countries and about 28%  in  low and 
middle income countries (Mathers et al., 2006). However, in some developing countries, such as 
India,  the  burden  of  CVD  is  rising.  The  estimated  prevalence  of  coronary  heart  disease  is 
around  3–4%  in  rural  areas  and  8–10%  in  urban  areas  among  adults  older  than  20  years, 









essentially  consisting  of  lipoproteins  deposition,  which  bind  to  the  extracellular  matrix 
components, such as proteoglycans. At a later stage, chemical modifications such as lipoptotein 
oxidation  and  non  enzymatic  glycation  occur.  In  lipoprotein  oxidation,  the  lipoproteins 
undergo oxidative modifications and forms hydroperoxides, lysophospholipids, oxysterols and 
chlorotyrosyl moieties, whereas  in  non  enzymatic  glycation, which  is  especially  relevant    in 
diabetic  patients with  sustained  hyperglycemia,  apolipoproteins  and  other  structural  arterial 
proteins  undergo  glycation  and  lose  their  natural  protective  function.  These  events  further 
accelerate  atherogenesis.    After  accumulation  of  extracellular  lipids,  leukocytes  such  as 
lymphocytes  and  monocytes  are  recruited  within  fatty  streaks.  This  is  favored  by  the 
constituents  of  oxidatively  modified  LDL  molecules,  as  well  as  by  a  few  cytokines,  like 
intereukin‐1(IL‐1) and tumor necrosis factor  (TNF‐), which stimulate expression of adhesion 
molecules  and  receptors  on  the  surface  of  endothelial  cells.  Lymphocytes  and  monocytes 
penetrate  the  endothelial  layer  and  take  up  residence  in  the  intima.  There,  monocytes 
differentiate into macrophages and transform into lipid‐laiden foam cells through the uptake of 
lipoprotein particles by receptor‐mediated endocytosis. Some of the foam cells may die as result 
of  apoptosis  and  result  in  the  formation  of  a  lipid  rich  center,  called  the  necrotic  core. 
Mononuclear phagocytes release a number of growth  factors, such as platelet derived growth 
factor  (PDGF),  fibroblast  growth  factor  (FGF)  and  other  cytokines,  which  stimulate  the 
proliferation of smooth muscle cells migrated from tunica media into the intima. This event in 
turn stimulates the additional deposition of extracellular matrix. The lesions with accumulation 
of  macrophage‐derived  foam  cells  are  transformed  into  fibro‐fatty  lesions  with  the 
accumulation of fibrous tissue and smooth muscle cells. These plaques also accumulate calcium, 
bound  to  bone‐associated  proteins,  such  as  osteocalcin,  osteopontin  and  bone morphogenic 
proteins. The process of atherosclerosis has been recently reviewed in detail by many reviewers 
(Insull 2009,  Falk 2006, Virmani et al., 2002, Glass et al., 2001, Libby 2001, Lusis 2000).  
Several  risk  factors  contribute  to  plaque  formation.  These  are  classified  into  two  categories: 








strategies  interfering  with  the  molecular  mechanisms  of  disease  onset  and  progression  is 
absolutely required. In this context, the appreciation of the potential value of gene therapy has 
been  steadily growing over  the  last  few years. The utilization of nucleic acids as  therapeutic 
tools  for CVD  is  currently envisaged  in at  least  three main areas:  i)  treatment of  cardiac and 





The  term  ischemia was  first used by  the German pathologist Rudolf Virchow.  It derives  from 




with  chronic  coronary  artery  disease  (CAD),  with  stable  angina  pectoris.  These  patients 
experience discomfort or pain in the chest or left arm, induced by physical activity or in stress, 
which  can  be  relieved  by  rest  and/or  sublingual  nitroglycerin.  A  second  group  consists  of 
patients which present with acute coronary syndromes (ACSs), divided into patients with acute 
myocardial  infarction  (MI)  with  ST‐segment  elevation  (STEMI)  at  their  presenting 
electrocardiogram  and  patients  with  unstable  angina  or  non‐ST‐segment  elevation  MI 
(UA/NSTEMI), accompanied by elevated levels of serum enzymes troponin T or I, and creatine 




Myocardial  ischemia  is diagnosed by different  tests,  including: 1) electrocardiography  (ECG), 
which  records  the  electrical  conduction  activity  of  the  heart;  2)  exercise  tolerance  test,  to 
evaluate  the  functional reserve of  the heart; 3) echocardiography,  to evaluate  the condition of 
valves and chambers of  the heart, and measure cardiac  function; 4) contrast angiography  (CT 
angiography/MR angiography), to assess the presence of atherosclerotic plaques in the coronary 
arteries; 5) nuclear ventriculography, to analyse the size of the heart chambers and their blood 




prevent complications. The  line of  treatment consists of  the use of drugs such as anti‐platelet 
agents  (aspirin,  dipiridamole  or  clopidrogrel)  to  prevent  thrombus  formation,  anti‐anginal 
drugs (amlodipine or bepridil) to minimise the rate of occurrence as well as severity of angina 
attacks,  inhibitors of angiotensinogen converting enzyme  (ACE  inhibitors, such as benazepril, 
captopril or ramipril) to lower blood pressure and protect the heart, beta‐blockers (metoprolol 
or  propranolol)  to  lower  heart  rate,  blood  pressure,  and  oxygen  use  by  the  heart,  calcium 
channel  antagonists  (amlodipine,  diltiazem  or  verapamil)  to  relax  arteries,  lowering  blood 
pressure  and  reducing  strain  on  the  heart,  diuretics  to  lower  blood  pressure  and  treat 















the  femoral artery and  the balloon  is positioned, under angiographic guidance, at  the  level of 
the atherosclerotic plaque  in  the coronary artery. The balloon  is  then  inflated  to mechanically 
destroy  the  plaque  and  restore  vessel  perviousness.  Concomitant  with  angioplasty,  an 
endovascular tubular prosthesis (stent) is usually positioned in correspondence with the artery 




alternative  to  CABG  in  the  treatment  of  angina;  as  already  reported  above,  CABG  is  only 
superior to PCI in a selected group of patients with high risk lesions. 
In certain conditions, rupture of the atherosclerotic plaque causes acute MI through the sudden 




pharmacological  treatment.  The  former  consists  in  primary  PCI,  that  is  balloon  angioplasty 
performed  in  emergency  conditions, with  or without  stent  placement.  Primary  PCI  usually 
restores blood  flow  in more  than  90% of patients.  If  this procedure  is delayed more  than  90 
minutes from the initial medical contact, pharmacological thrombolysis can be attempted. This 
is achieved by using  thrombolytic agents containing plasminogen activators  (streptokinase or 
tissue  plasminogen  activator  ‐  tPA).  These  are  enzymes  that  transform  plasminogen  into 










result  from  atherosclerosis,  embolism  or  thrombus  formation,  or  any  other  inflammatory 
process lead to stenosis. Patients may present with acute or chronic ischemia.  
Similar  to  CAD,  there  are  several  predisposing  factors  to  PAD,  such  as  smoking,  obesity, 








(Hirsch et al., 2001, Crigui et al., 1985): patients, while walking, are  forced  to stop  repeatedly 
due  to  leg pain,  typically  in  the  calves. Pain  is due  to  the accumulation of  lactic acid, which 
stimulates peripheral pain receptors  ‐ consequent  to muscle activity  in anaerobiosis, since  the 











The  mechanism  of  blood  vessel  formation  involves  three  processes:  vasculogenesis, 
angiogenesis and arteriogenesis (Storkebaum et al., 2004). The term vasculogenesis traditionally 
refers to the de novo synthesis of blood vessels during embryonic development. In this process, 
a primitive  capillary network  is  formed  from  angiogenic progenitor  cells,  called  angioblasts, 
which differentiate into endothelial cells and coalesce to form an initial vascular plexus (Risau 
et al., 1995, Carmeliet 2003). Antigenic markers common to angioblasts and hematopoietic stem 
cells  have  been  identified,  consistent  with  the  possibility  that  a  common  precursor 
(hemangioblast) might exist and be able to originate both hematopoietic and endothelial cells. 




times,  the  newly  formed  capillaries  progressively  mature  by  the  addition  of  mural  cells 
(pericytes  and  smooth muscle  cells)  allowing  proper  functionality,  and  a  vascular  network 
formed by larger vessels (arterioles and venules) is eventually formed. 
Finally,  in  addition  to  vasculogenesis  and  angiogenesis,  a  third  process  of  blood  vessel 
formation exists, known as arteriogenesis. This process consists  in  the  remodeling of existing 
arteries  to  increase  their  luminal  diameter  in  response  to  physiological  stimuli  of 
vasoconstriction  or  vasodilatation.  A  classic  example  of  arteriogenesis  in  the  adult  is  the 
formation  of  a  collateral  network,  visible  upon  angiography,  in  response  to  the  progressive 
occlusion of an arterial vessel by an atherosclerotic plaque. In this process, vessels are generated 
to become medium and large arteries with properly developed tunica media (to control patency 
of vascular  lumen),  in order  to  functionally meet  the demand of  tissue perfusion  (Heli et al., 
2006).  
If  we  observe  the  anatomy  of  blood  vessels,  capillaries  are  made  up  of  a  single  layer  of 
endothelial  cells  with  supporting  vascular  pericytes,  whereas  arteries  and  veins  consist  of 
multiple  layers  (from  inside  to outside):  tunica  intima,  the  inner most  layer  surrounding  the 
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lumen  composed  of  endothelial  cells,  pericytes  and  basement membrane;  tunica media,  the 
middle  layer  composed  of  smooth muscle  cells  and  extracellular matrix;    tunica  adventitia, 
which  is particular prominent  in  large vessels, consisting of fibroblasts and their extracellular‐ 
matrix (Figure 1.1). 
 
Figure  1.1  During  vasculogenesis,  endothelial  progenitor  cells  develop  into  primitive 
vascular network, which  expands  further with  the  recruitment  of SMC  and pericytes  and 
develops  into  fully  functional  vascular  network.  Lymphatic  network  emerges  from 
transdifferentiation of veins (Carmeliet 2005). 
 
In physiological conditions,  the major  stimulus  for  the process of angiogenesis  is hypoxia.  In 
hypoxic  conditions,  cells  in  the  tissue  start  sensing  the  reduced O2  concentration  and  initiate 
vascular responses to increase expression of genes encoding angiogenic growth factors. In this 
response  pathway,  the  central  element  is HIF‐1,  a  heterodimeric  transcription  factor  able  to 
activate  expression  of  a  series  of  genes.  Among  the  induced  genes  are  several  angiogenic 
cytokines and their receptors. Among these, members of the vascular endothelial growth factor 
(VEGF) family and their receptors (VEGFR) are the most powerful, initial responsive elements 












able  to  induce vascular permeability preferentially  through VEGFR‐1  signaling  (Takahashi  et 
al., 2004). 
The  function of  the different VEGF  family members  are mainly mediated by  the  cell  surface 
tyrosine‐kinase  receptors VEGFR‐1  (flt‐1), VEGFR‐2  (KDR/flk‐1)  and VEGFR‐3  (flt‐4), whose 
relative  affinity  and  distribution mediate  the  biological  effect  (Carmeliet  et  al.,  1999). More 
specifically, VEGF‐A binds VEGFR‐1 and ‐2; VEGF‐B and PlGF selectively bind VEGFR‐1, while 





























7  introns,  (Tischer  et  al.,  1991), with  a  coding  region  of  about  14  kb. The VEGF  pre‐mRNA 
undergoes alternative splicing to produce at least eight different protein isoforms, composed of 
121, 165, 189 (Tischer et al., 1991), 145 (Poltorak et al., 1997), 162 (Lange et al., 2003), 165b (Bates 




VEGF165   only  in  the carboxy‐terminal six amino acids  (resulting  in change of  the amino acid 
sequence  form  CDKPRR  to  SLTRKD)  (Harper  and  Bates,  2008).    Surprisingly,  this  isoform   
seems to bind VEGFR‐2 with the same affinity as VEGF165, but it lacks any angiogenic property, 















VEGF‐A  binds with  high  affinity  to  two  tyrosine  kinase  receptors:  Flt‐1(fms‐related  tyrosine 
kinase  1)  or VEGFR‐1  and  Flk‐1(Fetal  liver  kinase  1)/KDR(kinase  insert domain  receptor)  or 
VEGFR‐2, as well as to a non tyrosine kinase co‐receptor: neuropilin‐1 (NP‐1) (Ferrara, 2004).    
All  the  isoforms (with  the exception of VEGF121, which  is acidic and freely soluble) are highly 
basic, poorly diffusible  in nature.    In particular,  the  longest  isoforms,  once  released  into  the 
extracellular environment, bind to heparin sulfate proteoglycans (HSPGs) on the cell membrane 
and to the extracellular matrix at various degrees, with the only exception of VEGF121, as it lacks 
the  heparin  binding  domain. VEGF‐A165, which  is  the  predominant  isoform  in  vivo,  has  an 
intermediate capacity to bind HSPGs (Ferrara, 2004).    




Shibuya,   2005).    In   particular,   hypoxia, via   Hypoxia    Inducible   Factor   1    (HIF‐1)    is    the  
major  positive  regulator  of VEGF  expression.  Hypoxic  conditions  induce  accumulation  of  
the   highly  instable      subunit     of     HIF‐1,      leading      to      the      formation     of     an     active 
transcriptional  activator  that  binds  to  the  Hypoxia  Responsive  Elements (HRE)  in  the  5ʹ  
flanking   region   of    the   VEGF   promoter   (Pages   and Pouyssegur, 2005).   Hypoxia  is a   key  
factor    in  stabilizing   VEGF   mRNA by   binding   of    regulatory   proteins  to  3’ untranslated 
region  (UTR),   and  in  translating VEGF mRNA     via  Internal Ribosomal Entry Site sequences 
present  in the 5ʼ UTR (Stein et al.,1998). VEGF  is expressed  in most of the cell types  including 
vascular  smooth  muscle  cells,  chondrocytes,  epithelial  cells,  neutrophils,  macrophages, 
monocytes, mesenchymal cells, pituitary and pancreatic endocrine cells, hepatocytes and even 
many tumor cells types. The  VEGF165   isoform  is  the  one  preferentially  expressed by most 
tissues  (followed   by VEGF121   and   VEGF189),  it  is secreted as a homo‐dimer   with   moderate  
affinity  for  heparin and  is  a powerful  inducer  of  endothelial cell  migration,  proliferation,  





and  angiogenesis.  The  non  redundant  role  of  the  different  VEGF  isoforms  in  vessel 
development  is highlighted by    the   observation    that VEGF164     mice  (which only express  the 
VEGF164 isoform) are  normal  and  healthy,  while  VEGF120   puppies (which only express the 
VEGF121  isoform)      exhibit  serious     vascular      remodelling     defects,      including     defective   
branching (Stalmans   et   al.,   2002). 
Even    the quantity of VEGF‐A  is critical  in order  to obtain normal vessel development, since  
VEGF‐A  is  haploinsufficient  (Carmeliet  et  al.,  1996;  Ferrara  et  al., 1996).  Recent  data  have 
pointed  out  the  importance  of  VEGF  also  in  vessel maintenance: VEGF produced by ECs is 
crucial  for vascular homeostasis,  through    a    cell‐autonomous     VEGF    signaling mechanism  
(Lee   et   al.,   2007);     this observation confirms  the fundamental and complex role of VEGF  in 
vessel biology. 
VEGF is considered as survival factor for endothelial cells, based on the experiments conducted 
both  in  vitro  and  in  vivo  (Gerber  et  al.,  1998,  Alon  et  al.,  1995).  In  vitro,  VEGF  prevents 
endothelial  cell  apoptosis  in  serum  starved  conditions  by  binding  selectively  to  its  Flk‐1 
receptor but not  to  its Flt‐1 receptor,  followed by  the activation of  the phosphatidylinositol 3‐
kinase  (PI3 kinase)/Akt pathway  (Gerber et al., 1998). The major  indications of  the capacity of 
VEGF to act as a survival factor for endothelial cell in vivo come from experiments performed 
by  exposing  the  retinal  vasculature  of  newborn mice  to  hyperoxia  in  order  to  reduce VEGF 




molecule.  For  instance,  VEGF  has  direct  action  on  a  variety  of  neural  cells.  Its  neuronal 
protective function was observed in mice with reduced VEGF levels within the nervous system, 
as these mice developed motor neuron degeneration. Further studies revealed its important role 
in preventing neuronal death after acute  spinal  cord or  cerebral  ischemia  (Storkebaum et al., 
2004).  In  addition,  VEGF  also  displayed  a  potent  activity  in    promoting    survival    and  
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regeneration   of   skeletal   muscle cells  (Arsic et al., 2004; Germani et al., 2003) and   seems  to 
have a role in liver homeostasis as well (LeCouter et al., 2003). 
As  far  as  disease  conditions  are  concerned,  up‐regulation  of VEGF‐A was  implicated  in  the 
pathogenesis  of  tumors,  age  related‐macular  degeneration,  proliferative  retinopathy, 
rheumatoid arthritis, psoriasis, polycystic ovary syndrome, ascites and brain edema. In contrast, 
lower  levels  of  VEGF‐A  associated  with  amyotrophic  lateral  sclerosis  and  pre‐eclampsia 
(Ferrara 2004).  
Finally,  in our  laboratory we observed an effect of VEGF‐A165 on bone marrow  (BM) derived 
CD11b+  cells,  as  these  cells  expressed  VEGF  receptors.  In    particular    we    observed    the 






alternatively  spliced  isoforms,  having  186  and  167  amino  acids,  have  been  identified.  These 
isoforms differ at their carboxy‐terminal ends, as a consequence of a shift  in the open reading 
frame (ORF). Both have a high degree of homology at  the amino  terminus with VEGF‐A, and 
the shorter  form contains all  the 16 cysteine residues present  in VEGF‐A165. Since  the VEGF‐B 
gene also contains a signal peptide, it is considered a secreted factor. The gene presents a ~5 kb 





VEGF‐B167.  It differs  from VEGF‐B186  in  lacking exon 6 and  its C‐terminus  contains a  strongly 
basic cystein rich heparin binding domain, similar to VEGF‐A and other related growth factors, 
which  is  absent  in VEGF‐B186. VEGF‐B186  is  indeed  less  basic, more  hydrophobic  and  highly 
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soluble  in nature  (Olofsson  et al. 1996a).   However, Northern blot analysis of human  tissues 
showed  that  both  isoforms  are  similarly  abundant  in  heart,  skeletal muscle,  pancreas,  and 
prostate (Olofsson et al. 1996b).  






different  reading  frame  in  VEGF‐B167  and  VEGF‐B155  respectively  compared  to  longest 
isoform  VEGF‐B186.  The  STOP  codon  of  VEGF‐B167  and  VEGF‐B155  are  located  41  bases 
downstream of the STOP codon of VEGF‐B186  
 
The  different  VEGF‐B  isoforms  are  secreted  as  disulfide‐linked  homodimers,  but  can  form 
heterodimers  with  other  VEGF  members  and  still  act  as  endothelial  cell  growth  factors 
(Olofsson et al., 1996b). 
VEGF‐B has a wide range of tissue distribution. It is highly expressed in heart, brain, testis and 
kidney cells    (Lagercrantz et al., 1996) and  less  in developing muscle, bone, pancreas, adrenal 
gland, and in the smooth muscle cell layer of several larger vessels (Olofsson 1996a).   
From  in vitro experiments,  it was  found  that VEGF‐B186 has a peculiar  regulatory  function  in 





was  studied  in  two  different mice models  of  arthritis:  antigen  induced  arthritis  (AIA)  and 
collagen  induced  arthritis  (CIA).    In  both  conditions,  VEGF‐B‐/‐  mice  displayed  significant 
reduction in synovial inflammation with increase in vessel density and swollen knee joints after 
7  days  of  intra‐articular  injection  of  the  inflammatory  stimulus  (methylated  bovine  serum 
albumin (mBSA) in AIA and chick type II collagen (CII) in CIA) (Mould et al., 2003).   
In addition to this phenotype, VEGF‐B‐/‐ mice displayed vascular dysfunction, reduction in heart 
size,  thickened  ventricular  wall  and  impairment  in  recovery  of  energy  metabolism  after 
coronary occlusion even  though  they are healthy and  fertile,  thus  indicating a specific role of 
VEGF‐B  in development or function of  the coronary vasculature (Bellomo et al., 2000).   When 
the  heart  function  was  analyzed  by  ECG,  VEGF‐B  knockout  mice  had  atrial  conduction 
abnormalities with prolonged PQ  interval. From  these data,  it was concluded  that VEGF‐B  is 




myocardium whereas  it has a minor  role  in vessel growth  in  skin,  retina,  lung and  ischemic 
limb  (Li  et  al.,  2008). Mice  expressing  cardiac  specific  VEGF‐B167  transgene  showed  cardiac 
hypertrophy  with  increase  in  size  of  blood  vessels  and  have  lower  heart  rate  and  blood 
pressure.  However,  this  cardiac  hypertrophy  had  no  affect  on  normal  cardiac  function.  
Interestingly, these mice had alteration in lipid metabolism, indicating a role of VEGF‐B on this 
function (Karpanen et al., 2008).  
Louzier  et  al.  (2003)  assessed  the  effects  of  VEGF‐B  in  chronic  hypoxic  pulmonary   
hypertension  by  investigating  VEGF‐B‐/‐  mice  and  over‐expressing  both  VEGF‐B  isoforms 
through adenoviral‐mediated delivery of  the genes  to  the rat  lungs. No significant differences 
were  found  in  the  pulmonary  hemodynamics,  right  ventricular  hypertrophy,  distal  vessel 




increase  in  eNOS  expression  and vascular permeability  in  the  lungs  after  5 days of VEGF‐A 
overexpression.  
Adenoviral mediated  intra‐myocardial  gene  transfer  of  VEGF‐B186  isoform  was  reported  to 
induce  angiogenesis  and  arteriogenesis  in  ischemic myocardium  of  pigs  and  rabbits.  These 
effects were  reported  to  be mediated  through G‐protein  signaling  pathway  via  activation  of 
neuropilin receptor‐1. Cardiomyocytes were protected from apoptosis and had metabolic effects 
by  inducing expression of  fatty acid  transport protein‐4 and  lipid and glycogen accumulation 
(Lahteenvuo et al., 2009). The results of  these experiments, however, were potentially blurred 
by  the pro‐inflammatory  response  to  first‐generation adenoviral vectors, which were used  to 
delivery the VEGF‐B186 gene to the myocardium.  
Again related to lipid metabolism, VEGF‐B was reported to have a role in endothelial targeting 
of  lipids  to peripheral  tissues. VEGF‐B  is highly expressed  in heart and brown adipose  tissue; 
both  these  tissues  are  enriched with mitochondria  to metabolize  fatty  acids,  a major  energy 
source (Hagberg et al., 2010). In VEGF‐B‐/‐ mice, lipids are accumulated in these tissues instead 
of  being  transported  into  white  adipose  tissue,  and  the  tissue  lipid  uptake  appeared 
compromised.  By  comparing  the  expression  pattern  of  VEGF‐B  with  the  distribution  of 
mitochondrial  proteins,  there  was  strong  correlation,  different  from  VEGF‐A  and  PIGF. 
However,  a  deeper  analysis  of  this  VEGF‐B‐/‐  phenotype  indicated  that  VEGF‐B  does  not 
regulate or  influence mitochondrial gene expression, but  its co‐expression with mitochondrial 
proteins produced a novel regulatory mechanism with tight coordination between endothelial 
uptake  and  mitochondrial  lipid  utilization.  In  particular,  these  resulted  supported  the 
conclusion that VEGF‐B affects the uptake of long chain fatty acids (LCFAs) by endothelial cells 
from  the  circulation  and  their  further  transport  to  the  surrounding  tissues  for mitochondrial 
processing;  this regulation would be mediated by  interaction with VEGFR‐1 and neuropilin‐1 
(Hagberg et al., 2010).  




ALS  (amyotrophic  lateral sclerosis).  It also protected cultured primary motor neurons against 
degeneration  and  the  magnitude  of  protection  was  remarkably  higher  when  studied 
comparatively with VEGF‐A  and  other  classical  neurotrophic  factors,  such  as  brain  derived 
neurotrophic  factor  (BDNF), and    ciliary neurotrophic  factor  (CNTF)  (Poesen   et al., 2008).  In 
addition, VEGF‐B regulates neurogenesis in the adult brain in both in vitro (Sun et al., 2004) and 
in vivo  (Sun et al., 2006). Finally, VEGF‐B  isoforms are abundantly expressed  in all grades of 
human astrocytomas, even more than VEGF165 and VEGF121 ; of notice, in cultured glioblastomas 
cells,  the  levels  of  expression  of  VEGF‐B  appear  insensitive  to  conditions  like  hypoxia  and 
glucocorticoid  treatment (in contrast, dexamethasone  is known  to reduce VEGF‐A expression) 
(Gollmer et al., 2000). 
Li  et  al.  (2008b)  observed  that  VEGF‐B  is  a  potent  apoptosis  inhibitor  by  suppressing  the 
expression  of  the  BH3  (Bcl‐2 homology domain  3)‐only  proteins  (Bmf,  Hrk,  Bad,  Bid,  Bim) 
and  other  apoptotic  related  genes  (TNF‐α,  Trp53inp1,  Casp8,  Bak,  Bax),  through  the 
activation of VEGFR‐1, both  in  the brain and  in  the retina, without  inducing angiogenesis.  Its 
antiapoptotic  activity  was  tested  in  two  conditions  such  as  axotomy‐induced  neuronal 





(VEGFR):    VEGFR‐1    (Fms‐related    tyrosine    kinase;  Flt1), VEGFR‐2  (Kinase  insert Domain 
Receptor;KDR or Fetal  liver kinase; Flk1)   and   VEGFR‐3      (Flt4),   expressed   by   several   cell  










Figure  1.5  Intracellular  domains  of  dimerized  and  activated  VEGFR‐1  is  shown  with 
tyrosine‐phosphorylation sites, which are  indicated by numbers. Circled R  indicates use of 
the  phosphorylation  site.  Dark  blue  square  indicates  the  position  of  tyrosine  residue. 
Binding  of  signaling  molecule;  PLCγ,  phospholipase  C‐γ  (dark  blue  oval)  to  certain 
phosphorylation  site  (boxed  number),  initiates  the  signaling  cascade.  Final  biological 





1992, Olofsson  et  al.,  1998,  Park  et  al.,  1994,  Takahashi  et  al.,  2004). Northern  blot  analysis 
showed that it is highly expressed in placenta and, at lower levels, in liver, muscle, kidney and 
choriocarcinoma cells. In rats, it is abundant in tissues and is expressed highly in lungs (Shibuya 









different  and multifaceted. VEGFR‐1  has  a  10‐fold  higher  affinity  for VEGF‐A  compared  to 
VEGFR‐2 (Waltenberger et al., 1994), however its activator function on endothelial cells is very 
limited or absent. For  this  reason,  it was  suggested  that  the  receptor might act as a negative 
regulator of angiogenesis by acting as a decoy receptor, subtracting VEGF‐A  from binding  to 
VEGFR‐2.  This  function  was  supported  by  the  early  embryonic  phenotype  of  VEGFR‐1 
knockout  mice.  These  mice  displayed  abnormal  vascular  channels  and  died  in  utero  at 
embryonic day 9.5,  indicating  that VEGFR‐1  is essential for  the organization of  the embryonic 
vasculature, normal endothelial cell‐cell or cell‐matrix  interactions, but not for endothelial cell 
differentiation  (Fong  et al., 1995).  In  contrast, VEGFR‐2 null mutant mice  exhibited  impaired 
endothelial and hematopoietic cell development. Knocking out  the  tyrosine kinase domain of 
VEGFR‐1  in mice had no affect on vascular development,  further  indicating  that Flt‐1 differs 
from  Flk‐1  in  showing  higher  binding  affinity  to  VEGF,  but  having  lower  kinase  activity 
(Hiratsuka et al., 1998). Therefore, it has been assumed that VEGFR‐1 acts  as  a  VEGF‐A  trap, 
preventing  excessive  VEGFR‐2  activation  during  embryonic  development (Shibuya, 2001). 
A  physiological  role  of  this  endogenous  VEGF‐A  trap was  shown  to  be  be  physiologically 
present  in adult  life: a   soluble   VEGFR‐1VEGFR‐1,   known   as   sFlt1   and expressed   also   by  
human    placenta    (Shibuya    et    al.,    1990),    is    essential    in  order    to    preserve    corneal  
avascularity  (Ambati  et  al.,  2006;  Ambati  et  al., 2007).  
Beside  interacting  with  VEGFR‐2,  thus  either  synergising  or  inhibiting  VEGF‐A  activity, 
VEGFR‐1 can also interact with NP‐1. This latter event plays an active role in the migration of 








Despite  its  ability  to  bind  VEGF‐A  with  more  than  10‐fold  higher  affinity  than  VEGFR‐2, 
VEGFR‐1 only undergoes weak   phosphorylation,   even    if   all kinase   motifs   are   conserved  
(Waltenberger  et  al.,  1994).  Relevant  to  this issue,  VEGFR‐1  and  VEGFR‐2  share  a  43%  of  
overall   homology,    lower    in  the   extracellular   domain    (33%)   and   higher    in    the   kinase  
domains (70%). Nevertheless, the mechanism responsible for VEGFR‐1 kinase‐impaired activity 
is still debated. Several VEGFR‐1 tyrosine residues were identified as potentially phosphoryla‐





hepatic  stellate  cells  in  vitro.  In  another  report,  it was  observed  that  activation  of VEGFR‐1 
through VEGF‐B has strong anti apoptotic action in rescuing neurons in the retina and brain of 












cell  types,  such as various  types of  stem  cells  (Rafii  et al., 2003), CD34/AC133‐positive bone‐




the main  receptor  for VEGF‐A,  it plays a major  role  in both angiogenesis and vasculogenesis 
(Millauer et al., 1993).  
Extensive experimental evidence showed that VEGFR‐2 signaling is required for cardio vascular 
development  (Shalaby  et  al.,  1995)  and  it  plays  a major  role  in  neovasculari‐  zation  in  both 
physiological  and  pathological  conditions.  During  development,  VEGFR‐2  expression  is 
detectable  from E7.5  in mesodermal cells, which  then migrate and differentiate  into primitive 
ECs  (Shalaby  et  al.,  1995). During  adult  life,  VEGFR‐2  is  expressed mostly  in  vascular  and 
lymphatic  ECs,  even  if  lower  levels  of  VEGFR‐2  are  detected  in  haematopoietic  stem  cells, 
neurons,  osteoblasts  as  well  as  megakaryocites  (Matsumoto  and  Claesson‐Welsh,  2001). 
Yamashita et al. (2000) observed that FLK positive cells derived from embryonic stem cells can 
act  as vascular progenitors;  these  cells  can differentiate  into  endothelial  and mural  cells  and 
form mature vessels in three‐dimensional cultures and in chick embryos  
In several organs,  the activities of  this receptor extend beyond angiogenesis. For  instance,  the 




al.  (2008)  defined  a  role  for  VEGF‐A  mediated  activation  of  VEGFR‐2  as  an  inhibitor  of 
neovascularization, on the basis of its capacity to disrupt vascular smooth muscle cell function. 
VEGF‐A can indeed suppress the assembly of a receptor complex consisting of platelet derived 
growth  factor  receptor‐B  (PDGFRB)  and  VEGFR‐2,  thus  decreasing  pericyte  coverage, 
preventing  vessel  maturation  and  promoting  endothelial  cell  proliferation.  Another  report 
showed that a secreted form of VEGFR‐2 (sVEGFR‐2) can inhibit developmental and reparative 
lymphangiogenesis  induced  by  VEGF‐C.  Tissue‐specific  loss  of  sVEGFR‐2  in  mice  at  birth 
induced  spontaneous  lymphatic  invasion  in  a developed mouse model of  alymphatic  cornea 
and  hyperplasia  of  skin  lymphatics  without  affecting  blood  vasculature.  In  contrast, 
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administration  of  sVEGFR‐2,  inhibited  the  process  of  lymphangiogenesis  but  not 
hemangiogenesis  when  tested  in  different  models  such  as  mouse  model  of  corneal 




VEGFR‐3/Flt4  constitutes  the  receptor  for  the  VEGF‐C  and  VEGF‐D  family  members.  The 
observation  that,  in  adults, VEGFR‐3  expression  is  restricted  to  the  lymphatic  endothelium, 
together with  the  availability of genetic models,  essentially  linked  this  receptor  to  lymphatic 
development  and maintenance  (Kaipainen  et  al.,  1995,  Veikkola  et  al.,  2001).  In  particular, 
VEGFR‐3  signaling is required for  lymphatic  EC  sprouting,  as  well  as for lymphatic  vessel  
maintenance through  the  inhibition  of  apoptosis  (Alitalo  et  al.,  2005).  Nonetheless, VEGFR‐
3 gene knockout mice  exhibit defects  in  arterial‐venous  remodelling  of  the primary vascular 





vascular  density,  vessel  branching  and  EC  proliferation    in      different mouse    angiogenesis  
models  (Tammela  et  al.,  2008).  
VEGFR‐3   is  also  found  to  be  up‐regulated  in  the tumor  microvasculature,  thus opening 
the possibility  to exploit VEGFR‐3    targeting agents  to  inhibit  tumor growth  (Saharinen et al., 
2004). The   extension   of    the VEGFR‐3     role   not   only    to    lymphatic   biology,   but   also    to 
pathological  and  embryonic  development, warrants  further  studies  to  define  the molecular 
mediators of these diverse activities, still incompletely explored.  
As  already mentioned  in  the  case of VEGFR‐1, VEGFR‐3  signaling  can be modulated by  the 
interaction  with  VEGFR‐2  and  other  co‐receptors,  such  as  NP2.  The    formation    of    these  
complexes    is   biologically    relevant    and,  for    example,   VEGFR‐2‐VEGFR‐3     heterodimers  
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might    form    in    vivo  both  in  lymphatic  cells  and  subtypes  of ECs,  resulting  in differential 
phosphorylation sites and eventually differential signaling (Dixelius et al., 2003).  
All these observations suggest that VEGFR‐3, besides  its fundamental role  in  lymphatic vessel 




Neuropilins  (NP1  and  NP2),  initially  identified  as  receptors  for  class  3  semaphorins,  in   
association     with     plexin      family      receptors,     mediate  repulsive  axon   guidance    in    the  
developing   nervous    system    (Fujisawa, 2004).   Even    if   NP1   and   NP2    share   only   44%  





















NP1  is a  functional,    transmembrane   receptor,   able    to   mediate   signaling  from structurally 
distinct  ligands  during  nervous  system,  heart  and  vascular  development.  In  particular, NP1 
expression in EC is required for cardiovascular development (Gu et al., 2003), and is important 
for  the  formation  of  the primitive  capillary  plexus, partially  independently  from  blood  flow 
(Jones et al., 2008).   It selectively binds the VEGF‐A165 isoform and it is expressed at high levels 
in  heart  and  placenta, moderately  in  lung,  liver,  skeletal muscle,  kidney,  and  pancreas,  and 
poorly in brain (Soker et al., 1998). 
Due   to    its   short   and   catalytically    inactive    intracellular   tail, NP1   has   been   traditionally 
considered a dead receptor, only   able   to   enhance   VEGF‐induced   signal through   VEGFR‐2  
interaction. On the contrary, recent  evidence  suggests  that NP1  mediates  HUVEC  adhesion  
to   extracellular matrix    (Murga   et   al.,   2005)   as   well   as  increases   VEGF‐A‐induced   EC  
survival   (Wang   et   al.,   2007),   independently from VEGFR‐2. Thus, NP1   seems   to   regulate  





The  term  heart  failure  (HF)  refers  to  a  clinical  syndrome,  in which  an  abnormality of  cardiac 
structure or  function  is responsible  for  the  inability of  the heart  to fill with or eject blood at a 
rate commensurate with  the  requirements of  the metabolizing  tissues. Clinically,  the cardinal 
symptoms of HF are  fatigue and dyspnea, associated with  the presence of pulmonary and/or 
peripheral  edema.  In  case  of  left  ventricular  failure,  patients may  have  pulmonary  edema, 
dyspnea even at  rest.  In case of  right ventricular  failure, patients may have ascites, edema of 
lower  limbs  and  hepatomegaly.  In  case  of  biventricular  failure,  patients  may  have  fluid 
accumulation between lungs and chest wall (pleural effusion).  
HF  and  its  complications  are  diagnosed  by  echocardiography  (to  measure  left  ventricular 






Current  standard  treatment  for  HF  includes  the  use  of  ACE  inhibitors,  diuretics,  calcium 
antagonists,  digoxin,  β‐blockers  or  antiplatelet  agents.  If  the  patient  couldn’t  respond  to 
medication,  surgical  interventions  are  preferred  to  implant  devices,  such  as  pacemakers, 
defribrillators  and  left  ventricular  assist  devices  (LVADs).  In  most  severe  cases,  heart 
transplantation can be considered. 
The etiology of HF  includes  coronary artery disease  (CAD)  (in 65‐70% of patients),  inherited 
cardiomyopathy, hypertension, hyperthyroidism or valvular abnormalities  (National  Institute 









the  heart  undergoes  several  changes,  collectively  referred  to  as  ventricular  remodeling, 
essentially due  to changes  in  loading condition. Among  the most common etiologies of HF  is 
ischemic heart disease.  In  this  case, disease progression  can be  schematically divided  in  two 
phases: an early phase (within 3 days from the ischemic event) during which the infarct region 
expands  and may  lead  to  cardiac  rupture,  and  a  late  phase  (after  the  first  3  days), which 
involves dilatation of ventricle, distortion  in shape and compensatory hypertrophy, paralleled 





myocytes  in  that  area  gradually  reduces, which  leads  to  loss  of  overall  contractile  function, 
particularly evident in the case of transmural infarcts (Pfeffer 1995). Additional changes, such as 
increase  in  end  systolic  and  end  diastolic  volumes  with  decrease  in  ejection  fraction  and 





hypertension  or  valvular  heart  disease,  or  even  to  an  intrinsic  stimulus  as  in  familial 
hypertrophic cardiomyopathy. Traditionally, it was believed that hypertrophy was an adaptive 




and  characterized. Physiological hypertrophy  is determined by physiological  stimuli  such  as 
exercise,  pregnancy  and  post  natal  growth,  and  consists  in  the  proportional  growth  of 
cardiomyocyte number, cardiomyocyte size and vascular network, without any cardiac fibrosis. 
Pathological hypertrophy is mainly seen in patho‐physiological stress conditions such as aortic 
stenosis,  neurohormonal  activation,  cardiac  injury  or  inflammation.  The  various  cellular 
changes    observed  in  pathological  cardiac  hypertrophy  are  increase  in  cell  size,  reduced 
cell:capillary ratio, increased fibrosis, increase in protein synthesis  concomitant with increase in 
contractile protein  content  into  sarcomeric units  (sarcomere higher  organization)  (Aoki  et  al. 
2000b,  Frey  et  al.,  2003)  and  induction  of  certain  genes  such  as  natriuretic   peptides    (ANF,  
BNP),    skeletal  α‐actins,  growth    factors    like  endothelin‐1,    insulin‐like    growth  factor‐1, 
transforming growth factor ‐β1 (Takahashi et al., 1994), sarcomeric  proteins  βMHC in rodents,  
myosin light chains 1α and 2α (Sutton et al., 2000, Sadoshima et al., 1992). 
One  of  the  factors  known  to  induce  compensatory/physiological  hypertrophy  of 
cardiomyocytes  is  thyroid hormone  (T3 or T4).  It  increases  speed of  systolic  contraction  and 
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diastolic  relaxation,  heart  rate,  while  it  decreases  vascular  tone  and  hypertrophy  of 
cardiomyocytes. By binding  to  its  receptors –α,  (predominant  isoform) and  ‐β on cardiomyo‐ 
cytes,  it  induces calcium flux  into the cell through activation of genes encoding SERCA2a and 
myofibrillar proteins, such as α MHC and through the downregulation of β MHC. T3 stimulates 





Pathological hypertrophy  is caused by several  factors. Among  these,  the α‐adrenergic agonist 
phenylephrine  (PE)  constitute  widely  used  agents  to  study  the  molecular  mechanisms  of 
pathological hypertrophy. PE blocks norepinephrine at  α  ‐adrenergic  receptors  (α  ‐1 and  ‐2), 
members of the 7‐transmembrane spanning   Gq   protein‐coupled   receptor   family and exerts 
positive  inotropic  and  chronotropic  effects  on  cardiomyocytes  (Srivastava  et  al.,  1977).  In 
neonatal  rat  myocardial  cells,  α‐adrenergic  agonists  or  endothelin‐1  activate  hydrolysis  of 
phosphatidylinositol and generates two potential intracellular signals, inositol phosphates and 






such  as  reduced  expression  levels  of  SERCA2a,  αMHC  and  increased  expression  levels  of  β 
MHC (Dillmann 2010, Ross et al., 1990, Chien et al., 1991). Following  is a description of a few 






RyR2  protein  is  activated  by  a  relatively  small  increase  in  Ca+2  concentration  within  the 











‐  PGC1α  (peroxisome  proliferator  activated  receptor‐γ  co‐activator)  belongs  to  family  of 
transcription  co‐activators  involved  in  regulation  of  cellular  energy metabolism.  It  is  a  co‐
activator of PPARα  (peroxisome proliferator‐activated  receptor  α). Both activators  induce  the 
expression  of  enzymes  involved  in  fatty  acid  oxidation  and  of  other  proteins  involved  in 
mitochondrial energy transduction/production (mitochondrial biogenesis); the overall result of 
this shift in gene expression is the transformation of muscular tissue into fibrous tissue, which is 
more oxidative and  less glycolytic  in nature.  In cardiac hypertrophy,  the expression  levels of 
PGC1α  are markedly  decreased  and  cause  shift  in  the  cardiac metabolism  from  fatty  acid 
oxidation  to glycolysis  (Lehman 2002).  In keeping with  this concept, cultured cardiomyocytes 
respond  to PE by down‐regulating PGC1α,  thereby suppressing  fatty acid oxidation  (Lehman 
2002). 




6  isoforms, 4 of which are predominantly expressed  in  skeletal,  cardiac, vascular and enteric 
smooth muscles. They are α‐skeletal actin, α‐cardiac actin, α‐smooth muscle actin and γ‐smooth 
muscle  actin. Among  these, one of  the  isoforms of Skeletal  α  actin,  Skeletal  α  actin  2‐  is  the 
predominant isoform in cardiac muscle; its expression is induced by G protein coupled receptor 
signaling  and  is  considered  as  a  genetic  marker  for  hypertrophy.  In  newborn  rats,  it  is 
distributed uniformly in all myocardial fibrils, whereas in adults, it is limited to a small portion 












whole angiogenic process.  In addition,  several molecules, known  to be  somehow  involved  in 
one  of  the  multiple  steps  of  angiogenesis  (Fibroblast  Growth  Factor‐1,  Angiopoietin‐1, 
Transforming Growth Factor‐ and others) have been proposed as potential angiogenic factors 
for gene therapy and their efficacy has been so far proved in preclinical experimentation. 
The  success  of  heart‐directed  gene  therapy  has  become more  realistic  thanks  to  the modern 
surgical  approaches  that  allow  to deliver  genes  efficiently  into  the  coronary  vessels  or  even 
directly into the myocardium. In particular, the approaches that have reached the clinics so far 
mainly  entail  the  injection  of  the  therapeutic  genes  into  the    coronary  arteries  by  arterial 
catheterization  or  the  direct  administration  to myocardium  through  a minimal  thoracotomy  
34 
 
(for  instance, during CABG surgery). Alternatively, experiments  in  large animal models have 
shown the feasibility of a retrograde delivery, by injecting the therapeutic vectors into coronary 
sinus,  possibly  associated  to  an  increase  in  the  venous  pressure,  in  order  to  enhance  the 
retrograde flow. 
As in other fields, the success of a cardiovascular gene therapy application mainly depends on 
three major parameters, namely  the choice of an appropriate  therapeutic gene,  the delivery of 





types  after  in  vivo  injection,  for  in  vivo  applications,  adenoviral  vectors  are  notably  limited 
because  of  their  strong  immunogenicity  and  capacity  to  stimulate  a  potent  inflammatory 
response (Yang et al. 1996). In addition, major safety concerns about a wider use of these vectors 
have  been  raised  by  the  death  of  a  young  patient  recruited  in  a  gene  therapy  trial  for  the 
treatment of a rare metabolic disorder  (OCT deficiency). This  lethal event was most probably 
due  to a systemic  inflammatory  response  to  the vector  triggered by  the expression of several 
wild type adenoviral genes by the transduced cells (Lehrman 1999).  
For these reasons, AAV  is becoming the vector of choice for a growing number of pre‐clinical 






Members of  this genus are widely diffuse  in nature: well over 100 AAV variants have  so  far 






years, AAV  has  been much  popularized  as  a  safe  viral  vector  in  gene  therapy  applications 
because of its interesting favorable characteristics. It indeed transduces post mitotic tissues such 
as  muscle,  brain,  heart  and  retina  at  high  efficiency  and  maintains  long  term  persistence 
transgene expression without any inflammatory or immune response (Favre et al., 2001).  
Structure:‐ The wild type AAV genome is 4. 7kb in length with two open reading frames (ORFs) 
encoding  for  Cap  and  Rep  genes  for  the  synthesis  of  capsid  and  replicative  proteins, 
respectively. It uses two different promoters and an alternative included exon to produce four 
protein  isoforms  (Rep 78, 68, 52 and 40)  from  its Rep gene and  three different products  (VP1, 
VP2, VP3) from its Cap gene. The coding sequence is flanked by two 145 bp inverted terminal 
repeats (ITRs), which have complementarity in their first 125 bp and form T‐shaped hairpins at 
both  ends  of  the  genome.  These  palindromic  sequences  are  the  only  cis‐acting  elements 
important for all major functions of AAV (viral DNA replication, assembly of the viral particles, 























The  life  cycle of wild  type AAV  strictly depends on  the presence or  absence of host  cell  co‐
infection with a helper virus. Under non‐permissive conditions (i.e. without a helper virus), the 
AAV genome  integrates at a specific site (AAVS1) on human chromosome 19q13.3 (Dutheil et 
al., 2000, Kotin  et al., 1992, Linden  et al., 1996), and  establishes  latent  infection  for  indefinite 
periods of time. This peculiar characteristic might potentially open the gate for safe insertion of 
exogenous genes into the human genome, which is a highly desirable goal in the field of gene 
therapy. However,  site  specific  integration entirely depends on  the  function of  the AAV Rep 
proteins,  this  gene  is  removed  from  the  vector  DNA  in  order  to  control  its  unregulated 
expression, which  is  toxic  to  infected  cells  (Marcello  et  al.,  2000).   The  current generation  of 
AAV vectors persists  inside non dividing cells mainly as extra chromosomal, concatemerized 
DNA (Schnepp et al., 2005). 




backbone  suitable  for  vector  production.  The  traditional method  for  rAAV  production was 
based on co‐transfection of vector plasmid together with a secondary plasmid, supplementing 
the Cap  and  Rep  gene  functions,  into Adenovirus‐infected  cells  (usually HEK  293  or HeLa 
cells).  Recently,  adenovirus  co‐infection  was  substituted  by  the  use  of  a  single  plasmid 
assembling both the required AAV and adenoviral genes (providing helper functions), in order 
to reduce number of plasmids and to eliminate contaminants (Grimm et al., 1998). 
AAV  can  be  purified  by  different methods.  The  classical method  of  purification  is  density 
gradient (CsCl or ioxidanol) centrifugation. It is effective for small scale production, and yields 
highly  pure  viral  preparations  suitable  for  research  studies.  The  viruses  are  centrifuged  to 
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equilibrium  in a CsCl salt, so  that  they are separated  from  the contaminants and collected  in 
bands on the basis of their buoyant densities. The limitations in this process are cytotoxicity of 
CsCl,  variable  quality  of  vector  preparations,  significant  loss  of  infectivity  and  aggregation 
during storage. More  recently,  iodixanol has been used as an alternative  to CsCl  to minimize 
toxicity. It prevents aggregation of rAAV particles and doesn’t affect infectivity. For large scale 
production, chromatographic separation  is widely used,  including  ion exchange, gel  filtration 
and hydrophobic interaction. The purification by ion‐exchange chromatography is based on the 
net  charge  of  proteins  on  the  exterior  of  the  viral  capsid  and  the  net  charge  of  the  surface 
proteins  which  depends  on  pH  of  the  exposed  amino  acid  groups.  Size‐exclusion  column 
chromatography or gel filtration chromatography is used to separate mature viral particles from 
partially  assembled  capsids, proteins  and DNA  fragments.  It  is  the method of  choice  for  the 
purification  of  viruses  of  different  sizes.  The  main  disadvantages  in  this  method  are  the 







The  main  goal  of  this  approach  is  to  increase  oxygen‐rich  blood  supply  through  the 
development of new collateral blood vessels in ischemic areas. Traditionally, new blood vessel 
formation  in  the  adult  life occurs  through  capillary  sprouting  from pre‐existing vessels. This 
process is initiated by the metabolic activation, proliferation and migration of endothelial cells, 
concomitant with vast remodelling of the extracellular matrix (Risau 1997). 
Over  the  last  15  years,  several  cytokines  and  growth  factors  including  VEGF,  Hepatocyte 





the  main  genes  so  far  considered  for  angiogenic  gene  therapy  studies  in  different  animal 
models.    
In physiological conditions, the main regulator of angiogenesis is hypoxia. In conditions of low 
oxygen  tension,  the  cellular  transcription  factor HIF‐1  (Hypoxia  Inducible Factor  –1)  is post‐
translationally stabilized and activates the expression of a vast series of genes, among which the 
vascular  endothelial  growth  factor  (VEGF)  and  its  receptors  are  required  in  all  phases  of 
angiogenesis (Liu et al., 1995). In keeping with its prominent role in the formation of new blood 
vessels,  VEGF  is  by  far  the  most  investigated  molecule  for  the  induction  of  therapeutic 
angiogenesis.  Several  experiments  have  been  performed with  the  various VEGF  isoforms  in 
different  animal models.  Following  is  a  short  description  of  the  results  obtained  by  a  few, 
selected,  paradigmatic  experiments.  Tsurumi  et  al.  (1996)  observed  that  intramuscular  (IM) 
injection of naked plasmid DNA encoding VEGF induced capillaries and collateral branching of 
existing  vessels  in  a  hind  limb  ischemia model  of  rabbits. Hao  et  al.  (2007)  compared  the 
angiogenic efficacy of human VEGF‐A165 delivered either as a plasmid (P) or by an adenoviral 
vector (Ad) in a rat myocardial infarction model and observed that in both cases, the biological 
effects,  such  as  maintenance  of  increased  arteriolar  density  and  improved  left  ventricular 
function,  were  similar.  In  another  experiment,  adenoviral‐mediated  VEGF  gene  transfer 
induced  the  formation  of  a  vast  vascular  network,  initiated  with  sprouting  of  capillaries, 
arterioles,  transformation  of  capillaries  into  arterioles  and  enlargement  of  large  arteries  and 
veins  in  a  hind  limb  ischemia model  in  rabbits  (Rissanen  et  al.,  2005). Gowdak  et  al.  (2000) 
demonstrated that intramuscular injection of AdVEGF‐A121 resulted in a significant lengthening 




model of mice. Long  term expression of AAV‐VEGF‐A165  induced massive cellular  infiltration 
with the formation of a large set of new vessels in the tibialis anterior muscle of rats (Arsic et al., 




concentration after 24 hours; however, at higher concentrations,  it promotes  increase  in vessel 
diameter as well as in the eNOS production, which is known to interact with downstream and 
upstream  targets  of  VEGF  and  stimulate  vasodilatation  and  vascular  permeability  during 
physiological  angiogenesis.  Intracardiac  injection  of AAV‐VEGF‐A165  induced  angiogenesis  in 
ischemic heart without any angioma formation (Su et al., 2000, Ferrarini et al., 2006). Lazarous et 
al.,  (1999)  investigated  the  effect  of  VEGF  when  delivered  pericardially  and  found  that  it 
maximized  collateral  perfusion  and  myocardial  collateral  development  in  canine  model  of 
progressive  coronary  occlusion  in  addition  to  angiogenesis.  Schwarz  et  al.,  (2000)  evaluated 
direct  intracardial  injection of plasmid encoding VEGF  in  the border zone of  infarct  tissue  in 
ischemic  rat hearts,  and  showed  significant  angiogenesis with  improved  regional blood  flow 
without any angioma formation at the site of delivery. Later, VEGF was tested in several phase I 
clinical  trials,  essentially  using  adenoviral  vectors  in  patients with  coronary  artery  disease. 
Intracardiac administration of VEGF‐A121  into  the  ischemic region showed an  improvement  in 
symptoms of angina without any adverse effects (Rosengart et al., 1999). 
An  alternative possibility  is  to use  gene  combinations, by mixing genes  that  should provide 
complementary  activities.  For  instance,  the  VEGF  gene  has  been  extensively  used  in 
combination with other angiogenic genes. Examples of these combinations  include VEGF/FGF 
(Kondoh et al., 2004), VEGF/PIGF (Zheng et al., 2006), VEGF/angiopoietin (Niagara et al., 2004, 
Arsic et al., 2003) or multiple  isoforms of VEGF  (Whitlock et al., 2004). The  rational of using 
gene combinations  is  to provide  functions  that operate  in  subsequent  steps of  the angiogenic 




small and  large blood vessel  formation. For  instance, FGF‐2, FGF‐4 and FGF‐5 are believed  to 
have  peculiar  angiogenic  properties.  Safi  et  al.  (1999)  reported  that  intracardiac  delivery  of 





human  FGF‐5  in  an  ischemic  porcine model  showed  significant  improvement  in myocardial 
blood  flow with evidence of angiogenesis already evident at 2 weeks after  the  treatment and 
lasting until 12 weeks (Giordano et al., 1996).  






conditions  by HVJ‐liposome  transfection  and  found  a  significant  increase  in  the  number  of 




transcript  produces  2  isoforms:  PIGF‐1  and  ‐2.  In‐vivo,  PIGF‐1  gene  transfer  determined  a 
potent neo‐vascularisation in two models of neoangiogenesis, namely the rabbit cornea and the 
chicken chorioallantoic membranes, yet  its angiogenic effect was  less  significant compared  to 
VEGF or FGF (Ziche et al., 1997).  
PDGF  is a cationic glycoprotein existing  in 5 different  isoforms: PDGF‐AA, PDGF‐AB, PDGF‐
BB, PDGF‐CC and PDGF‐DD (Colciago et al. 2009). They all bind to the tyrosine kinase (RTK) 
cell surface receptors PDGFR‐α and β. They are expressed widely  in human  tissues  (Tallquist 
and Kazlauskas 2004), promote proliferation, migration and survival of several derived cells of 






(Cao  et  al.,  2003).  Another  isoform,  PDGF‐CC,  delivered  through  an  osmotic  minipump 
enhanced post‐ischemic revascularization in the heart and limb of mice, possibly by promoting 






of  IGF‐1, vessels  ceased  to grow  and mature  in  the  avascular  retina  even  in  the presence  of 
sufficient VEGF levels; on the other side, when IGF‐1 levels were up‐regulated to a critical level, 






factors  (such  as  angiopoietins  ad  others), which  act  at  later  time  points  to  promote  vessel 
maturation. Angiopoietins exist in 2 isoforms: angiopoietin‐1 (Ang1) and angiopoietin‐2 (Ang‐
2).  Ang‐1  interacts with  the  Tie‐2  receptor  on  the  endothelial  cell  surface  and  reduces  the 
permeability of the newly formed vasculature (Arsic et al., 2003, Asahara et al., 1998, Davis and 
Yancopoulos  1999,  Thurston  et  al.,  2000).  The  two  ligands  for  Tie2,  (Ang1  and Ang2) were 
originally described in tissue culture experiments as pro‐angiogenic (Suri et al., 1996) and anti‐
angiogenic  (Maisonpierre et al., 1997),  respectively. The  corneal pocket assay has  shown  that 
both  Ang1  and  Ang2  similarly  act  synergistically  with  VEGF‐A  to  promote  vessel  growth 
(Asahara et al., 1998). In particular, transcorneal  injection of recombinant human Ang‐2 in the 
context  of  the  transient  ocular  microvessel  network  of  the  papillary  membrane  (which 
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represents  a  unique  in  vivo  model  to  study  the  effects  of  vascular    regulators)  promoted 
proliferation, migration of endothelial cells, rapid increase in capillary diameter, remodelling of 
the basal lamina and sprouting  of  new  blood  vessels in the presence of endogenous VEGF‐A; 
in  contrast,  it  promoted  endothelial  cell  death  and  vessel  regression  in  the  absence  of 
endogenous VEGF‐A  (Lobov  et  al.,  2002). However,  the  data  available  over  these  factors  in 
describing their function is largely controversial.  
NO  is  synthesized  from  L‐arginine  in  endothelial  cells  by  the  enzyme  nitric  oxide  synthase 
(NOS3).  NOS3  regulates  vasomotor  tone  and  blood  flow  by  inhibiting  smooth  muscle 





Beside  all  the  above  mentioned  genes,  other  candidate  therapeutic  genes,  currently  under 
investigation  to  induce  therapeutic  angiogenesis,  include  Del‐1  (developmentally  regulated 
endothelial  locus  1)  (Zhong  et  al.,  2003),  early growth  response‐1  (Abdel‐Malak  et  al.,  2009), 
adrenomedullin  (Tokunaga et al., 2004), sonic hedge‐hog  (Kusano et al., 2005), PR39  (Li et al., 
2000), stromal cell derived factor‐1α (Hiasa et al., 2004), Ets‐1(Sato et al., 2001), Id‐1(Nishiyama 
et al., 2005), endocrine gland‐derived VEGF,  a few cytokines such as monocyte chemoattractant 
protein‐1  (Ito  et  al.,  1997),  granulocyte  colony  stimulating  factor  (Okazaki  et  al.,  2006)  and 








Based  on  these  mechanisms,  some  important  molecules  under  study  are  SERCA2a, 
Phospholamban (PLN), Parvalbumin (PV), Protein phosphatise 1 inhibitor‐1(PP‐1‐H‐1), S100A1, 
Adenyl cyclase(AC)6 and GRK2.   
In  the  failing myocardium,  a  critical  observation  is  that  the  loss  of  activity  of  serum  Ca+2 
ATPases causes functional loss of calcium reuptake (Hasenfuss et al., 1994). In keeping with this 
finding,  intracoronary  delivery  of  Adv‐SERCA2a  in  a  rat  heart  failure  model  showed 
improvement in left ventricular function and survival rate 28 days after treatment (Del Monte et 
al., 2001). Similar results were obtained by AAV1‐SERCA2a administration through epicardial 
coronary artery  infusion  in a HF model  in pigs with mitral valve  impairment  (Kawase et al., 





contractile  defect  in  response  to  ß‐adrenergic  stimulation  (Luo  et  al.,  1994).  In  a  therapeutic 




2002,  Iwanaga et al., 2004). The mutant was also  tested  in  sheep, using an adenoviral vector, 
administered through an intracoronary route (Kaye et al., 2007).  
Decrease in intracellular Ca+2 sequestration causes prolonged relaxation, which is characteristic 
of disastolic dysfunction  in HF patients. Correcting  the diastolic dysfunction  is an alternative 
approach.  Wahr  et  al.  (1999)  hypothesized  that  expression  of  the  Ca+2  binding  protein 
parvalbumin  in  cardiac  myocytes  would  lead  to  increased  rates  of  Ca+2  sequestration  and 
mechanical relaxation. Parvalbumin  (PV)  is a high affinity calcium binding protein belongs  to 




for diastolic dysfunction. The  isolated cardiomyocytes  from DS  rats were  transduced with an 
Ad  vector  containing  an  β‐parvalbumin  isoform.  It was  observed  that  the  transduced  cells 
showed  faster relaxation  than control cells  (Rodenbaugh et al., 2007). In another study,  it was 
revealed  that Adv‐mediated parvalbumin  transduction  in  cardiomyocytes  isolated  from dogs 
with  thoracic aorta constriction  (TAC) showed  improvement  in relaxation kinetics along with 
depressed sarcomere shortening (Hirsch et al., 2004).  
S100A1 is another protein abundantly expressed by cardiomyocyets and playing multiple roles 
in Ca+2  cycle.  It belongs  to S100 protein  family, which  includes  several EF‐hand Ca+2 binding 
proteins.  It  regulates  RyR  and  SERCA2a.  In  diastole,  S100A1  stabilises  RyR  (to  minimise 
frequency of Ca+2  levels) and  increases release of Ca+2 during systole.  In addition,  it augments 
SERCA2a  activity  during  relaxation.  It was  observed  that  S100A1‐/‐ mice  and  heterozygotes 
S100A1‐/+ have normal cardiac function under baseline conditions, but the contraction rate and 
relaxation rate were significantly reduced in response to ß‐adrenergic stimulation. Induction of 
pressure overload by TAC  for a period of 3 weeks  in  these mice caused deterioration of  left‐
ventricular contractility  indicating that the  levels of S100A1 are essential for cardiac reserve to 
acute and chronic hemodynamic stress (Du et al., 2002). Intra‐coronary AAV‐mediated S100A1 
delivery  showed  an  enhancement  in  cardiac  function  and  reversal  of  left  ventricular 
remodelling after MI in rats (Pleger et al., 2007). 





γ  subunits  at  the  plasma  membrane  (Iaccarino  et  al.,  2004).  The  delivery  of  AdV‐βARKct 
peptide via percutaneous intracoronay catheterization in post MI‐rabbits rescued heart from HF 
and improved its contractile function (Shah et al., 2001). Similarly, Adenylyl cyclase‐6 (AC6) is 
an  enzyme  that  catalyzes  the  transformation  of  ATP  into  cyclic  AMP,  and  is  important  in 
cardiac  cycle  in  response  to adrenergic  stimulation.    In humans, Adenylyl  cyclase  exists  in 9 
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isoforms,  of  which  isoform  5  and  6  are  predominant  in  the  heart.  The  concentrations  of 
ßAR/Gαs/AC complex  in cardiac myocytes are 1:200:3,  indicating  that ßAR and AC represent 
the limiting components in ßAR‐mediated transmembrane signaling (Gao et al., 1999). In earlier 
studies,  it was  demonstrated  that  overexpression  of AC6  did  not  activate  cAMP  generation 
chronically.  But  its  overexpression  in  transgenic  mice  with  Gαq  overexpression  showed 
improvement  in LV  function, generation of  cyclic AMP  levels, dysfunction of ßAR  signaling, 




a  longer medial  life  span.  They were  also  protected  from  hypertrophy,  apoptosis,  fibrosis, 

















2.1    Persistent  expression  of  AAV‐2‐mediated  VEGF‐A  and  VEGF‐B  in  normal  rat 
myocardium 
AAV2  has  the  potential  to  drive  persistent  gene  expression  in  post‐mitotic  tissues,  such  as 
skeletal, cardiac and neuronal  tissues. In order  to validate  the persistence of  the expression of 
the  two  transgenes VEGF‐A  and VEGF‐B upon AAV  serotype  2‐mediated  gene  transfer, we 
generated two AAV2 vectors containing the VEGF‐A and VEGF‐B cDNAs under the control of 
the  CMV  IE  promoter  and  delivered  them  into  the  left  ventricular  free wall  of  normal  rat 
myocardium at  the dose of 5×1010 AAV viral genomes  (vg) per animal. Control animals were 






days after viral  inoculation  (Figure 3.1.A, B). These  results were consistent with our previous 






Figure  3.1  Effects  of  AAV‐mediated  VEGF‐A  and  VEGF‐B  expression  in  normal  rat 
myocardium.  A,  B)  Levels  of VEGF‐A and VEGF‐B transgene transcripts were evaluated by 
real‐time PCR  analysis over  total ventricular RNA  extracted  90 days  after vector  injection. 




In  our  previous  studies,  we  observed  that  the  prolonged  expression  of  VEGF‐A  produces 
angiogenesis  in  the  skeletal muscle  (Arsic  et  al.,  2003, Zacchigna  et  al.,  2008).  Similarly, we 
wanted  to  investigate  the effect of VEGF‐A and VEGF‐B on normal  rat myocardium after 30 
days from vector delivery. The heart samples were analyzed by immunofluorescence using anti 
CD‐31  and  anti  ‐SMA  antibodies  to  detect  endothelial  and  smooth  muscle  cells  (SMC), 
respectively.  (Figure  3.2)  In  the  case  of  samples  treated with VEGF‐A,  there was  a marked 










injected  with  AAV‐LacZ  (control),  AAV‐VEGF‐A,  and  AAV‐VEGF‐B,  as  indicated.  Right 
panels: enlarged views. Capillaries were detected using FITC‐conjugated L. esculentum lectin 














Figure  3.4   A  very modest  angiogenic  response was  triggered  by VEGF‐B  in  healthy  rat 
myocardium. Left panel: frozen section showing endothelial cells stained with lectin in green 
and mural  cells with  anti‐NG2  antibodies  in  red. Right  panel:  paraffin  sections  showing 











infarction  by  echocardiography.  Rats  (n=10/group)  underwent  myocardial  infarction  by 
permanent  ligation of  the  left  coronary descending  artery  and vectors  (AAV‐VEGF‐A, AAV‐
VEGF‐B, AAV‐LacZ  or  saline) were  delivered  immediately  after  the  ligation  at  the  dose  of  
5×1010  viral  particles  in  the  peri‐infarct  area.  Cardiac  function  was  analysed  by 











Global  cardiac performance was assessed by measuring  left ventricular  (LV) ejection  fraction 



























The  regional  contractile  response  of LV was  assessed by measuring  anterior wall  thickening 
(AWTK) and posterior wall thickening (PWTK) (Figure 3.8 A, B). In case of infarct hearts treated 
with VEGF‐B, at both 1 and 3 months after cardiac gene   transfer,   the   LV   end‐systolic   wall  






after MI,  showing  LV  end‐systolic  anterior wall  thickening  (AWTK)  and  LV  end‐systolic 
posterior wall thickening (PWTK). Values are expressed as means ±SE. *P<0.05. 
 
Similarly,  the LV anterior wall end‐diastolic   and   end‐systolic    thickness  (AWTd and AWTs, 
respectively) of the border zone, which are indices of regional mass, were selectively preserved 












after MI.    LV  anterior  wall  end‐diastolic  thickness  (AWTd),  and  end‐systolic  thickness 





Taken  together,  these data unanimously  indicated  that prolonged expression of both VEGF‐A 
and VEGF‐B markedly improved recovery of LV performance after infarction. 
 
2.4    Analysis  of  cardiac  tissues  by  histo‐pathological  studies:  morphometric  analyses  of 
infarct samples 
From  echocardiographic  analyses, we  observed  that  the  improvement  in  LV  function  upon 
VEGF‐B gene transfer was due to preservation of LV mass. To confirm this result, we examined 





of  contractile  tissue  was  paralleled  by  a  reduction  in  the  fibrotic  area  (Figure  3.10  A  for 
representative  cross  sections  and  Figure  3.10 C  for  high magnification  view  of  the  extent  of 
fibrotic substitution). The infarct size was determined as 36.2± 6.0% of the LV in control animals 






transfer   A) Representative Azan  trichrome  staining  of  LV  transverse  sections  of  control, 
AAV‐VEGF‐A and AAV‐VEGF‐B‐injected hearts. B) Quantification of infarct size (% of LV). 





2.5  Analyses  of  vector  genomes  and  their  incorporated  transgenes  in  the  injected 
myocardium 
The heart samples were analysed  to confirm  the persistence of vector genomes  in  the  injected 
myocardium at the end of the experimental period (Figure 3.11A). Likewise, transgene (VEGF‐
A,  VEGF‐B)  expression  was  also  maintained,  as  quantified  by  real‐time  PCR  by  using 



















The  heart  samples  were  analysed  by  immunoflorescence  and  compared  to  non‐infarcted 
samples  to  find  any  angiogenic  response  produced  by  either  VEGF‐A  or  VEGF‐B.  A 














Figure  3.12    Histological  analysis  of  infarcted  hearts  3  months  after  gene  transfer.  A) 
Visualization  of  vessels    by    immunofluorescence    in    the    peri‐infarcted    area    (green,  






and  histopathological  studies, we wanted  to  explore  the  possibility  that  these  factors might 




Total  RNA  was  extracted  from  primary  cultures  highly  enriched  in  ‐actinin  positive 













The expression  levels of  the  three  receptors were also analysed by placing cardiomyocytes  in 
two different conditions, such as hypoxic environment  (2%O2) and oxidative stress  (H2O2 100 











The  expression  patterns  of  VEGF  receptors  (VEGFR‐1,  VEGFR‐2,  NP‐1)  were  analysed 
quantitatively by western blot in neonatal cardiomyocyte lysates (Figure 3.15, top panel).  
Most notably,  these  receptors appeared  to be  functional,  from  the  immunoprecipitation   with  
specific   anti‐VEGFR‐1 and   anti‐VEGFR‐2   antibodies   and  then  from   Western blot   analysis  







Figure 3.15   Cardiomyocytes   express    functional   VEGF    receptors C) Top panel: Western 
blotting  showing  specific  detection  of  VEGFR‐1,  VEGFR‐2,  and  Np1  in  cell  lysates  of 
neonatal  cardiomyocytes,  with  or  without  stimulation  with  fetal  calf    serum    (FCS),  
recombinant  VEGF‐A,  or  VEGF‐B,  as  indicated.  Bottom panel: immunodetection of VEGF 




Later, we were  interested  to analyze receptor expression  in samples of adult rat myocardium. 
Frozen  sections  were  taken  and  stained  with  receptor‐specific  antibodies  by 
immunofluorescence (Figure 3.16). In these sections, VEGFR‐2 and NP‐1 were localized between 




Figure 3.16    Immunofluorescence  staining of VEGFR‐1, VEGFR‐2, and Np1 on histological 
sections of frozen adult rat heart tissue. Larger pictures on the left and magnifications on the 
right  show  fluorescence  in  all  three  channels  (red,  receptors;  green,  sarcomeric  ‐actinin; 
blue, cell   nuclei);   smaller   pictures   show   2‐channel   fluorescence   (top:   blue/red; bottom: 






The preservation of LV myocyte mass and  the reduction  in  the  infarct size  in animals  treated 
with  VEGF‐A  and  VEGF‐B  suggested  that  these  factors  might  have  either  stimulated 
cardiomyocyte proliferation or prevented their death. 
To start assessing the first hypothesis, we investigated the effect of VEGF‐A and VEGF‐B on rat 
neonatal  cardiomyocytes.  Under  standard  culture  conditions  (Collesi  et  al.,  2008),  0.2%  of 







BrdU   immunostaining   (red;   arrows)   with   or   without exposure to recombinant VEGF‐B. 
Right panel: quantification of BrdU‐positive nuclei. 
 
We  also  explored  the  possibility  that  expression  of  two  factors    after   AAV‐mediated    gene  




this purpose, we  injected a subset of  infracted animals with BrdU. However,  in keeping with 
the in vitro data, we failed to detect any increase in number of BrdU‐positive proliferating cells 
within the infarct border zone in treated animals compared to controls (data not shown). 
The  alternative possibility was  that VEGFs  exerted protective  role  against  ischemic death  of 
cardiomyocytes.  To  test  this  hypothesis,  we  exposed  cardiomyocytes  to  hypoxia  for  48  h 
followed by 24 h  reoxygenation either  in  the absence or presence of  recombinant VEGF‐B or 
VEGF‐A. By TUNEL assay, we observed  that  the percentage of apoptotic cells dropped  from 
~17.2± 3.3%  in controls  to 7.6 ± 1.2 and 8.0± 1.0%  in   VEGF‐A   and   VEGF‐B  treated   cultures,  
respectively (*P<0.05 in both cases; Figure 3.18).  
 
Figure  3.18    VEGFs  protect  cardiomyocytes  from  apoptosis  in  vitro.  Left  panels: 













Figure  3.19  Left  panels:  representative  images  of  a  cell  viability  assay  based  on  the 





role  against  apoptosis,  as  assessed  by  counting  TUNEL‐positive  nuclei  in  the  infarct  border 
zone at 48 hr after  infarction. The number of TUNEL positive cells were significantly  lower  in 
animals  injected  with  either  AAV‐VEGF‐A  or  AAV‐VEGF‐B  compared  to  controls  (from 






Figure  3.20      Detection  of  apoptotic  nuclei  in  vivo  at  day  3  after  MI.  Right  panels: 







Besides protection  from apoptosis, we observed  important changes  in regional contractility  in 
the infarcted rats treated with VEGF‐A and VEGF‐B. These changes suggested that these factors 
might have direct influenced cardiomyocyte activity. To explore this assumption, we selected a 
series  of  genes  involved  in  cardiac  contractile  function  in  cells  treated  for  24  hr  with 
recombinant VEGF‐A and VEGF‐B in‐vitro. 
The  selected  genes  were:  MHC,  MHC  to  analyze  the  composition  of  the  contractile 
apparatus,  SERCA2a,  RYR  to  analyze  calcium  handling  pathways,  PGC1  to  analyze 
mitochondrial energetics and skeletal ‐actin and cardiac natriuretic peptides (ANF and BNP) 
as  typical  markers  of  hypertrophic  response.  The  expression  profiles  of  these  genes  in 
cardiomyocytes  treated  with  recombinant  factors  was  determined  in  two  experimental 
conditions: response  to ‐adrenergic agonist phenylephrine and response  to  thyroid hormone 
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tri‐iodo  L‐  thyronine  (T3).  These  compounds  are  known  to  induce  characteristic  myocyte 
hypertrophy  responses,  essentially  consisting  in  the  up‐regulation  of  fetal  genes  (increase  in 




Both  VEGF‐A  and  VEGF‐B were  found  to  increase  the  expression  of  MHC  (which  is  the 
predominant contractile protein in adult rodents; Tardiff et al., 2000) and to repress expression 
of  MHC,  similar  to  T3,  but  different  from  PE  (P<0.05  between  VEGF‐treated  and  control 




Figure  3.21  Cardiomyocyte  treatment  with  both  VEGF‐A  and  VEGF‐B  induces  a  gene 
expression pattern proper of compensatory hypertrophic response. Results of real‐time PCR 
quantification  of  the  levels  of  expression    of    the    indicated    genes    in    neonatal    rat  
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From  these observations,  it  is  clear  that both VEGF‐A  and VEGF‐B  evoke  a gene  expression 










commonly associated with pathological LV  remodelling,  involving  significant  (P<0.05) higher 
expression  of  MHC  and  sk  ‐actin  contractile  proteins,  an  increase  in  levels  of  cardiac 





Figure  3.22   AAV2‐mediated   VEGF‐B    and   VEGF‐A    expression    prevents  pathological  
hypertrophy   gene   expression    in    the   myocardium   of  infarcted  rats. RNA was extracted 
from  the  left ventricle of control and AAV2‐VEGF‐B‐ and AAV2‐VEGF‐A  injected rats at 3 
months after MI. Real‐time PCR quantifications of the levels of expression of the indicated 




evident  upon  VEGF‐B  overexpression.    In  the  VEGF‐A  and  VEGF‐B‐treated  hearts,  the 
expression  levels of gens  such  as MHC, ANF, BNP, SERCA2a,  and RYR   were   unchanged  
when  compared    to   normal    animals.  In  addition,  expression  of   MHC    and   PGC1 was  





















Further  studies were  carried  out  at  ICGEB  Trieste  to  better  define  the mechanisms  of  these 
effects  by  histo‐pathological  analysis.  To  investigate  whether  the  protective  action  was 
mediated by a process of angiogenesis,  the LV  samples were  stained with  immunoflorescent 
lectin and anti‐α‐SMA antibodies,  in order  to detect endothelial and vascular  smooth muscle 
cells,  respectively. We  found  that  the capillary density was  reduced by 15%  in AAV‐Control‐







Figure  3.1  A)  Representative  photomicrographs  of  myocardial  tissue  showing  double 
immunoflorescence staining for endothelial  (lectin+, green) and vascular smooth muscle  (α‐




Cardiomyocytes  cross  sectional  area  from  the  dog  hearts  was  measured  to  detect  any 
hypertrophic response. The cross‐sectional area was significantly  increased  in both paced and 
non paced, AAV‐VEGF‐B‐treated compared  to normal hearts  (Figure 3.2 A and B). However, 










The observed preservation of LV  contractility gave  rise  to  the assumption  that AAV‐VEGF‐B 
might have inhibited cardiomyocyte loss, which usually occurs during dilated cardiomyopathy. 
To  analyze  the  extent  of  apoptosis  in  our  experimental  samples, we  used  both TUNEL  and 
Caspase  activity  assays.  The  amount  of  TUNEL‐positive  nuclei  was  approximately  8‐fold 
increased  in AAV‐control  relative  to normal hearts; whereas  it was half  in  the hearts  injected 









Figure  3.3  Cardiomyocyte  apoptotic  nuclei  (white  arrows)  by  TUNEL  (red)  analysis. 















indicating  similar  transduction  efficiency  and  persistence  of  AAV  vectors  in  both  groups 
(Figure 3.5, left panel). In contrast, VEGF‐B expression was undetectable in both uninjected and 
AAV‐Control‐injected (not shown) animals, while it was readily detectable at the site of AAV‐





Figure  3.5  Levels  of  AAV  genomes  and  AAV‐mediated  transgene  expression  in  the 
myocardium of transduced animals. Left   panel:   the   amount   of   AAV   genomes   was   not  
significantly  different  between AAV‐VEGF‐B  and  AAV‐Control  LV  myocardium  at  the  
injection    site  (n=  5/  group). Right panel: The murine VEGF‐B167  transgene  transcript was 
clearly  expressed  at  the  injection    site    and    detectable    also    in    the    LV    remote    site,  
although  the  level  were approximately 85% lower (n= 5/group). 
We  also  quantified  the  endogenous  expression  levels  of VEGF‐B167  and VEGF165  by  real  time 
PCR,  since  it  is  known  that  decreased  endogenous  expression  of  VEGF‐A165  may  cause 
downregulation  of VEGFR‐1  (Abraham  et  al.,  2000).  In  the  case  of VEGF‐B167,  there was  no 
significant difference  among  the  groups, whereas  in  the  case  of VEGF165  the  expression was 
0.87±0.4  in AAV‐VEGF‐B,  0.63±0.1  in AAV‐Control  (normalized  to Hprt  gene  values,  P<0.05 
versus normal) and 1.05±0.1 in normal (data not shown). We further quantified the expression 
levels of the VEGF receptors VEGFR‐1, VEGFR‐2 and neuropilin‐1, in the heart samples of the 

















From both Caspase  and TUNEL  assays,  it was  evident  that VEGF‐B  counteracts  loss of both 
cardiomyocytes and  capillary endothelial  cells  in  the  failing myocardium. To  further  confirm 
the anti‐apoptotic  role of VEGF‐B, we analyzed  the phosphorylation pattern of Akt, which  is 
known  to  exert  an  antiapoptotic  activity  in  cardiac  failure  conditions,  as well  as  of  its  two 
downstream  targets  (cytosolic  target  GSK‐3β  and  nuclear  target  FoxO3a).  Akt  hyper‐
phosphorylation was detected  in both AAV‐Control  and AAV‐VEGF‐B‐treated  failing hearts. 
Quite  interestingly,  when  analyzing  its  targets,  the  levels  of  protein  expression  were  not 
significantly different  among groups, but  their phosphorylation was  significantly  reduced  in 





























4.1    Cardiac  gene  transfer  of  VEGF‐A  and  VEGF‐B  exerts  beneficial  activities  after 
myocardial infarction in rats and in heart failure in dogs 
The major  conclusion  that  can  be  drown  from  the  studies  presented  in  this  thesis  is  that  a 
persistent expression of VEGF after myocardial infarction exerts prolonged beneficial effects in 
terms of   contractility, prevention of pathological LV  remodelling, and preservation of viable 
cardiac  tissue. All  our  findings  are  consistent with  the notion  that VEGF  exerts  these  effects 
through  the  activation  of  VEGFR‐1  expressed  by  cardiomyocytes.  In  particular,  we  have 
observed  that:  1)  isolated  rat  cardiomyocytes  express  VEGFR‐1;  2)  VEGFR  tyrosine  kinases 
become  activated on binding  to  the  recombinant VEGFR‐1  ligands PlGF  and VEGF‐B;  3)  the 
levels of expression VEGFR‐1 are  selectively up‐regulated  in pathological  conditions,  such as 
hypoxia and oxidative stress; 4) most notably, cardiomyocyte treatment with VEGF‐B activates 
a  peculiar  gene  expression  program,  reminiscent  of  that  observed  during  compensatory 
hypertrophy.  In  this  context,  the  localization  of  VEGFR‐1  in  the  intercalated  disks  between 
adjacent cardiomyocytes appears very interesting, since these structures also act as mechanical 
stress sensors during muscle contraction, and support synchronized cardiomyocyte contraction 
(Hoshijima,  2006).  However,  the  functional  significance  of  VEGFR‐1  localization  at  these 
structures remains an outstanding question, which will require additional investigation.  
In  addition  to  these  supporting  evidences,  obtained  by  using  an  experimental  model  of 
myocardial  infarction  in rats,  the cardioprotective role of VEGF‐B was also proven  in another 
model,  namely  pacing  induced  dilated  cardiomyopathy  in  dogs.  Pacing‐induced  dilated 
cardiomyopathy is one the well studied and widely used experimental model to understand the 
pathophysiology of  congestive heart  failure  (CHF). Earlier, different  techniques were used  to 
study  CHF,  such  as  the  generation  of  pressure  load  by  aortic  or  pulmonary  stenosis,  the 
production of volume overload by aortic insufficiency, arteriovenous shunt, the induction of MI 
by  coronary  ligation  or  embolism,  or  use  of  myocardial  toxic  drugs  (adriamycin, 
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catecholamines).  However,  none  of  these  techniques  are  as  effective  as  pacing  induced 
cardiomyopathy in mimicking the entire pathophysiology of human CHF (Moe et al., 1999). The 
advantages of  this method are: 1)  It avoids  surgical  trauma associated  to procedures  such as 
thoracotomy  and  pericardectomy,  which  significantly  interfere  with  heart  physiology  and 
function  2)  Continuation  of  pacing  for  a  prolonged  period  of  time  helps  to  understand 
sequential  changes  3)  The  magnitude  of  the  stimulus  can  be  controlled  precisely  by  a 
programmed  pacemaker  4)  It  produces  several  clinical  symptoms  of  human  CHF,  such  as 






rat, because  they  closely  recapitulate  the  sequential  changes  of human HF  in  a  reproducible 
manner. In the canine model, the major changes observed from the early phase of pacing to the 
progression  of CHF,  are  impairment  of  left  and/or  right  ventricular  systolic  pump  function, 
which  leada  to progressive cardiac enlargement and hypertrophy. These changes persist until 
the onset of typical symptoms of CHF. Of notice, chronic rapid pacing causes a marked dilation 
of  cardiac  chambers  without  or  with  little  hypertrophic  response.  Morphometric  analyses 
reveals  a  severe  loss  in  cardiomyocyte  number  and  an  increased  volume  of  the  remaining 
cardiomyocytes  (reactive  hypertrophy), with  significant  increase  in  their  length  to  diameter 
ratio.    The  cardiac  fibrillar  collagen  network  is  altered  and  associated  to  the  appearance  of 
interstitial  edema  and  disintegration  of  collagen  fibres  (Moe  et  al.,  1997).  Hemodynamic 
changes occur within minutes after inception of pacing, mainly consisting in a drop in cardiac 
output, with  a  slower  decrease  in mean  arterial  pressure.  These  parameters  are maintained 
almost  unchanged  until  progression  into  CHF  (Elsner  et  al.,  1995).  From  echocardiographic 
analyses, the most common observations are a continuous increase in LV volume and decrease 






In  our  experiments,  transduction  of  failing dog  hearts with VEGF‐B167  exerted  a  remarkably 
beneficial effect. In particular: 1) after 4 weeks of tachypacing, hearts transduced with VEGF‐B167 
maintained  a  LV  end‐diastolic  pressure  compatible  with  physiological  pulmonary  blood 
oxygenation,  and  LV wall  thickness  and  both  global  and  regional  contractile  function were 
either not significantly changed or preserved compared to baseline; 2) there was no alteration in 
the  density  of  LV  microvessels  endowed  with  smooth  muscle  wall  upon  VEGF‐B167  gene 
transfer and only a modest prevention of the capillary rarefaction found in control‐paced dogs, 
thus ruling out a major angiogenic activity of this factor; 3) the  low rate of apoptosis and   the 
normalized    levels   of   active    capsase‐9   and    ‐3    in myocardial  tissue upon VEGF‐B167 gene 
transfer  indicate  a  potent  antiapoptotic  and  pro‐trophic  action  of  VEGF‐B167,  which  likely 
averted both  cardiomyocyte    and  endothelial    cell    loss;  4)  the  antiapoptotic kinase Akt was 
more active in the failing heart, as previously found in human and tachypacing‐induced heart 










One of our previous  studies on  the effect of VEGF‐A165 gene  transfer  to  infarcted dog hearts, 
revealed a marked  functional  improvement within 48 hours after VEGF‐A165 gene delivery, a 




2002).  Hence,  the  observation  that  VEGFs  might  directly  act  on  cardiomyocytes  is  not 









(Arsic et al., 2004, Messina et al., 2007). Along with  these,  several groups have described  the 
effective  role  of  VEGF‐A  on  various    cells  of  hematopoietic  origin  and  its  importance  in 
mediating monocyte  chemotaxis  (Barleon et al., 1996), hematopoietic stem cell survival (Gerber 
et al., 2002),   mobilization of endothelial progenitor cells (Lyden et al., 2001), and the selective 
recruitment  of  a  population  of  bone  marrow‐derived,  CD11b+  mononuclear  cells  which  is 
essential for vessel maturation at the sites of adult neoangiogenesis (Zacchigna et al., 2008). In 
keeping with these findings, in our experimental models, the prolonged expression of VEGF‐B 




possible  angiogenic  role  of  VEGF‐B when  delivered  exogenously  in  vivo,  as  shown  by  the 
promotion of unrestricted  angiogenesis  (Silvestre  et  al.,  2003),  the  ability  to potentiate  rather 
than  induce  angiogenesis  when  transgenically  expressed  in  endothelial  cells  (Mould  et  al., 
2005), the induction of selective revascularization of the ischemic myocardium but not of other 
organs  (Li et al., 2008a) and  the non‐angiogenic effect  in several  tissues after adenoviral gene 











AAV  vectors  currently  represent  the  only  available  system  to  deliver  genes  to  the  adult 
myocardium and to obtain a prolonged expression over time. Other vector systems, such as the 
first generation  adenoviruses used  in other  studies,  are  fraught with  the  induction of potent 





not  immunogenic  and do not  cause  inflammation  (in  contrast  to  first  and  second generation 
adenoviral vectors); as a consequence,  therapeutic gene expression usually  lasts for month‐ or 
year‐long periods.  In  this  respect,  it  is however worth mentioning  that, while  this conclusion 
certainly holds  true  in mouse, pig and dog, which are not  the natural hosts of human AAVs, 
from which most of the vectors are currently derived, it might be different in humans and non‐
human  primates,  where  the  pre‐existing  immunity  against  the  virus  in  some  cases  might 
determine the elimination of the transduced cells over the first weeks post‐inoculation. ii) AAV 
vectors  do  not  integrate  into  the  host  cell  genome,  however  persist  in  an  episomal  form, 
probably  in as head‐to‐tail or head‐to‐head extrachromosomal concatamers,  in non‐replicating 
cells;  therefore,  they  avoid  the  problem  of  insertional mutagenesis  (in  contrast  to  retroviral 




et  al.,  1994; Dutheil  et  al.,  2000);  since  the  gene  coding  for  this protein  is not present  in  the 
vectors,  site‐specific  integration does  not  occur.  iii)  Possibly  as  a  consequence  of  the  lack  of 
integration into the transduced cells chromosomes, therapeutic gene expression is not subject to 
significant methylation  and  silencing  (in  contrast  to  retroviral  vectors)  (Snyder  et  al.,  1997, 
Challita  et  al.,  1994);  iv)  AAV  vectors  can  be  generated  at  high  titers,  thus  allowing  the 
simultaneous expression of different genes from the same cells or tissues. This property could 
be of great importance in light of the possibility to deliver multiple growth factor coding genes, 
for  example  for  gene  therapy  to  induce  functional  therapeutic  angiogenesis  or  to  improve 
cardiac  function during heart  failure, or  for  the administration of multiple shRNAs  to  inhibit 
different proteins acting along a same metabolic pathway (see Introduction). v) AAV vectors do 
not  experience  the  problem  of  transcriptional  interference  from  different  promoters.  The 



















(Brusselmans  et  al.,  2005)  and  skeletal muscle  cells  (Arsic  et  al.,  2004, Germani  et  al.,  2003). 
Protection  from  apoptosis  was  clearly  evident  when  VEGF‐B  was  administered,  in  both 
cultured  cardiomyocytes  and  after myocardial  infarction  in  vivo,  suggesting  that  a  relevant 
receptor mediating  the  antiapoptotic  effect was  VEGFR‐1.  The  experiments  in  dogs  further 
confirmed  the antiapoptotic and protrophic actions of VEGF‐B167 by maintaining a  low rate of 
apoptosis  and by normalizing  the  levels of  active  capsase‐9  and  ‐3  in myocardial  tissue. The 
recent observations  that VEGF‐B  rescues  retinal and motor neurons  from apoptosis  (Li et al., 
2008,  Poesen  et  al.,  2008)  and  inhibits  the  expression  of  a  number  of  proapoptotic  genes  in 
noncardiomyocyte cells (Li et al., 2008) are fully consistent with our conclusion.  
In addition  to protection  from apoptosis, VEGF‐B  transduction  in  the heart elicited a peculiar 
gene expression profile, consisting of the activation of αMHC and the repression of βMHC and 
skeletal α‐actin, and the increase in SERCA2a, RYR, and PGC1α gene expression, together with 
the  increase  in  the  levels  of  the  cardiac  natriuretic  peptide  mRNAs.  This  pattern  of  gene 
expression resembles the gene expression induced by the thyroid hormone T3, which is usually 
considered  a marker  of  benign,  compensatory  hypertrophic  response  to  cardiac  stimulation 










Of  note,  in  our  experiments,  VEGF‐A  and  VEGF‐B  equally  protected  cardiomyocytes  from 
apoptosis and induced a beneficial gene expression profile; however, VEGF‐B scored superior to 
VEGF‐A  in  preserving  LV  function  after  myocardial  infarction.  These  observations  might 
86 
 
indicate  that  the  two  factors  activate  VEGFR‐1  differently  either  by  exploiting  different  co‐
receptors or by prolonging  the activation of VEGFR‐2 by VEGF‐A, which might be somehow 




In  conclusion,  our  findings  show  that  VEGF‐B  exerts  a  marked  beneficial  effect  on  both 
infarcted myocardium and pacing induced heart failure condition by preventing loss of cardiac 
mass,  by promoting  cardiac  contractility  and  by delaying  the progression  of pacing‐induced 
























The  rAAV vectors used  in  this  study were based on  the pTR‐UF5  construct, provided by N.  
Muzyczka  (University of Florida, Gainesville,FL). The  coding  sequences of  the VEGF165 and 
VEGF‐B  cDNAs  were  obtained  by  RT‐PCR  amplification  from  HL60  and  293  cell  RNA 
respectively and  cloned  in  the  vector  under  the  control  of  CMV  promoter  to substitute 
GFP gene. Cloning and propagation of AAV plasmids was  carried out  in  the  JC 8111 E.  coli 
strain.  Infectious AAV2 vector particles were generated    in   293   cells,   cultured    in   150‐mm‐
diameter   Petri   dishes,    and  then  co‐transfected  each plate  containing  15  μg  of  each  vector 
plasmid  together with 45  μg   of    the   packaging/helper   plasmid,   pDG    (provided   by    J.A. 
Kleinschmidt,   Heidelberg,   Germany),   which  can  express   AAV    and    adenovirus  helper 
functions.  Viral  stocks  were  obtained  by  CsCl  gradient  centrifugation  (Arsic  et  al.,  2003, 
Zacchigna et al., 2008).  rAAV  titers were determined by measuring  the copy number of viral 
genomes  in  pooled,  dialyzed  gradient  fractions  by  competitive  PCR  procedure.  In  this,  the 
primers and the competitors were mapped in the CMV promoter region which was common for 





Primary  cultures  of  cardiac  myocytes  were  prepared  by  following  the  variation  from  the 
original  method  described  by  Simpson  et  al.,  (1982),  Orlowski  et  al.,  (1990).  Hearts  were 
removed  from  1‐day‐old Wistar  rats  anaesthetized  by  ether  under  aseptic  conditions.  The 
ventricles were minced into 2‐3‐mm3 fragments.  






The  dissociated  cells  were  collected  by  centrifugation  and  resuspended  in  growth  media 
(MEM/PB12  with  5%  calf  serum).  To  enrich  myocytes  selectively,  dissociated  cells  were 










the  culture  dish  during  the  preplating  procedure.  Until  the  second  passage,  cells  were 
maintained in the same culture medium (DMEM with 10μg/ml gentamicin) but with 10% fetal 






multiwell  slides  coated with  0.2%  gelatin  (for  immunofluorescence  staining).  The  cells were 
treated  with  rhVEGF‐A  (100  ng/ml),  rhVEGF‐B  (100  ng/ml),  rmuPlGF  (100  ng/ml)  (R&D 
Systems),  thyroid  hormone  (100  nM;  Sigma)  and  phenylephrine  (20  μM;  Sigma).  To  detect 
VEGF  receptors,  growth  factor  stimulation was  performed  at  37°C  for  7 min  in  serum‐free 




Apoptosis was  induced  by  culturing  serum‐starved  cells  for  48 h  at  37°C  in    5% O2/95% N2 
atmosphere  using  hypoxia  incubator  (Billups‐Rothenberg,  San  Diego,  CA)  and  then  the 
conditions were  changed  to 20% O2  for additional 24 h. Cells were  fixed  in 3% PFA and 2% 
sucrose  in  PBS.  Apoptotic  cells were  visualized  by  TUNEL  (TdT‐mediated  dUTP  nick  end 
labeling) assay, using in situ cell death detection kit, TMR red (Roche Diagnostics) according to 
the manufacturerʹs instructions. In case of rat samples, at least 10 high‐magnification fields were 





Total  RNA was  extracted  from  isolated  cardiomyocytes,  fibroblasts, Human Umbilical Vein 
Endothelial Cells (HUVEC) and from left ventricular myocardium of rats and dogs using TRIzol 
reagent  (Invitrogen,Carlsbad,  CA,  USA)  according  to  manufacturerʹs  instructions.  It  was 
digested  by  DNAse  I  and  then  reverse  transcribed  by  using  random  hexameric  primers 
(Invitrogen).  Then  cDNA  was  used  as  template  to  quantity  expression  levels  of  rat  VEGF 
receptors  (VEGFR‐1,  VEGFR‐2,  NP‐1),  canine  VEGF  receptors  (VEGFR‐1,  VEGFR‐2,  NP‐1), 
canine’s  specific VEGF‐B167 and VEGF‐A165, vector  transgenes VEGF‐A, VEGF‐B as well as  α‐
MHC,  β‐MHC,  skACT,  ANF,  BNP,  SERCA2a,  RYR2  and  PGC1α.  The  housekeeping  genes 
GAPDH or rat’s specific and canine’s specific HPRT were used  individually for normalization 
of  the  results. All  the amplifications were performed on BIO‐RAD  (CFX96  real  time  system), 
using pre‐developed and custom‐designed assays  (Applied Biosystems Foster City, CA, USA) 
or SYBRGreen (Bio‐Rad Laboratories, Hercules, CA, USA). 
For  the  detection  of  vector  specific  DNA  in  heart  samples,  total  DNA  were  purified  by 


























































EDTA;  1% NaDoc;  1%  Triton  X‐100;  and  0.1%  SDS)  containing  90  μg/ml    PMSF,    100    μM  
NaVO4,   50   mM   NaF,   20   μg/ml aprotinin, and 20 μg/ml leupeptin (Sigma‐Aldrich). Protein 
concentration  was  determined  by  the  Bradford  method  (Bio‐Rad  Laboratories);  200  μg  of 
proteins  was  resolved  on  6%  SDS‐PAGE  and  transferred  to  nitrocellulose membranes  (GE 
Healthcare, New York, NY, USA). Immunoblots were blocked in 5% bovine serum albumin in 
TBS‐Tween  (50 mM Tris‐HCl, pH 7.4; 200 mM NaCl; and 0.1% Tween 20). Membranes were 
incubated   with   the   following   primary   antibodies   (dilution 1:1000) overnight at 4°C: rabbit 
poly‐clonal  anti‐Flk‐1  (C‐1158;  Santa  Cruz  Biotechnology,  Santa  Cruz,  CA,  USA),  rabbit 





in  Tris‐buffered  saline  and  0.1%  Tween  20  in  blocking  buffer  and  incubated  with  the 
appropriate HPR‐conjugated  secondary  antibodies  for  45 min  at  room  temperature. Proteins 
were  detected  by  enhanced  chemiluminescence  (GE  Healthcare).  In  vivo  VEGF  receptor 
tyrosine phosphorylation was  evaluated  by Western  blot  analysis with  anti‐phosphotyrosine 
antibodies  on  immunoprecipitates. Two milligrams  of  cell  lysates was  incubated with  either 
rabbit polyclonal anti‐Flk‐1 (C‐1158; Santa  Cruz  Biotechnology)  or  rabbit  polyclonal  anti‐Flt‐
1  (C‐17;  Santa  Cruz  Biotechnology)  antisera  coupled  to  Sepharose‐Protein A  (20 ml  packed 
beads/ml  lysate)  overnight  at  4°C  in  agitation.  Sepharose‐protein  A  bound  proteins  were 
washed  4  times  with  RIPA  buffer  and  separated  on  6% SDS–polyacrylamide gels followed 
by  immunoblotting with either   mouse   monoclonal   anti‐phosphotyrosine   antibodies  (PY20; 
Biolegend)  or  with  anti‐Flk‐1  specific  phosphotyrosine  antibodies    (VEGF‐Receptor2‐Y1175;  
Cell  Signaling,  Beverly, MA, USA). 




were  resolved  on  SDS‐PAGE  minigels  and  transferred  to  nitrocellulose  membranes  (GE 
Healthcare).  They were  incubated  with  the following  primary  antibodies  (dilution  1:1000)  
overnight    at    4°C:    rat   monoclonal HSC70    (SPA‐815ʹ    StressGen   Assay   Designs),    rabbit  
polyclonal  anti‐Akt,  rabbit polyclonal  anti‐pAkt  (Thr  308),  rabbit  polyclonal  anti‐pGSK‐3β  
(Ser  9),  rabbit polyclonal  anti  cleaved‐caspase  3,  rabbit   polyclonal  anti‐pFoxO3a  (Thr32),  











The  animal  was  intubated  with  16‐guage  i/v  catheter  intra‐tracheally  and  connected  to 
ventilator (Model 131, Nemi scientific inc.) through PE tubing at the rate of 60 to 65 breaths/min 




blunt  dissection.  The  region  of  left  IInd  vertebral  space  was  dissected  carefully  without 
damaging the lung lobes. The IInd intercostals space was opened widely. The pericardium was 
severed and heart was exposed. Left anterior descending artery was ligated close to left atrium 
with  7/0 mono  filament  nylon  (ref‐1647G,  Ethicon  Inc,  USA).  Ten  μl  of  recombinant  AAV 
vectors were administered  in  three  separate  injections  into  the viable myocardium bordering 
the  infarct  using  tuberculin  syringe  (30G)  (Accu‐fine‐ref‐03543307001, Roche).  The  chest was 
closed, followed by muscle layer and then skin with 4/0 braided silk (Medacta International S.A. 
ref‐S2019).  
Animal  care  and  treatment  were  conducted  in  conformity  with  institutional  guidelines  in 





The  animals were  sedated with  50%  of  the  anaesthetic  dose  used  during MI.  Transthoracic 
echocardiography was  performed  at  one  and  three months  after MI with  echocardiography 
system  (MyLab  30,  Esaote,  Genoa,  Italy)  equipped  with  a  12‐MHz  linear  transducer,  as 
previously described  by Ventura  et  al.,  (2007)  and  Sahn  et  al.,  (1978). Analysis was done  as 









immediately  and  washed  in  PBS.  The  left  ventricle  including  interventricular  septum  was 
dissected out carefully    from atria and  right ventricle   and  then cut  into 3‐ 4   pieces of equal 













For detection  of VEGF  receptors,  immunofluorescence was performed  on  frozen heart  tissue 














3  days  after MI.  The  sections were  permeabilised with  2%  triton X  100  in  PBS  followed  by 
blocking  in  with  5%  FBS  in  PBS  contain  2%  triton  X  100  for  1hr.  The  primary  antibody: 
sarcomeric  α  actinin  (EA‐53, Abcam,  Cambridge MA, USA) was  used  and  diluted  1:100  in 
blocking buffer,  then  followed by  labelling as per manufacturer guidelines  (in  situ  cell death 
detection  kit, TMR  red, Roche Diagnostics). The nuclei were  counter  stained with DAPI  (H‐
1200, Vector laboratories, CA).  
In  case  of  dog  samples,  the  number  of  apoptotic  cardiomyocytes  was  calculated  as  the 
percentage  of  the  TUNEL  positive  per  1000  total  cardiomyocyte  nuclei.  All  Images  were 
acquired  at  room  temperature  with  a  DMLB  upright  fluorescence  microscope  (Leica 
Microsystems, Wetzlar, Germany)  equipped with  charge  coupled  device  camera  (CoolSNAP 
CF;  Roper  Scientific,  Trenton, NJ,  USA)  using MetaView  4.6  quantitative  analysis  software 
(MDS Analytical Technologies, Toronto, Canada).  
The  cardiomyocyte  cross‐sectional  area  in  canine’s  samples  was  quantified  from 
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ABSTRACT Mounting evidence indicates that the func-
tion of members of the vascular endothelial growth factor
(VEGF) family extends beyond blood vessel formation.
Here, we show that the prolonged intramyocardial expres-
sion of VEGF-A165 and VEGF-B167 on adeno-associated
virus-mediated gene delivery determined a marked im-
provement in cardiac function after myocardial infarction
in rats, by promoting cardiac contractility, preserving
viable cardiac tissue, and preventing remodeling of the
left ventricle (LV) over time. Consistent with this func-
tional outcome, animals treated with both factors showed
diminished fibrosis and increased contractile myocar-
dium, which were more pronounced after expression of
the selective VEGF receptor-1 (VEGFR-1) ligand VEGF-B,
in the absence of significant induction of angiogenesis.
We found that cardiomyocytes expressed VEGFR-1,
VEGFR-2, and neuropilin-1 and that, in particular,
VEGFR-1 was specifically up-regulated in hypoxia and on
exposure to oxidative stress. VEGF-B exerted powerful
antiapoptotic effect in both cultured cardiomyocytes and
after myocardial infarction in vivo. Finally, VEGFR-1
activation by VEGF-B was found to elicit a peculiar gene
expression profile proper of the compensatory, hypertro-
phic response, consisting in activation of MHC and
repression of MHC and skeletal -actin, and an increase
in SERCA2a, RYR, PGC1, and cardiac natriuretic pep-
tide transcripts, both in cultured cardiomyocytes and in
infarcted hearts. The finding that VEGFR-1 activation by
VEGF-B prevents loss of cardiac mass and promotes
maintenance of cardiac contractility over time has obvious
therapeutic implications.—Zentilin, L., Puligadda, U.,
Lionetti, V., Zacchigna, S., Collesi, C., Pattarini, L., Ruozi,
G., Camporesi, S., Sinagra, G., Pepe, M., Recchia, F. A.,
Giacca, M. Cardiomyocyte VEGFR-1 activation by
VEGF-B induces compensatory hypertrophy and pre-
serves cardiac function after myocardial infarction.
FASEB J. 24, 000–000 (2010). www.fasebj.org
Key Words: apoptosis  adeno-associated virus, angiogenesis 
gene therapy  gene expression
Members of the vascular endothelial growth factor
(VEGF) family and their receptors are essential regulators
of vasculogenesis, angiogenesis, and vessel mainte-
nance in both embryo and adults (for reviews, see refs.
1–4). In particular, the 165-aa isoform of VEGF-A
(VEGF-A herein for brevity) possesses full angiogenic and
arteriogenic activity, mainly through binding to VEGFR-2,
which stimulates pathways important for mitogenesis,
migration, and survival of endothelial cells (4, 5).
VEGF-A also binds VEGFR-1 with an affinity that is
10 times higher than that of VEGFR-2 (6); however,
the significance of this interaction remains elusive,
especially since this receptor appears unable to trans-
duce an angiogenic signal in endothelial cells (7).
Multiple evidence suggests that VEGF-B, a VEGFR-1-
exclusive ligand that is produced in a heparin-binding
isoform of 167 aa (VEGF-B167) and a diffusible isoform
of 186 aa (VEGF-B186) (7, 8) might selectively be active
in the myocardium. Indeed, the VEGF-B gene, shows
prominent expression in the heart during embryonic
development (9), and mice with knockouts for this
factor display a mild cardiac phenotype, characterized,
at least in one strain, by decreased heart size (10). In
addition, recent evidence indicates that transgenic
mice specifically expressing VEGF-B167 in the myocar-
dium undergo massive myocardial hypertrophy, in the
absence of a significant increase of cardiac angiogene-
sis (11).
A few studies have also explored the effects of
VEGF-A and VEGF-B in the heart after myocardial
infarction. In particular, VEGF-B167 was described to
significantly increase revascularization of the infarcted
myocardium; however, it failed to enhance vascular
growth in the skin or ischemic limb (12). The reasons
1 These authors contributed equally to this work.
2 Correspondence: CGEB Trieste, Molecular Medicine
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for the selective cardiac benefit of VEGF-B delivery
remained unexplained. Another recent study, entailing
the delivery of VEGF-B186 after infarction in pigs and
rabbits using adenoviral vectors, indicated that the
factor induced myocardial-specific angiogenesis and
arteriogenesis and, most notably, improved myocardial
function a few days after vector injection (13). As far as
VEGF-A is concerned, in a previous study of acute
myocardial infarction in dogs, we observed that the
sustained expression of this factor, delivered to the
heart using an adeno-associated virus (AAV)-based vec-
tor determined remarkable recovery of the regional
myocardial contractility, up to 4 wk after injury (14).
Surprisingly, the improvement in myocardial function
started to be significant as early as 48 h after vector
injection, a temporal frame not compatible with the
formation of new blood vessels and suggestive of a
direct effect of VEGF on resident cardiomyocytes, ad-
ditional to angiogenesis (14).
Taken together, this variegated information leaves a
series of essential questions outstanding, including to
what extent the cardiac effects of the VEGFs are sec-
ondary to the induction of angiogenesis or directly
exerted onto myocardial cells, which is the receptor
involved, and how long the beneficial effect exerted by
the factors lasts after cardiac injury. To provide answers
to these questions, we took advantage of the possibility
of delivering in vivo VEGF-A and VEGF-B167 (herein
VEGF-B for brevity) to the heart using vectors based on
the AAV, and to assess their effects for prolonged
periods of time both in normal conditions and after
myocardial infarction. Over the past few years, these
vectors have gained increasing popularity due to several
favorable characteristics, in particular, their ability to
transduce postmitotic cells, including cardiomyocytes,
at high efficiency and to drive gene expression for very
prolonged periods of time in the absence of noticeable
inflammation (15, 16).
Here, we show that the AAV-mediated, intramyocar-
dial expression of VEGF-A and, most notably, of
VEGF-B determines a marked improvement in cardiac
function after permanent coronary artery occlusion in
rats, ensuing from the direct protection of cardiomyo-
cytes from apoptosis and up-regulation of genes driving
compensatory, hypertrophic response. These results
clearly indicate that the role of VEGFs in the heart
extends beyond their angiogenic properties, and point
toward VEGFR-1 signaling as an important mediator of
cardiomyocyte function, with clear therapeutic implica-
tions.
MATERIALS AND METHODS
Production, purification, and characterization of rAAV
vectors
rAAV vectors were prepared by the AAV Vector Unit at ICGEB
Trieste (http://www.icgeb.org/avu-core-facility.html), as de-
scribed previously (17, 18). AAV titers were in the range of 1 
1012 to 1  1013 genome copies (gc)/ml.
Animal studies and echocardiography
Animal care and treatment were conducted in conformity
with institutional guidelines in compliance with national and
international laws and policies (European Economic Com-
munity Council Directive 86/609, OJL 358, December 12,
1987), after institutional review board approval. Myocardial
infarction (MI) was produced in male Wistar rats at 2 mo of
age, by permanent left anterior descending coronary artery
ligation, as described previously (19). After ligation, they were
immediately injected into the LV with 10 l of recombinant
AAV vectors, corresponding to 5  1010 gc, with 3 separate
injections into the viable myocardium bordering the infarct
using a tubercoline syringe with a 30-gauge needle. Four
groups of animals were studied (n10/group), receiving
AAV2-VEGF-A, AAV2-VEGF-B, AAV2-LacZ, or saline.
To evaluate global and regional LV function, transthoracic
echocardiography was performed before thoracotomy, 28 d and
3 mo after MI in sedated rats with a commercially available
echocardiography system (MyLab 30; Esaote, Genoa, Italy)
equipped with a 12-MHz linear transducer, as described previ-
ously (20). Analysis was as recommended by the American
Society of Echocardiography (21); all measurements were per-
formed by an experienced cardiologist and an echocardiogra-
phy expert blinded to treatment groups.
At the end of the echocardiography study, hearts were
collected, and the LV, including the interventricular septum,
was carefully dissected. After washing in PBS, each specimen
was cut into 4 or 5 pieces of equal thickness from base to apex,
fixed in 4% paraformaldeyde, and embedded in paraffin for
histological analysis. Infarct size was measured on 5-m-thick
sections as the percentage of (endocardialepicardial cir-
cumference of infarct area)/(endocardialepicardial cir-
cumference of LV).
For the detection of apoptosis in vivo, infarcted hearts were
collected and snap-frozen 3 d after MI. Frozen sections from
each sample were fixed in 4% buffered paraformaldehyde
(PFA) and then treated as described above for immunostain-
ing and TUNEL.
Isolation and treatment of neonatal rat ventricular
cardiomyocytes
Ventricular myocytes from 1- to 2-d-old rats were prepared
according to a previously detailed protocol, yielding 90%
purity (22). Cells were collected and plated at a density of 500
cells/mm2 into 100-mm dishes (for RNA and protein analy-
sis), or multiwell slides coated with 0.2% gelatin (for immu-
nofluorescence staining). When indicated, cells were treated
with rhVEGF-A (100 ng/ml; R&D Systems, Minneapolis, MN,
USA), rhVEGF-B (100 ng/ml; R&D Systems), thyroid hor-
mone (100 nM; Sigma, St. Louis, MO, USA) and phenyleph-
rine (20 M; Sigma). For the detection of VEGF receptors,
growth-factor stimulation was performed at 37°C for 7 min in
serum-free medium containing 4.5 g/L glucose, 0.1% w/v
BSA, 4 g/ml B12, 10 g/ml insulin, and 10 g/ml trans-
ferrin.
Apoptosis was induced by culturing serum-starved cells for
48 h at 37°C in a 5% O2-95% N2 atmosphere using a hypoxia
incubator chamber (Billups-Rothenberg, San Diego, CA,
USA) and then switching to 20% O2 for an additional 24 h.
Cells were then fixed in 3% PFA and 2% sucrose in PBS.
Apoptotic cells were visualized by the TUNEL (TdT-mediated
dUTP nick-end labeling) assay, using the in situ cell death
detection kit, TMR red (Roche Diagnostics, Mannheim, Ger-
many), according to the manufacturer’s instructions. At least
10 high-magnification fields were counted for each experi-
mental condition. Analysis of cardiomyocyte survival was
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performed using the Live&Dead assay (Molecular Probes,
Eugene, OR, USA) after treatment with 200 nM epirubicin
for 90 m in serum free medium.
Quantification of nucleic acids by real-time PCR
Total RNA from isolated cardiomyocytes or dissected LV
heart tissue samples was extracted using TRIzol reagent
(Invitrogen, Carlsbad, CA, USA) according to the manufac-
turer’s instructions, and reverse-transcribed using hexameric
random primers.
Quantification of gene expression was performed by real-
time PCR, using predeveloped and custom-designed assays
(Applied Biosystems, Foster City, CA, USA) or SYBRGreen
(Bio-Rad Laboratories, Hercules, CA, USA). Total RNA from
isolated cardiomyocytes or dissected LV heart tissue samples
was extracted using TRIzol reagent (Invitrogen) according to
manufacturer’s instructions and reverse transcribed using
hexameric random primers. The cDNA was used as a tem-
plate for real-time PCR amplification to detect the expression
levels of the rat VEGF receptors (VEGFR-1, VEGFR-2, NP-1), as
well as of -MHC, -MHC, sk -actin, ANF, BNP, SERCA2a,
RYR2, and PGC1. The housekeeping genes GAPDH and
HPRT were used to normalize the results.
For the detection of vector specific DNA in heart samples,
total DNA, purified by Proteinase K/phenol-chloroform ex-
traction method, was subjected to real-time PCR amplifica-
tion using a TaqMan probe and primers that specifically
match sequences in the CMV promoter, common to all AAV
vectors used in this study.
Sequences of primers and probes used
Primers
Rat PGC-1 F 5-TGCAGCCAAGACTCTGTATGG-3, R 5-
GGCAAAGAGGCTGGTCCTC-3; rat BNP: F 5-CAGCTCT-
CAAAGGACCAAGG-3, R 5-GCCCAAAGCAGCTTGAACTA-
3; rat HPRT: F 5-GCCCTTGACTATAATGAGCACTCAG-3,
R 5-GTAGATTCAACTTGCCGCTGTTT-3; mouse iVEGF-B:
F 5-TTGCACTGCTGCAGCTGGCTC-3, R 5-GCTGGGCAC-
TAGTTGTTTGA-3; CMV promoter: F 5-TGGGCGGTAG-
GCGTGTA-3, R 5-CGATCTGACGGTTCACTAAACG-3.
Taqman probes (assay)
Rat -MHC: (FAM)-Rn00568328_m1; rat -MHC: (FAM)-
Rn00568304_m1; rat RYR2: (FAM)-Rn01470303_m1; rat SERCA2a:
(FAM)-Rn00568762_m1; rat ANP: (FAM)-Rn00561661_n1; rat sk
-actin: (FAM)-Rn00570060_g1; rat Flk1: (FAM)-Rn 00564986_m1;
rat Flt1: (FAM)-Rn 01409523_g1; rat NP1: (FAM)-Rn 00435380_m1;
human VEGF-A165: (FAM)-Hs00173626_m1; rat GAPDH: (VIC)-
TaqMan Endogenous control (4352338E); CMV: (FAM)-
TGGGAGGTCTATATAAGC.
Histology and immunofluorescence
Vasculature staining was performed on paraffin-embedded
sections, blocked for 1 h with 2% BSA in PBS; endothelial
cells were detected using FITC-conjugated Lycopersicum escu-
lentum lectin (Vector Laboratories) and vascular smooth
muscle cells (VSMCs) using a Cy3-conjugated anti--SMA
mouse monoclonal antibody (clone 1A4, Sigma). Pericytes
were detected using a rabbit polyclonal anti-NG2 antibody
(Chemicon, Temecula, CA, USA) on 4% paraformaldehyde-
fixed frozen sections after overnight blocking with 5% horse
serum. The detection of VEGF receptors by immunofluores-
cence was performed on frozen sections (5 m thick), fixed
in IHC Zinc Fixative (Pharmingen, BD Biosciences, San Jose,
CA, USA), and blocked for 30 m with 5% goat or 5% horse
serum in PBS, depending on the secondary antibody.
The following primary antibodies were used for immuno-
fluorescence studies in cardiomyocytes: goat anti-mouse Flk-1
(AF644; R&D Systems), 1:100; goat polyclonal anti-mouse
Flt-1 (AF471; R&D Systems), 1:20; goat polyclonal anti-rat
neuropilin-1 (AF566; R&D Systems), 1:50; and mouse anti--
sarcomeric actinin monoclonal antibody (EA-53; Abcam,
Cambridge MA, USA), 1:100. Alexa Fluor 594 donkey anti-
goat, Alexa Fluor 594 donkey anti-rabbit, and Alexa Fluor 488
donkey anti-mouse were used as secondary antibodies (Mo-
lecular Probes). Nuclei were counterstained with DAPI.
Images were acquired at room temperature with a DMLB
upright fluorescence microscope (Leica Microsystems, Wet-
zlar, Germany) equipped with a charge-coupled device cam-
era (CoolSNAP CF; Roper Scientific, Trenton, NJ, USA) using
MetaView 4.6 quantitative analysis software (MDS Analytical
Technologies, Toronto, ON, Canada).
Immunoprecipitation and Western blot analysis
For the detection of VEGF receptors, freshly isolated cardio-
myocytes were allowed to attach in 100-mm dishes and then
left overnight in serum-free medium. Stimulation was per-
formed by incubating the cell cultures at 37°C for 7 min in 2
ml of serum or 2 ml of serum-free medium containing 50
ng/ml recombinant huVEGF-A165 and 100 ng/ml huVEGF-B.
After washing with PBS on ice, samples were lysed in RIPA
buffer (20 mM Tris-HCl, pH 7.4; 150 mM NaCl; 5 mM EDTA;
1% NaDoc; 1% Triton X-100; and 0.1% SDS) containing 90
g/ml PMSF, 100 M NaVO4, 50 mM NaF, 20 g/ml
aprotinin, and 20 g/ml leupeptin (Sigma-Aldrich). Protein
concentration was determined by the Bradford method (Bio-
Rad Laboratories); 200 g of proteins was resolved on 6%
SDS-PAGE and transferred to nitrocellulose membranes (GE
Healthcare, New York, NY, USA). Immunoblots were blocked
in 5% bovine serum albumin in TBS-Tween (50 mM Tris-HCl,
pH 7.4; 200 mM NaCl; and 0.1% Tween 20). Membranes were
incubated with the following primary antibodies (dilution
1:1000) overnight at 4°C: rabbit polyclonal anti-Flk-1 (C-1158;
Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit poly-
clonal anti-Flt-1 (C-17; Santa Cruz Biotechnology), mouse mono-
clonal anti-phospho-Tyrosine (PY20; Biolegend, San Diego, CA,
USA), goat polyclonal anti-rat neuropilin-1 (AF566; R&D Sys-
tems), and mouse monoclonal tubulin (B-5–1-2; Sigma). Mem-
branes were then washed in Tris-buffered saline and 0.1%
Tween 20 in blocking buffer and incubated with the appro-
priate HPR-conjugated secondary antibodies for 45 m at
room temperature. Proteins were detected by enhanced
chemiluminescence (GE Healthcare).
In vivo VEGF receptor tyrosine phosphorylation was evalu-
ated by Western blot analysis with anti-phosphotyrosine anti-
bodies on immunoprecipitates. Two milligrams of cell lysates
was incubated with either rabbit polyclonal anti-Flk-1 (C-1158;
Santa Cruz Biotechnology) or rabbit polyclonal anti-Flt-1
(C-17; Santa Cruz Biotechnology) antisera coupled to Sepha-
rose-Protein A (20 ml packed beads/ml lysate) overnight at
4°C with agitation. Sepharose-protein A-bound proteins were
washed 4 times with RIPA buffer and separated on 6%
SDS–polyacrylamide gels, followed by immunoblotting with
either mouse monoclonal anti-phosphotyrosine antibodies
(PY20; Biolegend) or with anti-Flk-1 specific phosphotyrosine
antibodies (VEGF-Receptor2-Y1175; Cell Signaling, Beverly,
MA, USA).
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Statistical analysis
One-way ANOVA and Bonferroni/Dunn’s post hoc test were
used to compare multiple groups. Pairwise comparison be-
tween groups was performed using the Student’s t test.
Dose-response effect was assessed by regression analysis. P 
0.05 was set as a threshold for statistical significance.
RESULTS
Long-term effects of AAV-mediated VEGF-B and
VEGF-A expression in normal rat myocardium
To comparatively assess the effects of VEGF-A and
VEGF-B, we generated two AAV vectors, based on AAV
serotype 2 (AAV2), expressing the respective cDNAs in
a constitutive manner from the CMV IE gene promoter.
The efficiency of transduction and expression of these
vectors were first assessed by injecting 5  1010 AAV
particles into the LV free wall of normal rats; control
animals were injected with either saline or AAV2-LacZ
(n6/group). As detected by real-time PCR quantifica-
tion, the levels of expression of the two transgenes was
persistent at both 30 d (not shown) and 90 d postinjec-
tion (Fig. 1A, B). Consistent with our previous observa-
tions (14, 17, 23), no inflammatory response was de-
tected in the animals injected with either saline or
AAV2-LacZ at either time point (data not shown). No
differences were detected between AAV2-LacZ- or sa-
line-injected animals in none of the parameters consid-
ered throughout this work, neither in normal nor in
infarcted animals. The results obtained in the two
groups were therefore pooled and collectively labeled
as control in all figures.
Representative images of the vasculature in the AAV-
injected and control hearts at 30 d after injection are
shown in Fig. 1C after staining with anti-CD31 and
anti-SMA antibodies to detect endothelial and smooth
muscle cells (SMCs), respectively. Consistent with our
previous findings in the normoperfused skeletal muscle
(17, 18), we observed that the prolonged expression of
VEGF-A in the heart determined a marked angiogenic
response, characterized by a significant increase in the
number of capillaries (Fig. 1D) and, most notably, of
small arteries in the 20- to 250-m-diameter range (Fig.
1E), with a consequent increase in the arteriole/capil-
lary ratio (Fig. 1F). In contrast, AAV2-VEGF-B had a
very modest angiogenic effect, with the exception of
the sporadic formation of enlarged vascular structures,
connected to the circulation, apparently devoid of
SMA- and NG2-positive mural cells (arrows in Fig. 1C
and Supplemental Fig. 1).
VEGF-B, a specific VEGFR-1 ligand, preserves
myocardial function after infarction
Next, we assessed the effects of the two vectors on
cardiac function after myocardial infarction. Rats
(n10/group) underwent permanent left descendent
coronary artery ligation and immediate injection into
the LV peri-infarcted area of 5  1010 viral particles of
AAV2-VEGFA, AAV2-VEGFB, AAV2-LacZ, or saline
(pooled control group). Global and regional LV func-
tion was analyzed by echocardiography at 1 and 3 mo
after infarction; representative M-mode echocardio-
grams at the latter time point are shown in Fig. 2A. The
LV ejection fraction (LVEF) and LV fractional shorten-
ing (LVFS) were significantly preserved in infarcted rats
injected with both AAV2-VEGF-B and AAV-VEGF-A,
compared to untreated animals, in the absence of
significant changes in heart rate (P0.05 for both
treatments at either time point; Fig. 2B, C, respectively).
Preservation of LV performance was significantly more
pronounced in the infarcted hearts treated with
Figure 1. Effects of AAV-mediated VEGF-B and VEGF-A
expression in normal rat myocardium. A, B) Levels of
VEGF-A (A) and VEGF-B (B) transgene transcripts evaluated
by real-time PCR analysis on total ventricular RNA extracted 90 d after vector injection. Transgene expression levels (n8)
are normalized for those of the endogenous HPRT gene. C) Left panels: representative immunostainings of the vasculature
in rat myocardium injected with AAV-LacZ (control), AAV-VEGF-A, and AAV-VEGF-B, as indicated. Right panels: enlarged
views. Capillaries were detected using FITC-conjugated L. esculentum lectin (Vector Laboratories), staining endothelial cells,
and VSMCs using a Cy3-conjugated anti-SMA mouse monoclonal antibody; nuclei were stained in blue with DAPI. Scale
bars  500 m. D, E) Quantification of capillary and arteriole density. F) Ratio between number of arteries and capillaries.
Values are expressed as means 	 se. *P  0.05.
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VEGF-B at 1 mo and, in particular, at 3 mo of treatment
(LVEF: 48	8 vs. 85	9%; LVFS: 29	8 vs. 52	7% in
control and VEGF-B animals, respectively; P0.05 in all
cases). At both time points, the LV end-diastolic diam-
eter (EDD) and LV end-systolic diameter (ESD) were
also significantly reduced in rats that had received
AAV2-VEGF-B (EDD: 7.9	1.2 and 6.8	0.8 mm; ESD:
5.9	0.7 and 3.8	0.9 mm in control and VEGF-B ani-
mals at 3 mo of treatment; P0.05 in all cases; Figs. 2D,
E, respectively).
The changes of regional cardiac contractility are
shown in Fig. 2F, G. At both 1 and 3 mo after cardiac
gene transfer, the LV end-systolic wall thickening
(AWTK) in the border zone of the infarcted hearts
injected with AAV2-VEGF-B was markedly improved
compared to control rats (18.5	3.0 vs. 32.2	2.9% for
control and VEGF-B at 3 mo; P0.05). Similarly, the LV
anterior wall end-diastolic and end-systolic thickness
(AWTd and AWTs, respectively) of the border zone,
two indexes of regional mass, were selectively preserved
in the infarcted hearts expressing VEGF-B (P0.05 in
both cases; Supplemental Fig. 2A, C). No changes in
the function and structure of the LV remote regions of
the infarcted hearts were observed in any experimental
group.
With the caveat that echocardiography in small ani-
mals might not provide sufficient sensitivity to detect
differences in thickening of the border zone of a small
MI, these data unanimously indicated that the pro-
longed expression of both VEGF-A and VEGF-B mark-
edly improved recovery of LV performance after infarc-
tion.
Animals were sacrificed at 3 mo by induction of
ischemia, and the hearts were examined for postinfarc-
tion fibrosis and chamber remodeling. Morphometric
analysis of trichromic-stained LV sections showed that
the anterior wall of infarcted control animals under-
went considerable thinning, consistent with the echo-
cardiographic results. In contrast, the AAV2-VEGFA-
and, more remarkably, the AAV2-VEGFB-treated hearts
showed significant preservation of contractile tissue
and reduction of the fibrotic area (see Fig. 3A for
representative cross-sections and Fig. 3C for high-mag-
nification view of the extent of fibrotic substitution);
the infarct size was determined as 36.2 	 6.0% of the
LV in control animals vs. 21.5 	 2.5 and 17.2 	 3.5% in
the VEGF-A- and VEGF-B-expressing animals, respec-
tively (P0.05 in both cases; Fig. 3B).
Molecular characterization of heart samples on ani-
mal sacrifice confirmed the persistence of the vector
genomes in the injected myocardium (Supplemental
Fig. 3A). Consistently, AAV-mediated expression of
both VEGF-A and VEGF-B was detected by real-time
PCR using transgene specific primers (Supplemental
Fig. 3B). The local expression of the transgenes did not
induce significant variation of the levels of VEGF recep-
tors mRNA (Supplemental Fig. 3C).
Similar to noninfarcted hearts (Fig. 1), the animals
treated with VEGF-A showed a significant increment in
the number of capillaries and arterioles, which was not
evident in those injected with AAV2-VEGF-B (see Fig.
3D for representative images and Fig. 3E, F for quanti-
fication of the number of capillaries and arterioles,
respectively).
Thus, the marked recovery of LV ventricular perfor-
mance after myocardial infarction, in particular, ob-
served on VEGF-B gene delivery occurred in the ab-
sence of significant induction of angiogenesis.
Cardiomyocytes express functional VEGF receptors in
vitro and in vivo
To explore whether VEGF exerted a direct effect on
cardiomyocytes, we first assessed the levels of expres-
sion of the VEGF receptors in these cells. A first set of
experiments was performed using total RNA extracted
from primary cultures highly enriched in -actinin-
positive cardiomyocytes by three subsequent subplating
steps (
90% purity; see Materials and Methods and ref.
22); these cultures were established along complemen-
tary cultures of -actinin-negative stromal cells (1%
-actinin positivity). Both cultures were maintained for
Figure 2. Echocardiographic analysis in AAV2-injected and control
mice at 1 and 3 mo after MI. A) Representative transthoracic
M-mode echographic profiles. B) LV ejection fraction (LVEF). C)
LV fractional shortening (LVFS). D) LV end-diastolic diam-
eter(EDD). E) LV end-systolic diameter (ESD). F) LV end-systolic
anterior wall thickening (AWTK). G) LV end-systolic posterior wall
thickening (PWTK). Values are expressed as means 	 se. *P 
0.05.
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7–14 d. We found that VEGFR-1, VEGFR-2, and Np1
were all expressed in neonatal rat cardiomyocytes,
albeit at levels that were 3 orders of magnitude lower
than those of human umbilical vein endothelial cells
(HUVECs); stromal cells only expressed VEGFR-1 and
Np1, not VEGFR-2 (Fig. 4A). Of potential interest,
expression of VEGFR-1 selectively increased when
cardiomyocytes were placed in a hypoxic environ-
ment (2% O2) or exposed to oxidative stress (H2O2
100 M); 
5 fold and 3-fold induction, respec-
tively; Fig. 4B).
Expression of VEGFR-1, VEGFR-2, and Np1 was also
detected by Western blot analysis in neonatal cardio-
myocyte cell lysates (Fig. 4C, top panel). Most nota-
bly, these receptors appeared to be functional, since
immmunoprecipitation using specific anti-VEGFR-1
and anti-VEGFR-2 antibodies followed by Western
blot analysis with anti-phosphotyrosine antibodies
revealed specific phosphorylation of both VEGFR-1
and VEGFR-2 in response to recombinant VEGF-A
and of VEGFR-1 in response to recombinant VEGF-B
(Fig. 4C, bottom panel).
Finally, expression of VEGF receptors was also de-
tected by immunofluorescence on histological sections
of frozen adult rat heart tissue (Fig. 4D). Of interest,
while the localization of VEGFR-2 and Np1 fluores-
cence was consistent with the prominent expression of
these receptors on vascular endothelial cells, VEGFR-1
appeared to cluster at the intercalated disks between
cardiomyocytes.
VEGF-A and VEGF-B inhibit cardiomyocyte apoptosis
The reduction in infarct size and preservation of mus-
cle mass in animals treated with VEGF-A and VEGF-B
suggested that these factors either stimulated the lim-
ited cardiomyocyte proliferation that is normally ob-
served in the infarct border zone (24) or prevented
delayed cardiomyocyte loss after infarction. The former
possibility was tested by evaluating the effects of the two
factors on cardiomyocyte proliferation. Under standard
culture conditions (22), 0.2% of neonatal cardio-
myocytes incorporate BrdU at d 1 after isolation; this
percentage was unchanged on addition of either re-
combinant VEGF-A or VEGF-B (Fig. 5A). We also
explored the possibility that the expression of the two
factors after AAV-mediated gene delivery in the in-
farcted hearts in vivo might promote regeneration of
the damaged cardiac tissue through stimulation of
cardiomyocyte replication or cardiac stem cell recruit-
ment. However, we failed to detect any increase in the
number of BrdU-positive, proliferating cells in infarct
border zone in any of the treated animals compared to
controls (data not shown).
An alternative possibility is that the VEGFs might
induce protection of cardiomyocytes against ischemic
death. To test this hypothesis, we exposed cardiomyo-
cytes to hypoxia for 48 h followed by 24 h reoxygen-
ation either in the absence, or presence, of recombi-
nant VEGF-B or VEGF-A. As revealed by a TUNEL assay,
the percentage of apoptotic cells dropped from
Figure 3. Morphometric and histological analysis of infarcted hearts 3 mo after gene transfer. A) Representative Azan trichrome
stainings of LV transverse sections of control and AAV2-VEGF-A- and AAV2-VEGF-B-injected hearts. B) Quantification of infarct
size (% of LV). C) High-magnification (200) microphotographs of trichrome-stained sections showing the extent of fibrotic
substitution of the infarcted scars (asterisks); arrows indicate new vessels in the VEGF-A expressing hearts. D) Visualization of
vessels by immunofluorescence in the peri-infarcted area (green, endothelial cells; red, -SMA cells; blue, cell nuclei).
E) Quantification of capillary density (FITC-lectin vessels). F) Quantification of -SMA arterioles. Values are expressed as
means 	 se. *P  0.05. Scale bars  200 m.
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17.2 	 3.3% of controls to 7.6 	 1.2 and 8.0 	 1.0%
in the VEGF-A and VEGF-B-treated cultures, respec-
tively (P0.05 in both cases; Fig. 5B). The protection
from death was also evident when cardiomyocytes were
exposed for 90 min to the cardiotoxic drug epirubicin.
Under these conditions, the number of dead cells in
the cultures added with either recombinant VEGF
decreased from 61.8 	 8.5% in controls to 13.8 	 6.0
and 11.2 	 4.2% in the VEGF-A and VEGF-B-treated
cultures, respectively (P0.05 in both cases; Fig. 5C).
Consistent with the conclusion that VEGF exerts an
antiapoptotic effect, we also observed that the number
of TUNEL-positive cells in the infarct border zone at
48 h after infarction was significantly lower in the
animals injected with either AAV2-VEGF-A or AAV2-
VEGF-B compared to controls (from 17.2	8.0 to
4.5	1.4 and 5.5	1.5%, respectively; n4/group; P 
0.05 vs. control in both cases; Fig. 5D).
VEGF-A and VEGF-B activate expression of genes
involved in the regulation of myocardial contractility
and metabolism
Besides protection from apoptosis, the changes in
regional contractility observed in the infarcted animals
treated with VEGF-A and VEGF-B also suggested that
these factors might directly affect cardiomyocyte activ-
ity. To further explore this issue, we analyzed the levels
of expression of a series of genes involved in cardio-
myocyte function in cells treated for 24 h with recom-
binant VEGF-A or VEGF-B. In particular, we evaluated
the expression profile of genes specifically involved in
cardiac contractility (MHC, MHC), intracellular cal-
cium handling (SERCA2a, RYR2), mitochondrial ener-
getics (PGC1), and of some typical genetic markers of
hypertrophy, such as skeletal -actin (sk -act) and
cardiac natriuretic peptides (ANF and BNP). The mod-
ifications in the levels of expression of these genes were
compared to those found in response to the -adren-
ergic agonist phenylephrine (PE) or to the thyroid
hormone triiodo-l-thyronine (T3). These compounds
are known to induce characteristic myocyte hypertro-
phy responses, consisting in the up-regulation of fetal
genes of pathological hypertrophy (including MHC,
sk -act, ANF, and BNP) in the case of PE (25, 26), while
reproducing physiological hypertrophy (increase of
MHC and SERCA2a, and repression of MHC tran-
scripts) in the case of T3 (27, 28).
Both VEGFs were found to increase expression of
MHC (which is the predominant contractile protein
in adult rodents; ref. 29) and repress that of MHC,
similar to T3, and different from PE (P0.05 between
VEGF-treated and control cardiomyocytes). VEGF-B
also inhibited expression of sk -act. Both factors pro-
moted elevation of the ANF and BNP transcripts and,
most notably, they also determined elevation of the
SERCA2a, RYR, and PGC1 mRNAs, similar to T3
(P0.05) (Fig. 6).
Taken together, these data indicate that both
VEGF-A and VEGF-B evoke, in isolated cardiomyocytes,
a gene expression program proper of compensatory
hypertrophy similar to that induced by the thyroid
hormone. Of note, this response can be initiated by the
sole treatment with VEGF-B, a selective VEGFR-1 li-
gand.
Figure 4. Cardiomyocytes express functional VEGF receptors. A) Levels of
expression of VEGFR-1, VEGFR-2, and Np1 by real-time PCR in rat -actinin-
positive neonatal cardiomyocytes, -actinin-negative cardiac stromal cells, and
HUVECs. B) Levels of expression of VEGF receptors in cardiomyocytes in
response to hypoxic (2% O2) or oxidative stress (H2O2 100 M). C) Top panel:
Western blotting showing specific detection of VEGFR-1, VEGFR-2, and Np1 in
cell lysates of neonatal cardiomyocytes, with or without stimulation with fetal
calf serum (FCS), recombinant VEGF-A, or VEGF-B, as indicated. Bottom
panel: immunodetection of VEGF receptor phosphorylation on stimulation.
VEGFR-1- or VEGF-2-specific immunocomplexes were probed with the indi-
cated anti-phosphotyrosine-specific antibodies. D) Immunofluorescence stain-
ing of VEGFR-1, VEGFR-2, and Np1 on histological sections of frozen adult rat
heart tissue. Larger pictures at left and magnifications at right show fluores-
cence in all three channels (red, receptors; green, sarcomeric -actinin; blue,
cell nuclei); smaller pictures show 2-channel fluorescence (top: blue/red;
bottom: blue/green). Arrows indicate VEGFR-1 clusters at the intercalated disks between cardiomyocytes. Scale bars  200
m. Values are expressed as means 	 se. *P  0.05.
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VEGF-B overexpression counteracts the induction of
genes involved in pathological LV remodeling after
myocardial infarction
To further explore the effects of VEGF receptor stim-
ulation in vivo, we also analyzed the expression profile
of LV tissue from a subset of AAV-transduced, infarcted
animals (n6/group) by real-time PCR. Consistent
with the echocardiography results, control animals at 3
mo after infarction showed the characteristic pattern of
gene expression commonly associated with pathologi-
cal LV remodeling, involving significant (P0.05) over-
expression of MHC and sk -act contractile proteins,
an increase in the cardiac natriuretic peptides, and a
decrease in the levels of SERCA2a, RYR, and PGC1
mRNAs as compared to normal rats (Fig. 7). Remark-
ably, these modifications were all significantly counter-
acted by both VEGF-A and, most notably, VEGF-B
overexpression. In the VEGF-A and VEGF-B-treated
hearts, the levels of MHC, ANF, BNP, SERCA2a, and
RYR were unchanged compared to normal animals;
those of MHC and PGC1 were even significantly
Figure 5. VEGFs protect cardiomyocytes from apoptosis in vitro and in vivo.
A) Recombinant VEGFs do not induce neonatal rat cardiomyocyte prolifera-
tion. Left panels: representative images of -actinin-positive cardiac myocytes
showing positivity to BrdU immunostaining (red; arrows) with or without
exposure to recombinant VEGF-B. Right panel: quantification of BrdU-positive
nuclei. B) VEGFs protect cardiomyocytes from apoptosis in vitro. Left panels:
representative images of TUNEL cardiomyocytes (arrows) exposed to hyp-
oxia for 48 h followed by 24 h with or without VEGF-B. Right panel:
quantification of TUNEL nuclei. C) Left panels: representative images of a
cell viability assay based on the simultaneous determination of live (green,
calcein) and dead (red, ethidium homodimer-1, Eth; arrow) cardiomyocytes
after in vitro exposure to epirubicin in the presence or absence VEGF-B. Right
panel: quantification of dead cells. D) Detection of apoptotic nuclei in vivo at
d 3 after MI. Right panels: representative images of TUNEL nuclei (arrows) in infarcted hearts from a control and a
VEGF-B-injected mouse; cardiomyocytes are stained by positivity to -actinin (green). Right: quantification of TUNEL
nuclei. Values are expressed as means 	 se. *P  0.05. Scale bars  20 m (A, D); 50 m (B, C).
Figure 6. Cardiomyocyte treatment with VEGF-A and VEGF-B induces
a gene expression pattern proper of compensatory hypertrophy re-
sponse. Results of real-time PCR quantification of the levels of expres-
sion of the indicated factors in neonatal rat cardiomyocytes after
exposure to recombinant VEGF-A, VEGF-B, phenylephrine (PE), or
thyroid hormone (T3). Values are expressed as means 	 se, after
normalization for HPRT expression. *P  0.05 vs. untreated control
cells (C).
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increased, and that of sk -act was decreased (P0.05
in all cases).
Collectively, these observations further support the
conclusion that VEGFR-1 stimulation by specific ligands
exerts a beneficial effect on the myocardial tissue.
DISCUSSION
A relevant conclusion of this study is that the continu-
ous expression of VEGF after myocardial infarction
exerts prolonged beneficial effects in terms of increase
in contractility, prevention of pathological LV remod-
eling, and preservation of viable cardiac tissue. All our
findings are consistent with the notion that VEGF
exerts these effects through the activation of VEGFR-1
expressed in cardiomyocytes: 1) isolated rat cardiomy-
ocytes express VEGFR-1; 2) VEGFR tyrosine kinases
becomes activated on binding to the recombinant
VEGFR-1 ligands PlGF and VEGF-B; 3) the levels of
expression VEGFR-1 are selectively up-regulated in
hypoxia and on oxidative stress; and 4) most notably,
cardiomyocyte treatment with VEGF-B activates a pecu-
liar gene expression program, reminiscent of that ob-
served during compensatory hypertrophy. In this con-
text, the localization of VEGFR-1 in the intercalated
disks between cardiomyocytes appears intriguing, since
these structures also act as mechanical stress sensors
during muscle contraction, besides supporting synchro-
nized cardiomyocyte contraction (30). Further studies
are clearly required to understand the functional sig-
nificance of VEGFR-1 localization at these structures. In
this respect, it might be worth noting that, both in
zebrafish and in cultured rat cardiomyocytes, VEGF-A
has been reported to exert a positive inotropic effect by
increasing calcium transients through its interaction
with VEGFR-1 and downstream PLC-1 activation (31).
The observation that VEGFs exert a direct activity on
cardiomyocytes is indeed not surprising. A large body
of evidence now indicates that expression of the VEGF
receptors is not restricted to endothelial cells and that
their ligands exert a variety of fundamental functions in
other cell types. These nonangiogenic functions of
VEGFs include, among others, the potential to prevent
neuronal cell death from ischemia and promote neu-
rogenesis (32, 33), the capacity to stimulate hepatocyte
regeneration after liver damage (34), and the ability to
promote osteoblast migration and differentiation (35,
36). In the skeletal muscle, we showed that VEGF-A
exerts a powerful regenerative effect after ischemic and
nonischemic muscle damage by promoting satellite cell
differentiation (23, 37). Finally, several groups have
described an effect of VEGF-A on various cells of
hematopoietic origin, showing that this factor is able to
mediate monocyte chemotaxis (38), hematopoietic
stem cell survival (39), mobilization of endothelial
progenitor cells (40), and the selective recruitment of a
population of bone marrow-derived, CD11b mononu-
clear cells, which are essential for vessel maturation at
the sites of adult neoangiogenesis (18).
The different VEGF receptors appear variably in-
volved in mediating these nonangiogenic functions of
their ligands. For example, skeletal muscle regenera-
tion appears to selectively require VEGFR-2, since PlGF
is ineffective at stimulating this process compared to
VEGF-A (23); in contrast, the effects on monocytes
require VEGFR-1 (38), those on hematopoietic progen-
itors are mediated by both VEGFR-1 and VEGFR-2
(39–41), and those determining the recruitment of
bone marrow-derived CD11b cells require the pres-
ence of Np1 (18).
The prolonged expression of VEGF-B in the heart
elicits only a modest angiogenic response compared to
VEGF-A, essentially consisting in the generation of
enlarged vessels devoid of -SMA-positive cells. A lack
Figure 7. AAV2-mediated VEGF-B and VEGF-A expression prevents
pathological hypertrophy gene expression in the myocardium of
infarcted rats. RNA was extracted from the left ventricle of control and
AAV2-VEGF-B- and AAV2-VEGF-A injected rats at 3 mo after MI. Values
are expressed as means 	 se of the real-time PCR quantifications of
the levels of expression of the indicated factors, after normalization for
HPRT. *P  0.05 vs. uninfarcted control hearts (C).
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of angiogenesis and presence of abnormally enlarged
capillaries was also recently reported in a VEGF-B-
transgenic mouse (11). An apparent controversy exists
concerning the possible angiogenic role of VEGF-B
exogenously delivered in vivo, ranging from promotion
of unrestricted angiogenesis (42), ability to potentiate,
rather than induce, angiogenesis when transgenically
expressed in endothelial cells (43), induction of selec-
tive revascularization of the ischemic myocardium but
not of other organs (12), or no angiogenic effect at all
in several tissues after adenoviral gene delivery (44, 45).
Recent work has also indicated that the delivery
VEGF-B to the infarcted myocardium in rabbits and
pigs using an adenoviral vector promoted angiogenesis
and arteriogenesis by acting on endothelial cells (13).
All these apparent discrepancies might be attributable
to differences in genetic background, phenotyping
methodology, use of different VEGF-B isoforms, or,
most important, use of different strategies for VEGF-B
overproduction (recombinant proteins, naked plasmid
DNA, or adenoviral vectors). In this respect, AAV
vectors currently represent the only available system to
deliver genes to the adult myocardium and allow their
prolonged expression over time. Other vector systems,
such as the first generation adenoviruses used in other
studies, are fraught with the induction of a potent
inflammatory and immune reaction (46), which, be-
sides blurring the biological response, restricts observa-
tion to a few days after vector inoculation.
Besides the possible direct modulation of cardiac
contractility, the main consequences of VEGF expres-
sion are, on one hand, the protection of cardiomyo-
cytes from apoptosis while, on the other hand, the
induction of a gene expression program of compensa-
tory hypertrophy. Cardiomyocytes thus join the list of
the numerous cell types in which different VEGF family
members exert a powerful antiapoptotic effect, includ-
ing endothelial cells (5), neurons (47), embryonic stem
cells, (48) and skeletal muscle cells (23, 49). Protection
from apoptosis was clearly evident when VEGF-B was
administered, in both cultured cardiomyocytes and
after myocardial infarction in vivo, again suggesting
that a relevant receptor mediating the antiapoptotic
effect was VEGFR-1. The recent observations that
VEGF-B rescues retinal and motor neurons from apop-
tosis (50, 51) and inhibits the expression of a number
of proapoptotic genes in noncardiomyocyte cells (50) is
fully consistent with this conclusion.
In addition to protection from apoptosis, VEGF-B
transduction in the heart elicited a peculiar gene
expression profile, consisting of the activation of
MHC and the repression of MHC and skeletal -ac-
tin, and the increase in SERCA2a, RYR, and PGC1
gene expression, together with the increase in the levels
of the cardiac natriuretic peptide mRNAs. This pattern
of gene expression resembles that induced by the
thyroid hormone T3, which is usually considered a
marker of benign, compensatory hypertropic response
to cardiac stimulation (52, 53). These findings appear
to be in full agreement with the recent observation that
a transgenic mouse overexpressing VEGF-B showed
clear signs of cardiac hypertrophy, but without compro-
mising cardiac function (11); with the report that
VEGF-B-knockout mice have smaller hearts (10); and
with the observation that the injection of the VEGF-B
protein after infarction leads to myocardial hypertro-
phy (54). Our results extend these findings further,
and show that these effects of VEGF-B are exerted
through direct activity on cardiomyocytes. Of note, in
our experiments, VEGF-A and VEGF-B equally pro-
tected cardiomyocytes from apoptosis and induced a
beneficial gene expression profile; however, VEGF-B
scored superior to VEGF-A in preserving LV function
after myocardial infarction. This observation might
either indicate that the two factors activate VEGFR-1
differently, for example, exploiting different corecep-
tors, or that the prolonged activation of VEGFR-2 by
VEGF-A might be somehow detrimental for the in-
farcted myocardium, for example, by inducing a leaky
vasculature. Further experiments will obviously be re-
quired to distinguish between these possibilities.
In conclusion, the finding that VEGF-B exerts a
marked beneficial effect on the infarcted myocardium
by preventing loss of cardiac mass and promoting
cardiac contractility has obvious therapeutic implica-
tions, in terms of both direct utilization of VEGF-B (or
PlGF) for therapeutic purposes and the identification
of alternative, synthetic activators of VEGFR-1.
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Intramyocardial VEGF-B167 Gene Delivery Delays the
Progression Towards Congestive Failure in Dogs With
Pacing-Induced Dilated Cardiomyopathy
Martino Pepe,* Mohammed Mamdani,* Lorena Zentilin,* Anna Csiszar, Khaled Qanud,
Serena Zacchigna, Zoltan Ungvari, Uday Puligadda, Silvia Moimas, Xiaobin Xu, John G. Edwards,
Thomas H. Hintze, Mauro Giacca, Fabio A. Recchia
Rationale: Vascular endothelial growth factor (VEGF)-B selectively binds VEGF receptor (VEGFR)-1, a receptor
that does not mediate angiogenesis, and is emerging as a major cytoprotective factor.
Objective: To test the hypothesis that VEGF-B exerts non–angiogenesis-related cardioprotective effects in
nonischemic dilated cardiomyopathy.
Methods and Results: AAV-9–carried VEGF-B167 cDNA (10
12 genome copies) was injected into the myocardium
of chronically instrumented dogs developing tachypacing-induced dilated cardiomyopathy. After 4 weeks of
pacing, green fluorescent protein–transduced dogs (AAV-control, n8) were in overt congestive heart failure,
whereas the VEGF-B–transduced (AAV-VEGF-B, n8) were still in a well-compensated state, with physiological
arterial PO2. Left ventricular (LV) end-diastolic pressure in AAV-VEGF-B and AAV-control was, respectively,
15.01.5 versus 26.71.8 mm Hg and LV regional fractional shortening was 9.41.6% versus 3.00.6% (all
P<0.05). VEGF-B prevented LV wall thinning but did not induce cardiac hypertrophy and did not affect the
density of -smooth muscle actin–positive microvessels, whereas it normalized TUNEL-positive cardiomyocytes
and caspase-9 and -3 activation. Consistently, activated Akt, a major negative regulator of apoptosis, was
superphysiological in AAV-VEGF-B, whereas the proapoptotic intracellular mediators glycogen synthase kinase
(GSK)-3 and FoxO3a (Akt targets) were activated in AAV-control, but not in AAV-VEGF-B. Cardiac
VEGFR-1 expression was reduced 4-fold in all paced dogs, suggesting that exogenous VEGF-B167 exerted a
compensatory receptor stimulation. The cytoprotective effects of VEGF-B167 were further elucidated in cultured
rat neonatal cardiomyocytes exposed to 108 mol/L angiotensin II: VEGF-B167 prevented oxidative stress, loss of
mitochondrial membrane potential, and, consequently, apoptosis.
Conclusions: We determined a novel, angiogenesis-unrelated cardioprotective effect of VEGF-B167 in nonischemic
dilated cardiomyopathy, which limits apoptotic cell loss and delays the progression toward failure. (Circ Res.
2010;106:00-00.)
Key Words: Heart Failure  Vascular Endothelial Growth Factors  Gene Therapy
Vascular endothelial growth factor (VEGF)-B, 1 of the 5members of the VEGF family,1 is relatively understud-
ied compared to VEGF-A, yet is emerging as a major
cytoprotective factor.2,3 Expressed in tissues with elevated
metabolism, including myocardium,4 the VEGF-B gene en-
codes for 2 isoforms, VEGF-B167 and VEGF-B186, which
selectively bind the receptors VEGFR-1 and neuropilin-1.4,5
Based on data from knockout and transgenic animals, this
growth factor is minimally angiogenic and its absence is
compatible with birth and growth, although it seems impor-
tant for physiological cardiac development.6–8 Li et al have
recently elucidated mechanisms responsible for VEGF-B–
induced cytoprotection: VEGF-B167, via VEGFR-1, down-
regulates genes of the apoptosis/cell death-related pathways,
in vitro, and can rescue neurons from apoptosis in mouse
models of retinal and brain damage.2 The same authors found
that, under pathological conditions, VEGF-B167, albeit unable
to induce blood vessel growth, is critically required for the
survival of newly formed vascular cells.3 We have later
shown that VEGF-B167 gene transfer in infarcted rat hearts
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attenuates remodeling and preserves viable cardiac tissue and
contractility in the absence of significant induction of angio-
genesis.9 This is suggestive of an angiogenesis-unrelated,
direct prosurvival effect of VEGF-B167 on cardiomyocytes;
however, no studies, to date, have tested a similar protective
role in cardiac diseases, such as dilated cardiomyopathy, not
associated with major vasculopathic/ischemic events. Al-
though it is not the principal cause of heart failure, dilated
cardiomyopathy is particularly malignant, accounting for the
majority of cardiac transplants in the US,10 and its underlying
etiology remains in most cases undetermined. By definition,
dilated cardiomyopathy is not caused by large necrotic tissue
loss consequent to coronary artery disease; hence, it would
not benefit from neoangiogenesis, whereas it is characterized
by modest and widespread myocardial fibrosis and increased
apoptosis.11,12 Interestingly, a clinical study found that in
dilated, but not in ischemic cardiomyopathy, a higher rate of
apoptosis was associated with a more rapidly deteriorating
clinical course.13 Moreover, experimental studies have shown
that a few hundred apoptotic cells per million are sufficient to
cause dilated cardiomyopathy, which can be prevented by
halting the mechanisms of cell death.14,15 It is also noteworthy
that cardiac VEGRF-1 expression is downregulated in pa-
tients with dilated, but not ischemic cardiomyopathy.16 Based
on these observations, we tested the hypothesis that VEGF-
B167 overexpression can attenuate the structural and func-
tional derangement of cardiac muscle in dilated cardiomyop-
athy. Our study was conducted in canine pacing-induced
heart failure, which remains to date one of the best available
preclinical models of human dilated cardiomyopathy. The
prevalence of apoptosis in dog hearts subjected to sustained
tachypacing is similar to that found in patients,17 and the time
course of failure is very predictable; therefore, this model
is well-suited to test potential cytoprotective and protro-
phic effects of VEGF-B167 delivery. To obtain sustained
expression over time, VEGF-B167 gene transfer was per-
formed by using recombinant adeno-associated virus of
serotype 9 (AAV9), a vector with marked cardiotropism.18
Mechanisms of cell protection were further tested in
cultured cardiomyocytes.
Methods
An expanded Methods section is available in the Online Data
Supplement at http://circres.ahajournals.org.
Surgical Instrumentation and AAV Delivery
Twenty-two adult, male, mongrel dogs (25 to 27 kg) were chroni-
cally instrumented as previously described.19,20 In addition, 2 pairs of
piezoelectric crystals were implanted in the midmyocardium of the
left ventricular (LV) free wall, orthogonal to the ventricular long
axis, 10 to 15 mm apart, to assess regional circumferential shorten-
ing. During surgery and following a random order, in 14 dogs the
heart was transduced with VEGF-B167 and in 8 dogs with the green
fluorescent protein (GFP) transgene by 10 intramyocardial injections
of 0.1 mL of AAV9 vectors (0.51011 genome copies per injection)
into the LV free wall, according to a predefined map (Online Figure
I). Some of the points of injection were previously tagged with
epicardial thick silk stitches to allow postmortem identification of the
spots. One injection was performed in between each of the 2 pairs of
piezoelectric crystals.
Experimental Protocol
Ten to 12 days after surgery and AAV delivery, baseline hemody-
namics, regional shortening, echocardiographic measurements were
taken and paired arterial and coronary sinus blood samples collected
in conscious, nonsedated animals, trained to lie down quietly and
unrestrained on the laboratory table. Data were taken at spontaneous
heart rate and after 10 minutes pacing at 210 bpm. Absolute
myocardial flow was measured by injecting stable isotope-labeled
microspheres, both at spontaneous heart rate and during pacing.21
After these baseline measurements, 8 of the 14 VEGF-B167–trans-
duced (AAV-VEGF-B group) and the 8 GFP-transduced dogs
(AAV-control group) were subjected to chronic LV pacing at 210
bpm for 3 weeks; then the rate was increases to 240 bpm for an
additional week. The same measurements performed at baseline (0
weeks pacing) were repeated at 3 and 4 weeks of pacing, except for
the microsphere injection and paired arterial and coronary sinus
blood sampling, which were repeated only at 4 weeks, when the
protocol was completed. Based on our previous studies in dogs
undergoing this pacing protocol, at 3 weeks dogs are still in
compensated failure,19,20 whereas at 4 weeks, they reach end-stage
heart failure, characterized by a LV end-diastolic pressure of
25 mm Hg, drop in arterial PO2, and dyspnea. The remaining 6
VEGF-B167-transduced dogs were monitored for 4 weeks but not
paced and used to assess potential functional and morphological
changes attributable to long-term VEGF-B167 overexpression in a
normal heart (AAV-VEGF-B nonpaced group).
At the completion of the protocol, the dogs were euthanized with
an overdose of sodium pentobarbital, the heart was weighed, and
transmural LV tissue samples were harvested from the AAV-injected
spots, ie, the anterolateral LV free wall, and from the remote LV
region, ie, the posterolateral LV free wall, close to the left posterior
descending coronary artery. They were immediately stored in liquid
nitrogen or phosphate 10% formalin and coded for blinded molecular
and histological analysis, or exsiccated for later counting of the
microspheres. Only for comparisons of macroscopic (cardiac weight)
and histological cardiac changes, we used data and tissue samples
obtained from a further group of 5 healthy dogs that, after full
recovery from chronic instrumentation, were euthanized because of
major failures of the implanted probes. This group is indicated as
“normal.”
Surgical instrumentation and protocol were approved by the
Institutional Animal Care and Use Committee of the New York
Medical College and conform to the guiding principles for the care
and use of laboratory animals published by the National Institutes of
Health.
Hemodynamics, LV Regional Shortening,
Echocardiographic Recordings and MVO2
See the Online Data Supplement.
Production, Purification, and Characterization of
Recombinant AAV Vectors
Mouse VEGF-B167 cDNA was incorporated into recombinant
AAV-9 prepared by the AAV Vector Unit at ICGEB Trieste
Non-standard Abbreviations and Acronyms
AAV-control paced dogs transduced with green fluorescent protein
AAV-VEGF-B paced dogs transduced with VEGF-B167
Ang II angiotensin II
GFP green fluorescent protein
GSK glycogen synthase kinase
LV left ventricular
MVO2 myocardial oxygen consumption per minute
VEGF vascular endothelial growth factor
VEGFR vascular endothelial growth factor receptor
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(http://www.icgeb.org/avu-core-facility.html), by a cross-packaging
approach whereby the AAV type 2 vector genome was packaged into
AAV capsid serotype 9. Methods for production and purification
were previously described.22 AAV titers were in the range of 11012
genome copies per milliliter.
Histology and Immunofluorescence
To determine alterations in microvascular density, endothelial cells
were detected using FITC-conjugated Lycopersicum esculentum
lectin and vascular smooth muscle cells using a Cy3-conjugated anti
-SMA mouse monoclonal antibody. The microvessel number was
normalized by the number of cardiac fibers. Apoptotic cells were
visualized by TUNEL and cardiomyocyte cross-sectional area was
measured.9,22
Isoprostane and Caspase-9 Activity in LV Tissue
Because the production of reactive oxygen species is increased in the
failing heart,23,24 we measured 8-isoprostane content, an index of
oxidative stress, and the activity of caspase-9, which increases in
response to oxidative mitochondrial damage, thus triggering the
apoptotic cascade. In LV tissue homogenates, 8-isoprostane was
measured by the EIA kit (Cayman Chemicals) and caspase-9
activity in LV homogenates was measured with a colorimetric
activity assay kit.
PCR, ELISA, and Western Blotting
Total LV DNA was extracted to detect AAV genomic DNA and
RNA was purified to quantify murine VEGF-B167 (AAV-carried
transgene) and dog VEGF-B167, VEGF-A165, VEGFR-1, VEGFR-2
and Neuropilin-1 transcripts. Dog serum samples from arterial and
coronary sinus blood were analyzed by ELISA for the presence of
mouse VEGF-B167 secreted in the circulation from the transduced
heart tissue. Western blot was used to quantify the activated/cleaved
caspase-3, which is the final common effector of the apoptotic
pathway, and to determine the activation state of Akt, a major
antiapoptotic kinase,25 and of 2 of its targets critically involved in the
positive regulation of apoptosis, namely GSK-3 and FoxO3a,
which are inactivated by phosphorylation in the cytosol and in the
nucleus, respectively.26–28
Cultured Cardiac Myocytes
Potential mechanisms of cytoprotection mediated by VEGF-B167
were studied in neonatal rat cardiomyocytes. There are many causes
of cell damage occurring in the failing heart, still partially unknown,
therefore we focused on a major one, namely the upregulated
angiotensin II (Ang II),29 one of the main activators of oxidative
stress.30 Cardiomyocytes were cultured and pretreated with murine
VEGF-B167 protein (100 ng/mL, for 24 hour) or vehicle. Then the
culture medium was added with Ang II (108 mol/L, for 24 hour).
After the treatment period the percent of TUNEL-positive cells, a
marker of apoptosis, and caspase-3 and -9 activities were assessed in
cell homogenates.
To elucidate downstream effects of Ang II, we tested Ang
II–induced mitochondrial O2
.- production and consequent damage.31
Neonatal rat cardiomyocytes were exposed to Ang II with and
without VEGF-B167 as described above. We then assessed Ang
II–induced mitochondrial O2.- production and total cell peroxide
production. Changes in mitochondrial membrane potential were
measured as they are a known downstream effect of Ang II–induced
oxidative stress. We have used these methods previously.32
Statistical Analysis
Data are presented as meansSEM. Statistical analysis was per-
formed by using commercially available software. Changes at
different time points in the same group and differences among
groups or in vitro data sets were compared by one- and two-way
ANOVA followed by Tukey post hoc test. For all of the statistical
analyses, significance was accepted at P0.05.
Results
Hemodynamics
The hemodynamic changes found in AAV-control were very
consistent with the typical evolution of this model of failure,
as previously described by us.18,19 LV end-diastolic pressure
(Figure 1) reached values 25 mm Hg after 4 weeks of
pacing, indicating a condition of end-stage, congestive heart
failure. However, VEGF-B167 delivery markedly attenuated
this increase, and, at 4 weeks, LV end-diastolic pressure
was still comparable to values found at 3 weeks in
AAV-control. Consistent with the development of conges-
tive heart failure, in AAV-control arterial PO2 decreased
from 90.02.9 mm Hg at baseline (PNS versus the AAV-
VEGF-B group) to 67.04.8 mm Hg after 4 weeks of pacing
(P0.05 versus baseline), whereas the better preserved dia-
stolic function in the AAV-VEGF-B group was reflected by
an arterial PO2 of 83.45.2 mm Hg at 4 weeks (PNS versus
baseline).
Figure 1. Changes in major hemodynamic pa-
rameters over the 4 weeks of chronic pacing.
A, Changes in LV end-diastolic pressure. B,
Changes in LV systolic pressure, dP/dtmax and
mean arterial pressure. n8 per group. Measure-
ments were taken with the pacemaker off.
*P0.05 vs 0 weeks (baseline) within the group;
#P0.05 between groups at same time point.
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Figure 1 shows other major hemodynamic changes. Com-
pared to AAV-control, VEGF-B gene delivery limited the fall
in LV systolic pressure, dP/dtmax and mean arterial pressure
during the pacing protocol. On the other hand, there were no
significant hemodynamic changes from baseline during the
4-week follow up in the AAV-VEGF-B nonpaced group (data
not shown).
Global and Regional Cardiac Function
Global cardiac function was evaluated by echocardiography
(Figure 2). Ejection fraction decreased significantly in both
groups, although it was better preserved in AAV-VEGF-B.
LV end-diastolic diameter increased significantly only in
AAV-control; however, the same trend was also present in
AAV-VEGF-B, and therefore there was no significant differ-
ence between the 2 groups. LV end-systolic diameter in-
creased significantly in both groups. Two parameters that did
not change significantly in AAV-VEGF-B during the pacing
protocol were the end-diastolic thickness and systolic thick-
ening of the LV free wall. As expected, there were significant
LV wall thinning and diminished systolic thickening in
AAV-control. Thickening is an index of regional contractile
performance that we measured along the selected plane of
echo scanning. To further explore regional changes in con-
tractile performance of the transduced LV areas, we measured
circumferential systolic shortening with piezoelectric crystals
(Figure 3), which, consistent with the echo data, decreased
significantly in AAV-control, but was markedly preserved in
Figure 2. Changes in echocardiographic param-
eters over the 4 weeks of chronic pacing. LVED
indicates LV end-diastolic; ED, end-diastolic; ES,
end-systolic; LVEDFW, end-diastolic thickness of
the LV free wall; LVSFW, LV systolic free wall.
Measurements were taken with the pacemaker off.
*P0.05 vs 0 weeks (baseline) within the group;
#P0.05 between groups at same time point; n8
per group.
Figure 3. A, Changes in 2 indexes of
regional contractile function calculated
from cyclic variations of the LV distance
(segmental length) between piezoelectric
crystals implanted in the LV free wall. The
surrogate of the regional stroke work was
obtained as the area of the LV pressure–
segmental length loop and normalized to
baseline (n8 per group). Measurements
were taken with the pacemaker off.
*P0.05 vs 0 weeks (baseline) within the
group and #P0.05 between groups at
same time point. B, Representative
pressure-length loops at 0 and 4 weeks
pacing.
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AAV-VEGF-B. The integral of the LV pressure-segmental
length loop provides a surrogate of regional stroke work, that,
expressed as a percentage of the baseline (0 weeks), fell
significantly by approximately 89% in AAV-control, but only
by 58% in AAV-VEGF-B, after 4 weeks of pacing. Figure 3B
shows 2 examples of changes in the pressure-length loops in
the 2 groups, with the remarkable preservation of regional
function in AAV-VEGF-B. Please note that the different
baseline loops in the 2 groups was attributable to the
unavoidable variability, from dog to dog, of the distance
between crystals placed during surgery, and for that reason
regional work in Figure 3A is expressed as percentage of
baseline. On the other hand, there were no significant changes
from baseline, in wall thickness and global and regional
function, during the 4-week follow up in the AAV-VEGF-B
nonpaced group (data not shown).
Coronary Flow and MVO2
The beneficial effects of AAV-VEGF-B delivery could be
possibly attributable to myocardial neoangiogenesis and
therefore enhanced blood perfusion and oxygen consumption.
We therefore measured coronary blood flow in the circumflex
coronary artery, which is responsible for the perfusion of a
large portion of the LV free wall, including the transduced
areas. Moreover, we measured absolute myocardial perfusion
in samples selectively taken from the AAV-injected spots.
As shown in the Table, no significant differences were
found between the 2 groups, both at spontaneous heart rate
and during acute pacing stress, at baseline and after 4
weeks of pacing. MVO2 displayed a trend toward increased
baseline values in AAV-VEGF-B compared to AAV-
control; however, these differences between the 2 groups
were not statistical significant, not even during acute
pacing stress.
Structural Changes at Macroscopic and
Microscopic Level
The heart weight to body weight ratio was 10.070.29 g/kg
in AAV-VEGF-B, 9.070.36 g/kg in AAV-control,
9.040.17 g/kg in nonpaced AAV-VEGF-B and 9.210.22
g/kg in normal (PNS for all comparisons). Histology
revealed an approximately 15% reduction in capillary density
in AAV-control compared to normal, which was prevented in
AAV-VEGF-B (Figure 4A and 4B). On the other hand, the
density of microvessels with -smooth muscle actin positive
wall was not significantly different among groups (Figure 4A
and 4C). Cardiomyocytes cross-sectional area was signifi-
cantly increased in both paced and nonpaced AAV-VEGF-B
compared to normal (Figure 4D and 4E), a local effect limited
to the site of injection that was evidently insufficient to
produce detectable LV hypertrophy. TUNEL-positive cardio-
myocyte nuclei were increased by approximately eightfold in
AAV-control and their number was halved in AAV-VEGF-B,
although still higher than normal (Figure 5A and 5B).
Consistently, caspase-9 activity was increased and cleaved
caspase-3 was clearly detectable only in AAV-control (Figure
5C and 5D).
Oxidative Stress and Activation State of Major
Regulators of Apoptosis
Total tissue isoprostane content was 37.95.4 pg/mg protein
in normal LV, increased to 84.05.8 pg/mg in AAV-control
group (P0.05), but was normalized in paced AAV-VEGF-B
(39.34.0 pg/mg).
Gene Expression of Murine VEGF-B167 and
Endogenous VEGF-B167, VEGF-A, VEGFR-1,
VEGFR-2, and Neuropilin-1
The murine VEGF-B167 transgene delivered via AAV was
expressed in the injection site and, to a much lesser extent, in
the remote site (Online Figure II). However, murine VEGF-
B167 protein concentration, both in arterial and coronary sinus
blood samples, was below the ELISA threshold of detection.
VEGF-A165 gene expression was (normalized to Hprt gene
values): 0.870.4 in AAV-VEGF-B, 0.630.1 in AAV-
control (P0.05 versus normal) and 1.050.1 in normal, yet
VEGF-B167 was not significantly different among groups
(data not shown). VEGFR-1 expression was reduced by
approximately fourfold and neuropilin-1 by approximately
50% to 30% in both of AAV-control and AAV-VEGF-B
compared to normal (Figure 6A). On the other hand, there
were no significant differences of VEGFR-2 gene expression
among groups.
Activation State of Akt, GSK-3, and FoxO3a
Protein expression of Akt was not significantly different
among groups; however, its phosphorylation was signifi-
cantly higher in AAV-control compared to normal and even
higher in AAV-VEGF-B (Figure 6B). We then examined
GSK-3 and FoxO3a, 2 targets of Akt phosphorylation, one
cytosolic and the other nuclear, both involved in the control
of apoptosis. The levels of protein expression was not
significantly different among groups, whereas, inconsistent
with Akt hyperactivation, their phosphorylation was signifi-
Table. Blood Flow in the Left Circumflex Coronary Artery in Myocardial Perfusion and in Cardiac Oxygen Consumption
0 Weeks (Pacing Off) 0 Weeks (Acute Pacing) 4 Weeks (Pacing Off) 4 Weeks (Acute Pacing)
AAV-Control AAV-VEGF-B AAV-Control AAV-VEGF-B AAV-Control AAV-VEGF-B AAV-Control AAV-VEGF-B
LCx CBF (mL/min) 33.144.03 35.632.91 43.646.37* 44.622.87* 34.124.12 31.502.25 41.345.45* 38.993.77*
Myocardial perfusion
(mL/min/g)
1.030.08 1.100.15 1.880.28* 1.750.16* 1.230.06 1.150.20 1.760.20* 1.730.17*
MVO2 (mL/min) 6.720.68 8.180.40 8.620.64* 12.061.24* 6.90.34 7.90.56 8.960.62* 9.521.68*
Blood flow in the left circumflex coronary artery (LCx CBF) in myocardial perfusion assessed by microsphere infusion and in cardiac oxygen consumption measured
at 0 weeks and at 4 weeks pacing, both at spontaneous heart rate (pacing off) and during acute (10 minutes) pacing stress (n6–8 per group). *P0.05 of acute
pacing vs pacing off.
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cantly reduced in AAV-control compared to normal. In
AAV-VEGF-B; however, physiological levels of pospho-
GSK-3 were reestablished, whereas phopho-FoxO3a was
superphysiological (Figure 6B).
Cultured Cardiac Myocytes
Decreased mitochondrial function in cardiomyocytes is one
of the earliest events of Ang II action, which leads to
mitochondrial depletion and increased apoptosis. In this
regard, we found that Ang II significantly increases apoptosis
in cultured cardiac myocytes (Figure 7A), which was consis-
tent with the activation of caspase-9 and -3 (Figure 7B and
7C). Moreover, treatment of cardiac myocytes with Ang II
results in significant cellular (Figure 7D) and mitochondrial
oxidative stress (Figure 7E through 7G), which are thought to
play a role in the induction of apoptotic cell death. Impor-
tantly, VEGF-B167 effectively protected cardiac myocytes
against both Ang II–induced apoptosis (Figure 7A and 7B)
and mitochondrial oxidative stress (Figure 7E through 7G).
Treatment of cardiac myocytes with Ang II resulted in a loss
of red fluorescence of J-aggregates and an increase in green
fluorescence of JC-1 monomer (Figure 7H), indicating loss of
mitochondrial membrane potential (m). All of these alter-
ations were attenuated or completely prevented in the pres-
ence of VEGF-B167, indicating a preservation of mitochon-
drial integrity.
Discussion
Our study shows that cardiac delivery of VEGF-B167 trans-
gene, obtained by no more than ten direct intramyocardial
injections of AAV-9 vectors, delays the progression of
pacing-induced dilated cardiomyopathy toward congestive
failure. After 4 weeks of tachypacing, hearts transduced with
VEGF-B167 maintained a LV end-diastolic pressure compat-
ible with physiological pulmonary blood oxygenation,
whereas LV wall thickness and global and regional contrac-
tile function were either not significantly changed or pre-
served compared to baseline. On the other hand, VEGF-B167
gene transfer did not affect myocardial blood perfusion and
oxygen consumption at spontaneous heart rate or during acute
Figure 4. A, Representative photomicro-
graphs of myocardial tissue showing
double immunofluorescence staining for
endothelial cells (lectin, green), vascular
smooth muscle cells (-SMA) (red),
whereas nuclei were stained with DAPI
(blue). B and C, Microvessel density
was normalized by the number of car-
diomyocyte fibers. D and E, ITC-
conjugated lectin (green) was used to
stain myocardium and quantify cardio-
myocyte cross-sectional area. *P0.05
vs normal; n6 per group.
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pacing stress. Consistently, VEGF-B167 transgene did not
alter the density of LV microvessels endowed with smooth
muscle wall, whereas it prevented the slight capillary rarefac-
tion found in control paced dogs. The low rate of apoptosis
and the normalized levels of active capsase-9 and -3 in
myocardial tissue suggest antiapoptotic and protrophic ac-
tions of VEGF-B167, which likely averted both of cardiomyo-
cyte and capillary endothelial cell loss. Interestingly, the
antiapoptotic kinase Akt was more active in the failing heart,
as previously found in human and tachypacing-induced heart
failure,33,34 and yet the phosphorylation/inactivation of 2
major targets of this kinase in cytosolic and nuclear compart-
ments, ie, GSK-3 and FoxO3a, known as important proapo-
ptotic mediators,26–28 was significantly reduced compared to
normal hearts. Consistent with its antiapoptotic action,
VEGF-B167 transduction re-established normal levels of
GSK-3 and FoxO3a phosphorylation.
VEGF-B167 and Oxidative Stress
The determinants of apoptosis, in the failing heart, are
notoriously numerous, and VEGF-B167 transgene likely coun-
teracted more than one of them. We focused on oxidative
stress, a well recognized cause of myocardial cell damage in
various forms of failure,17,23,24 which is indirectly revealed by
fingerprints such as 8-isoprostane and can be triggered by
several factors, in particular the locally produced angiotensin
II.30 In paced dogs transduced with VEGF-B167, tissue
8-isoprostane concentration was not significantly different
from normal, suggesting a mechanism of protection
against oxidative stress. Such mechanism was further
tested in cultured cardiomyocytes exposed to angiotensin
II: VEGF-B167 displayed an action previously unrecog-
nized for this factor, ie, blocked the sequence oxidative
stress3mitochondrial damage3apoptosis.30,31 This adds to
cell trophic state enhancement and antiapoptotic effects of
VEGF-B167 on cultured cardiomyocytes exposed to other
insults such as hypoxia/reoxygenation or the genotoxic agent
epirubicin, recently shown by us.9
Angiogenesis-Unrelated Myocardial Protection
The capability to mitigate the pathogenesis of heart failure
without inducing angiogenesis, thus via a direct cytoprotec-
tive and protrophic action, has been previously attributed to
other families of growth factors, for instance the fibroblast
growth factor-5.35 However, as regards the VEGF family, this
is a new paradigm. In fact, the rationale that has thus far
driven experimental and clinical protocols with gene delivery
of VEGF-A, the best known and most widely used VEGF, in
hearts with ischemic36 and even nonischemic injury,37 is that
the therapeutic outcome of this factor is attributable to
neoangiogenesis and consequent perfusion enhancement.
However, substantial evidence indicates that the expression
of the VEGF receptors VEGFR-1 and -2 is not restricted to
endothelial cells, but is present also in other cell types
including cardiomyocytes,9,38 and that their ligand VEGF-A
exerts further fundamental functions, beyond proangiogen-
esis.1 In a study on VEGF-A165 gene transfer to infarcted dog
hearts, we observed a functional improvement within 48
hours, a temporal frame not compatible with the formation of
new blood vessels and suggestive of a direct protective effect
on cardiomyocytes,38 as proposed also by other authors.39
More recently, we found that VEGF-B167 gene transfer in
infarcted rat hearts caused minimal angiogenesis and yet was
as much beneficial as VEGF-A.9 The ensuing question was
whether the direct cytoprotective action of a VEGF member,
per se, is sufficient to delay the progression of a form of heart
failure unrelated to major coronary alterations. The ideal
molecular probe to address this question was VEGF-B, a
selective ligand of VEGFR-1, not mediating angiogenesis,
and therefore devoid of additional, confounding outcomes of
Figure 5. A and B, Cardiomyocyte apo-
ptotic nuclei (white arrows) by TUNEL
(red) analysis. Cardiomyocytes are
stained with -actinin (green). Bars:
#P0.05 vs AAV-control; n4 per
group. D, Representative Western blot-
ting analysis of activated/cleaved
caspase-3 (17 kDa). The bands were not
detectable in normal and AAV-VEGF-B,
indicating virtually no cleavage.
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new vessel formation in diseased myocardium. Compared to
VEGF-A, very little was known about the actions of VEGF-B
in response to cell damage until seminal studies published
over the past 2 years showed its marked antiapoptotic and
cytoprotective effects both in vitro and in vivo.2,3 These
recent findings led us to the hypothesis that cardiac gene
transfer of VEGF-B167 could ameliorate the evolution of a
form of heart failure not caused by tissue loss from ischemic
injury. Dilated cardiomyopathy was a well-suited target to
test our hypothesis, because, by definition, it is characterized
by ventricular chamber dilation in the absence of coronary
disease and, independent of its cause that remains in many
cases unrecognized, its pathogenesis involves severe cell
damage leading to apoptotic death. We used pacing-induced
heart failure, a long established model of dilated cardiomy-
opathy that, although limited as any other model, reproduces
many features of the human disease, including cardiomyocyte
damage and rate of apoptosis.17 We now found a further,
interesting analogy,16 ie, decreased gene expression of
VEGF-A, but not VEGF-B167, associated with VEGFR-1 and
neuopilin-1 downregulation, even in the AAV-VEGF-B
group, whereas VEGFR-2 was not significantly altered. This
suggests that supplementary, exogenous VEGF-B might have
compensated for the reduced availability of its specific
receptors VEGFR-1 and neuropilin-1 that, different from
VEGFR-2, do not mediate angiogenesis.
Local Versus Global Effects of VEGF-B167
Gene Transfer
The method of gene delivery used yielded transduction that
was highest in the LV site of injection, and detectable also,
albeit much lower, in the remote site. It remains unclear how
such nonhomogeneous distribution could affect global LV
function, with repercussions on systemic hemodynamics. We
could not find measurable levels of mouse VEGF-B167 in
arterial and coronary sinus blood, ruling out a relevant cell
secretion. Nonetheless VEGF-B167 gene transfer was suffi-
cient to induce a local increase in the cardiomyocyte cross
sectional area, but not as high to determine superphysiolog-
ical or even untoward structural changes, such as neoangio-
genesis and cardiac hypertrophy. Presumably, an excessive
VEGF-B167 overexpression would have caused marked hy-
pertrophy, as described in transgenic mice.8 In this regard, it
is interesting to note that, in infarcted rabbit and pig hearts,
other authors have very recently found therapeutic angiogen-
esis induced by intracoronary gene delivery of the diffusible
isoform VEGF-B186 in addition to antiapoptotic effects in
cultured cardiomyocytes.40 Perhaps such difference relative
Figure 6. A, Real-time PCR quan-
tification of VEGFR-1, VEGFR-2,
and neuropilin-1 (NP-1) gene
expression. B, Western blotting
analysis of activating phosphory-
lation of Akt and inactivating
phosphorylation of its down-
stream targets GSK-3 and
FoxO3a. *P0.05 vs normal; n6
per group.
8 Circulation Research June 25, 2010
 by Mauro Giacca on May 3, 2010 circres.ahajournals.orgDownloaded from 
to our results is attributable to the kinetics and dynamics of
the diffusible VEGF-B186 isoform and/or to the level of its
expression and/or to the presence of large areas of ischemia,
a condition in which, as proposed by a recent report, this
growth factor is critically required for the survival of newly
formed vascular cells.3
Study Limitations
At least 2 limitations of our study should be pointed out. First,
VEGF-B167 gene delivery was performed during surgical
instrumentation, before and not after starting the pacing
protocol, and the study was only in part blinded. However,
the present study was not designed as a preclinical trial, as its
primary goal was to test VEGF-B167-mediated cardioprotec-
tion in a model of progressive cardiac derangement. We
needed to minimize confounding variables related to AAV
delivery, therefore we chose to use multiple direct intramyo-
cardial injections in well defined points that could be visually
identified postmortem in animals that could be operated only
once. Nevertheless, no significant differences between groups
Figure 7. Percentage of TUNEL-positive nuclei
(A), caspase-3 and -9 activity normalized by pro-
tein concentration (B and C) and cellular peroxide
levels (D) in rat neonatal cardiac myocytes treated
with Ang II (108 mol/L) with or without VEGF-
B167. E, Representative fluorescent images show-
ing stronger MitoSox staining (red fluorescence)
in Ang II–treated cardiac myocytes than in
untreated controls (note also the increased num-
ber of early apoptotic cells exhibiting nuclear
accumulation of MitoSox). VEGF-B167 substantially
attenuated MitoSox fluorescence in Ang II–treated
cells (original magnification, 40). F, Increased
MitoSox staining localizes to the perinuclear mito-
chondria (counterstained with MitoTracker green)
of nonapoptotic Ang II–treated cardiac myocytes
(blue fluorescence: nuclear counterstaining). G
and H, Summary of flow cytometric data showing
relative MitoSox fluorescence (E) and J-aggregate:
JC-1 monomer fluorescence ratios in rat neonatal
cardiac myocytes treated with Ang II (108 mol/L)
with or without pretreatment with VEGF-B. Data
are meansSEM (n6). *P0.05 vs no Ang II;
#P0.05 vs no VEGF-B167.
Pepe et al VEGF-B167 in Dilated Cardiomyopathy 9
 by Mauro Giacca on May 3, 2010 circres.ahajournals.orgDownloaded from 
were noted at baseline, before starting the pacing protocol;
furthermore, we recently found VEGF-B167 transgene to be
effective when administered after and not before inducing
myocardial infarction.9 A second limitation concerns our data
on the percent of apoptosis measured by TUNEL-based
analysis. Compared to other studies,14,15,17 it seems overesti-
mated; however, it was not meant to provide an absolute
quantification, but rather an index to be interpreted together
with other changes such as oxidative stress and caspase
activation.
In conclusion, we provide novel evidence that VEGF-B167
is a cardiomyocyte protective factor capable of delaying
functional derangement in a model of severe cardiomyopathy
with high rate of apoptosis, without affecting myocardial
blood perfusion and inducing angiogenesis. Besides expand-
ing our knowledge on a relatively undervalued member of the
VEGF family, this study has also translational implications,
as it suggests a promising new candidate for gene therapy of
dilated cardiomyopathy, whose cure, at present, relies on
unsatisfactory pharmacological options.
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Carmeliet P, Alitalo K, Eriksson U, Ylä-Herttuala S. Vascular endothelial
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Novelty and Significance
What Is Known?
● Vascular endothelial growth factor (VEGF)-B, a selective ligand of the
receptor VEGFR-1, is a minimally angiogenic growth factor that
plays an important role in heart development and, when overex-
pressed, induces cardiomyocyte hypertrophy.
● The isoforms VEGF-B167 and VEGF-B186 can activate potent cytopro-
tective mechanisms in cells exposed to a variety of harmful
conditions.
● VEGF-B exerts a marked cardioprotective effect in ischemic/infarcted
hearts by binding VEGFR-1 expressed by cardiomyocytes.
What New Information Does This Article Contribute?
● VEGF-B167 gene delivery to the heart delays ventricular pump failure
in a dog model of nonischemic dilated cardiomyopathy, while not
inducing significant neoangiogenesis.
● VEGF-B167 attenuates oxidative stress and apoptosis, 2 interrelated,
major determinants of progressive tissue loss in nonischemic
dilated cardiomyopathy.
● Consistent with its cytoprotective effects in failing hearts, VEGF-B167
prevents oxidative stress and mitochondrial damage caused by
angiotensin II in cultured cardiomyocyte.
VEGF-B is emerging as a major cytoprotective factor; however,
no previous studies had tested its beneficial effects in nonis-
chemic cardiac diseases. VEGF-B167 cDNA carried by adeno-
associated viral vectors was delivered to the myocardium of
dogs developing tachypacing-induced dilated cardiomyopathy.
After 4 weeks of pacing, these dogs were still in a well-
compensated state compared to control dogs. Consistently,
hemodynamic and cardiac functional and morphological param-
eters were better preserved. Histological and molecular analysis
indicated that VEGF-B167 markedly attenuated oxidative stress
and cell apoptosis without inducing detectable neoangiogenesis.
The cytoprotective effects of VEGF-B167 were further elucidated
in cultured rat neonatal cardiomyocytes exposed to high con-
centrations of angiotensin II to mimic a recognized cause of
oxidative stress and cell damage occurring in failing hearts.
VEGF-B167 prevented oxidative stress, loss of mitochondrial
membrane potential, and, consequently, apoptosis. We provide
novel evidence that VEGF-B167 is a cardiomyocyte protective
factor capable of delaying the onset of decompensated failure in
a model of severe nonischemic cardiomyopathy, without altering
myocardial vascularization. Besides expanding our knowledge of
a less known member of the VEGF family, this study has also
translational implications, because it suggests a promising new
candidate for gene therapy of dilated cardiomyopathy, whose
cure, at present, relies on unsatisfactory pharmacological
options.
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Dogs were sedated with acepromazine maleate (1 mg/kg im), anesthetized with 
pentobarbital sodium (25 mg/kg iv) and ventilated with room air.  A thoractotomy 
was performed in the fifth intercostals space.  One fluid-filled Tygon catheter was 
inserted into the descending thoracic aorta and one in the left atrial appendage, while 
a silicon catheter was placed in the coronary sinus. A solid-state pressure gauge 
(Konigsberg Instruments, Pasadena, CA) was inserted into the LV through the apex. 
A Doppler flow transducer (Craig Hartley, Houston, TX) was placed around the left 
circumflex coronary artery, and two myocardial pacing leads were attached to the LV 
free wall. Two pairs of piezoelectric crystals were implanted in the mid-myocardium 
of the LV free wall, orthogonal to the ventricular long axis, 10-15 mm apart, to assess 
regional circumferential shortening. The viral vector was injected by the surgeon in a 
blind fashion. Wires and catheters were run subcutaneously to the intrascapular 
region and the chest was closed in layers. Antibiotics were given after surgery, and 
the dogs were allowed to fully recover for 7–10 days, then trained to lay quietly on 
the laboratory table.  
 
Hemodynamics, LV regional shortening and echocardiographic recordings 
Hemodynamic parameters were recorded on paper and also stored in computer 
memory at a sampling rate of 250 Hz. The piezoelectric crystals were connected to a 
sonomicrometer to measure cyclic changes in the segmental length. The best 
functioning pair of crystal was identified at baseline, before starting the pacing 
protocol, and then utilized for all the measurements from that point on. The segmental 
length was utilized to calculate percent segmental shortening and the area of the LV 
pressure-segment length loop, a surrogate of regional stroke work. These values 
served as indices of regional contractile function. Two-dimensional and M-mode 
echocardiography was performed (Sequoia C256; Acuson, Mountain View, CA) to 
measure ejection fraction, LV dimensions and wall thickness. Images were obtained 
from a right parasternal approach at the midpapillary muscle level, according to the 
criteria of the American Society of Echocardiography. Hemodynamics and echo were 
recorded and analyzed in a non blinded fashion. However, hemodynamics is 
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unequivocally quantifiable and objectively verifiable. On the other hand, in our 
Department, we have at least three experienced echocardiographists, and they 
customarily cross-evaluate their respective measurements. 
 
Myocardial blood flow and oxygen consumption 
Left circumflex coronary blood flow was measured with a pulsed Doppler flowmeter 
(Model 100, Triton Technology).  
Absolute myocardial flow was measured by injecting 5x106 of stable isotope-labeled 
15 μm microspheres (Biopal, Worcester, MA ) through the left atrial catheter, both at 
spontaneous heart rate and during pacing, while withdrawing blood reference samples 
from the aortic catheter. The neutron-activated isotopes contained in those 
microspheres allowed us to measure myocardial blood flow in selected regions of the 
ventricular wall, a method previously used by us (1) 
Blood gases were measured in a blood gas analyzer (Instruments Laboratory, 
Bedford, MA). PO2 was multiplied by 0.003 and added to O2 content measured by a 
hemoglobin analyzer (CO-Oximeter; Instrumentation Laboratory, Bedford, MA) to 
obtain total oxygen content (vol/vol). Myocardial oxygen consumption (MVO2) was 
calculated by multiplying the arterial-coronary sinus difference in total oxygen 
content by mean coronary blood flow. 
 
Histology and immunofluorescence 
To determine alterations in microvascular density, endothelial cells were detected 
using FITC-conjugated Lycopersicum esculentum lectin (Vector Laboratories) and 
vascular smooth muscle cells using a Cy3-conjugated anti α-SMA mouse monoclonal 
antibody (1A4, Sigma). Nuclei were counterstained with DAPI. All microvessels 
were normalized by the number of cardiac fibers. 
Apoptotic cells were visualized by the TdT-mediated dUTP nick end labeling 
(TUNEL) assay on frozen sections (5 μm thick), using the in situ cell death detection 
kit, TMR red (Roche Diagnostics) according to the manufacturer's instructions. Anti-
α-sarcomeric actinin monoclonal antibody (EA-53) 1:100 (Abcam, Cambridge MA, 
USA) was used to identify cardiomyocytes. The number of apoptotic cardiomyocytes 
was calculated as the percentage of the TUNEL positive per 1000 total cardiomyocyte 
nuclei. Images were analyzed using MetaView 4.6 quantitative analysis software 
(MDS Analytical Technologies, Toronto, Canada). 
 Finally, cardiomyocyte cross-sectional area was quantified from photomicrograph of 
FITC-conjugated Lycopersicum esculentum lectin stained paraffin histological 
sections, using ImageJ software (NIH). We have used these methods previously (2). 
 
PCR, ELISA and Western blotting 
Total DNA was extracted from LV tissue by proteinase-K digestion and 
phenol/chloroforme extraction. Real-time PCR amplification of AAV genomic DNA 
was performed on 100 ng of total DNA using primers and TaqMan probe designed to 
specifically recognize sequences on the CMV promoter present in all the AAV 
vectors used in this study.  
Total RNA was extracted from LV tissue using TRIzol reagent (Invitrogen) according 
to manufacturer instructions, DNAse I digested and reverse transcribed using 
hexameric random primers. The cDNA was then used as template for real-time PCR 
amplification of the murine VEGF-B167 (AAV-carried transgene) and dog VEGF-
BB167, VEGF-A165, VEGFR-1, VEGFR-2 and Neuropilin-1 trancripts. Both TaqMan 
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technology and Syber Green incorporation were used in real time reactions. Gene 
expression was normalized by hypoxanthine phosphoribosyl - transferase (HPRT). 
The sequences of the primers used are: 
 
CMV DNA:              Forward: 5’-TGGGCGGTAGGCGTGTA -3’,  
   Reverse: 5’-GATCTGACGGTTCACTAAACGAG-3’ 
 
Mouse VEGF-B167:  Forward: 5’-TTGCACTGCTGCAGCTGGCTC-3’,  
   Reverse: 5’-GCTGGGCACTAGTTGTTTGA-3’ 
 
Canine VEGF-B167:  Forward: 5’-AGAAGAAAGTGGTGCCATGG-3’,  
               Reverse: 5’-GCTGGGCACTAGTTGTTTGA-3’ 
  
Canine VEGF-A165:  Forward: 5’- AACCCTGGAGCGTTCCCTGT -3’,  
   Reverse: 5’- ACCGCCTGGGCTTGTCACAT-3’ 
 
Canine VEGFR-1:  Forward: 5'- AAATCTGCCTGTGGAAGGAATG -3' 
    Reverse: 5'- GCCTGAGCCATGTTCAAGGT -3' 
                                                Probe:          FAM-AACAGTTCTGCAGTA 
 
Canine VEGFR-2:  Forward: 5'- GGAACCGGAACCTCACCAT -3' 
    Reverse: 5'- GGCAGGTGTAGAGGCCTTCA -3' 
                                                Probe:          FAM- CGTAGGGTGAGGAAG 
 
Canine neuropilin-1:      Forward: 5'- GTCAGAGATTATCCTGGAATTTGAAAG-3' 
                 Reverse: 5'- GGCAGGTGTAGAGGCCTTCA -3' 
                                       Probe:          FAM- CGTAGGGTGAGGAAG 
 
Canine Hprt:            Forward: 5'- TCATTACGCTGAGGATTTGG -3' 
             Reverse: 5'- AGAGGGCTACGATGTGATGG -3' 
                                                
 
Dog serum samples were analyzed by ELISA for the presence of mouse VEGF-B167 
secreted in the circulation from the transduced heart tissue. A specific commercially 
available polyclonal antibody (R&D) against mouse VEGFB167 was diluted at the 
concentration of 100 ng/ml and added to 96-well plates coated overnight at 4°C with 
50 µl of undiluted or 1:50 diluted dog serum. Serial concentration, from 0,01 to 50 
ng/ml, of recombinant mouse VEGFB167 was used as control standard. Plates were 
blocked for 2 h at RT with PBS containing 5% BSA. After overnight incubation and 
extensive washing with PBS containing 0.05% Tween 20 plates were incubated for 
2hr at room temperature with an anti-goat HRP-labeled detection antibody.  
Following addition of 3, 3′,5 ,5′-Tetramethylbenzidine (TMB) substrate (Fisher 
Scientific), absorbance was measured at 450 nm using a fluorescence reader. 
Western blot was utilized to quantify the activated/cleaved caspase-3 and to determine 
the activation state of Akt, and of its two targets GSK-3β and FoxO3a. The 
constitutive form of heat shock protein of 70 kDa (HSC70) was used for loading 
control. Eighty µg of proteins were resolved on SDS-PAGE minigels and transferred 
to nitrocellulose membranes (GE Healthcare), which were incubated with the 
following primary antibodies (dilution 1:1000) overnight at 4°C: rat monoclonal 
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HSC70 (SPA-815' StressGen Assay Designs), rabbit polyclonal anti-Akt, rabbit 
polyclonal anti-pAkt (Thr 308), rabbit polyclonal anti-pGSK-3β (Ser 9), rabbit 
polyclonal anti cleaved-caspase 3, rabbit polyclonal anti-pFoxO3a (Thr32), rabbit 
polyclonal anti-Foxo3a (all from Cell Signaling) and rabbit polyclonal anti-GSK-3β 




Cultured cardiac myocytes 
Neonatal cardiomyocytes were prepared as follows. 1-3 day neonatal rat ventricles 
were disaggregated by mechanical dissection followed by repeated digestions in 
HBSS using 0.06% Collagenase (IV) (Worthington Biochemical, Lakewood NJ) and 
0.1 % trypsin.  Following repeated digestion cells were centrifuged at 300 x g for 10 
min and differentially plated to remove fibroblasts.  Myocytes were plated at a density 
equivalent to 6-8 x 10-6 cells/100-mm plate in DMEM/F12 (10%FBS, P/S, 0.1mM 5’-
bromo-2’deoxyuridine).  On the day following preparation the media was removed 
and fresh media added DMEM/F12, (5% HS, P/S) (3-4). 
Apoptosis was determined by flow cytometry (Millipore/Guava Easycyte Mini) using 
the Guava TUNEL Assay (Millipore) according to the manufacturer’s guidelines. 
Acspase-3 and -9 activities were measured using a Colorimetric Activity Assay kit, 
according to the manufacturer’s instructions (Chemicon International). Optical 
Density values were normalized to the  sample protein concentration (5-6)  
Ang II-induced mitochondrial O2.- production  was assessed by flow cytometry using 
MitoSOX Red (Invitrogen, Carlsbad CA), a mitochondrion-specific hydroethidine-
derivative fluorescent dye, as previously reported (5-7). Cell debris (low forward and 
side scatter), dead cells (Sytox Green and annexin V positive) and apoptotic cells 
(annexin V positive) were gated out for analysis. The data is presented as fold change 
in the median intensity of MitoSOX fluorescence when compared with the respective 
controls. To demonstrate the localization of MitoSox signal to mitochondria, the cells 
were counterstained with MitoTracker green and visualized by confocal microscopy. 
In separate experiments, the effects of VEGF-BB167 pretreatment on cardiomyocyte 
peroxide production was measured fluorometrically using the C-H2DCFDA 
fluorescence assay, as reported (5). Changes in mitochondrial membrane potential 
were detected by flow cytometry using the cationic carbocyanine dye 
5,5',6,6'tetrachloro-1,1',3,3'-tetraethylbenzimidazol-carbocyanine iodide (JC-1, 
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Figure I. Predefined map for AAV intramyocardial injections.  
Three injections were performed along the first diagonal of the left anterior 
descending (LAD) coronary artery and 7 along the second diagonal. The vector was 
never injected distal to the third diagonal. Two sites of injection corresponded to the 
space between the implanted piezoelectric crystals.   
 
 
Figure II. Levels of AAV genomes and AAV-mediated transgene expression in 
myocardium. 
Upper panel: the amount of AAV genome was not significantly different between 
AAV-VEGF-B and AAV-Control LV myocardium at the injection site. n= 5 per 
group. 
Lower panel. The murine VEGF-B167 transgene transcript was clearly expressed in 
the injection site and detectable also in the LV remote site, although the level was 
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MICROSURGICAL ARTEROVENOUS LOOPS AND
BIOLOGICAL TEMPLATES: A NOVEL IN VIVO CHAMBER FOR
TISSUE ENGINEERING
BENEDETTO MANASSERI, M.D.,1 GIUSEPPE CUCCIA, M.D.,1 SILVIA MOIMAS, M.Sc.,2 FRANCESCO STAGNO D’ALCONTRES, M.D.,1
FRANCESCA POLITO, M.D.,3 ALESSANDRA BITTO, M.D.,3 DOMENICA ALTAVILLA, M.D.,3 FRANCESCO SQUADRITO, M.D.,3
STEFANO GEUNA, M.D.,4 LUCIA PATTARINI, M.Sc.,2 LORENA ZENTILIN, Ph.D.,2 CHIARACOLLESI, Ph.D.,2
UDAY PULIGADDA, B.Sc.,2 MAURO GIACCA, M.D., Ph.D.,2 and MICHELE ROSARIO COLONNA, M.D.1*
Background: Microsurgical tissue engineering is an emerging topic in regenerative medicine. Here we describe a new microsurgical model
of bioengineering in rats based on the use of an arterovenous loop (AV) implanted into a commercially available crosslinked collagen/gly-
cosaminoglycan template. Methods: The microvascular loop was created between the femoral artery and vein and covered by the template
folded onto itself. The chamber was isolated from the outside tissue by an outer silicon layer to impede tissue ingrowth. Results: At
1-month postimplantation, the tissue chamber was found heavily vascularized, as assessed by laser Doppler perfusion analysis. Histologi-
cal examination showed that the AV loop was integrated into the collagen matrix of the template and that the whole template was filled
with a newly formed soft connective tissue. Most interestingly, the whole scaffold was found heavily vascularized, including the formation of
a large number of a-SMA-positive arterioles. Conclusions: The developed microsurgical chamber provides a highly vascular, isolated tool
for in vivo tissue engineering. VC 2007 Wiley-Liss, Inc. Microsurgery 27:623–629, 2007.
One of the central requirements in tissue engineering is
the possibility to induce neoangiogenesis or neovasculo-
genesis to provide adequate blood supply to the engi-
neered tissue and to sustain viability and growth of the
cells supporting regeneration.1 This requirement appears
particularly stringent for all in vivo applications of tissue
engineering, including the formation of new specialized
tissues (dermis, bone, cartilage, liver) or in plastic recon-
structive surgery.
Over the last few years, a number of interesting surgi-
cal models for in vivo tissue reconstruction have been
described.1–5 Several studies have shown that both artifi-
cial and natural scaffolds become vascularized upon in
vivo implantation, thus suggesting their potential useful-
ness as biological templates for tissue growth.1,2 Yet, the
search for the ideal scaffold is still open, especially con-
sidering that the vascularization of in vivo implanted
scaffolds strictly depends on the invasion of the scaffold
itself by a newly formed vasculature ensuing from the ad-
jacent tissues. As a consequence, these implanted tissues
are hardly removable from the sites of implantation and
lose their vascular connections upon transplantation.
A more appealing alternative to scaffold implantation
comes from the possibility of applying microsurgery tech-
niques for tissue prefabrication. Previous experience with
experimental prefabrication of flaps by vascular axes or
microsurgical arterovenous (AV) loop implantation has
proven effective in creating new vascular networks in the
implanted tissues.2–4,6,7 Moreover, the generation of
microsurgical AV loops already has applications in the
clinical field.8
Here we revisit the microsurgical AV loop model and
propose the utilization of a commercially available, cross-
linked collagen-glycosaminoglycan (GAG) template
(INTEGRATM) for the generation of highly vascular tissue
engineering chambers. We show that collagen chambers
that embed an AV loop, and are completely isolated from
the surrounding tissue in a month-long period, are filled
with newly formed soft connective tissue and become
heavily vascularized. These chambers represent excellent
in vivo experimental tools for tissue engineering.
MATERIALS AND METHODS
Animals
Ten male Wistar rats (weighing 200–300 g) were
used in the experiments. Animal care and treatment were
conducted in conformity with institutional guidelines in
compliance with national and EU laws and policies (EEC
Council Directive 86/609, OJL 358, December 12, 1987).
All procedures were carried out under general anesthesia
using Zoletil-Virbac (tiletamine plus zolazepam), 50 mg/
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kg in combination with xylazine, 20 mg/kg i.m. The ani-
mals were housed in single cages and fed ad libitum.
Construction of the AV Loop and Generation of
the Collagen Chamber
A microvascular loop was generated between the femo-
ral artery and vein using a vein graft harvested from the
controlateral leg. End-to-side anastomoses were performed
with 11/0 nylon sutures, both on recipient artery and vein.
After perfusion, the AV loop was embedded into a sand-
wich composed of a 2.4 cm 3 1.4 cm portion of a com-
mercially available bilayered dermal substitute template
(inner layer: matrix of bovine collagen-GAG; outer layer:
silicon; INTEGRATM). The template was secured on three
sides by multiple 9/0 silk sutures as a sandwich. including
the loop.
Laser Doppler Perfusion Imaging
A Laser Doppler (Laser Doppler Perfusion Imager,
Perimed, Sweden) was used to assay the blood flow in
the loop at day 0, before and after the application of the
scaffold, and at day 30. The laser Doppler source was
mounted onto a movable rack exactly 20 cm above the
rat limbs; the animals were under anesthesia and re-
strained on the operation table. The laser beam (780 nm),
reflected from moving RBCs in nutritional capillaries,
arterioles, and venules were detected and processed to
provide a computerized, color-coded image. Using image
analysis software (Laser Doppler Perfusion Imager,
Perimed), mean flux values representing perfusion were
calculated.
Histological Analysis
On day 30, the rats were anesthetized, the chambers
were exposed, the vessels ligated proximally and distally,
and the specimen immediately fixed in 10% formalin and
embedded in paraffin. Afterward, the animals were sacri-
ficed by intracardiac administration of pentobarbital so-
dium salt (975 mg/rat). Histological sections were either
stained with hematoxylin and eosin and Masson trichrom
stain, or processed for immunofluorescence. Cy3-coniu-
gated anti-a-SMA primary antibody (clone 1A4, Sigma)
diluted to 1:200 in blocking buffer was used to label
smooth muscle cells. DAPI (Vectashield) fluorescent
staining was used to recognize cell nuclei. Sections were
then analyzed by a Leica MLB upright fluorescence
microscope (Leica Microsystems, Wetzler, Germany)
equipped with a Coolsnap CF CCD camera (Roper Scien-
tific, Evry, France) and MetaView 4.6 software (Molecu-
lar Devices, Downingtown, PA).
RESULTS
An AV loop was created on the femoral vascular
bundle as shown in Figure 1. A vein graft was harvested
from one groin, and used as a microvascular loop
between the femoral artery and vein on the opposite leg
(Fig. 1A, panels a–d). The vein graft was harvested as
long as possible, with a mean length of 9 mm (range,
7–15 mm). Examples of AV loops in other animals are
shown in Figure 1B. After perfusion of the AV loop,
a bilayered collagen-GAG scaffold was folded onto
itself, maintaining the outer silicon layer, and secured
as a sandwich including the loop (Fig. 1A, panels e
and f).
The maintenance of the silicon layer of the template
ensures the complete isolation of the collagen matrix
from the surrounding tissue and blocks possible vessel
ingrowth from the outside. At day 30 after surgery, the
chamber was exposed and femoral vessels, proximally
and distally to the chamber, were assessed for patency.
The loop was found patent in 8 out of 10 animals. In all
animals, the chambers appeared surrounded by a dense
connective capsule (Fig. 2).
Perfusion was assessed by laser Doppler imaging im-
mediately after creation of the AV loop, after closure of
the collagen chamber (day 0) and at the end of the
experiment (day 30). All naked AV loops were evidently
perfused before closure of the collagen chambers (shown
in two representative animals in Fig. 3A). After suture of
the chambers, the perfusion signal was almost completely
quenched by the scaffold (Fig. 1B, upper panels). After
day 30, the chambers showed intense perfusion signals
with a diffuse pattern, suggestive of extensive neovascu-
larization. The bottom part of Figure 3B reports the quan-
titative analysis of perfusion, showing an approximate
threefold increase in blood flow.
Histological analysis of the collagen scaffold at day
30 showed an abundant new tissue, resembling a granula-
tion tissue surrounding the AV loop, filling all the free
spaces of the chamber (Fig. 4 and magnification in inset
a). The collagen trabeculae of the dermal scaffold were
still visible after 1 month from the implant and appeared
infiltrated by several cells (Fig. 4, inset b).
The integration between the template matrix with col-
onizing cells is clearer in Masson’s trichrom stained sec-
tions (Fig. 5), in which the collagen architecture of the
dermal scaffold was still easily recognizable. Masson’s
staining also revealed a remarkable number of new ves-
sels interspersed within the collagen trabeculae of the ar-
tificial tissue. This newly formed vasculature included
both enlarged vessels in the closed proximity of the
grafted vein wall (Figs. 5A and 5B) and smaller vessels
interspersed in the granulation tissue and dermal template
matrix (Figs. 5C and 5D).
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Further characterization performed by immunofluores-
cence using an antibody specific for smooth muscle a-
actin confirmed that several of the observed new vessels
were indeed small arterioles, which probably sprouted
from the vein loop and contributed to the perfusion of
the new tissue (Figs. 6A and 6B). This is in accordance
with the data obtained by laser Doppler analysis. As
expected, because of the increased blood flow, we
observed that the vein wall underwent a process of
remodeling with the presence of an increased layer of
smooth muscle cells (Figs. 6C and 6D).
DISCUSSION
The claim for organ and tissue substitution has
become a major requisite in modern medicine, creating a
demand for alternative sources of tissues. Tissue engi-
neering is contributing extensively to this field, with vas-
cularization of new tissue templates being one of the
most compelling, emerging topics. The vascular supply to
engineered tissues can either follow an extrinsic pathway
Figure 2. Chamber at 1 month after implantation. The picture
shows the specimen ready to be withdrawn and after the with-
drawal (inset) at day 30 post-op. A dense connective tissue enve-
lopes the chamber. [Color figure can be viewed in the online issue,
which is available at www.interscience.wiley.com.]
Figure 1. Microsurgical creation of an isolated collagen-GAG chamber surrounding an arterovenous loop. A: Chamber creation.
(a) Isolation of the femoral arterovenous (AV) bundle; (b) Microsurgical terminolateral (T-L) anastomosis (arrow) between the femoral
artery and the distal end of a vein graft harvested from the controlateral groin; (c) T-L anastomosis of the proximal end of the vein
graft with the femoral vein (arrow); (d) AV loop after surgical clamp release; (e) Embedding of the AV loop into the collagen-GAG
scaffold. The inset shows a small scaffold island ready for implantation; (f) Folding and suture of the collagen-GAG scaffold on itself.
The silicone outer layer of the scaffold does not allow tissue ingrowth into the chamber from the outside. B: Additional examples of
AV loops.
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or ensue from intrinsic vascularization. In the former par-
adigm, new vessels coming from the recipient bed invade
new tissue constructs. Important clinical examples have
already been provided in this respect.2 However, this
approach is usually hampered by the relatively limited
size of the implants.9 By contrast, intrinsic vasculariza-
tion occurs when new vessels develop directly from a
vascular axis of the host; plastic surgeons, by proposing
various models of flap prefabrication and prelamination,
have paved the way to new procedures for the generation
of intrinsic vascularized tissues. Over the last 30 years,
several models have been described, which are mostly
based on the generation of AV loops. In particular, Mor-
rison and coworkers have recently demonstrated that this
approach can be used for in vivo engineering of various
newly formed tissues.3,10–14 In fact, sandwiching an AV
loop between two layers of an artificial dermis induces
the formation of an internal new vascularized soft tissue
that resembles a connective or adipose tissue.3
Here we describe a new model of tissue engineering
based on the use of a commercially available crosslinked
collagen/GAG template as a new type of matrix to en-
velop an AV loop in the rat groin. We chose the AV
loop as the vascular carrier to promote neoangiogenesis
of the scaffold, since we have developed long-standing,
technical expertise in this surgical procedure. In the AV
loop model, the occurrence of sprouting angiogenesis has
been well described to depend on the development of
tensional and stress forces that disturb the integrity of the
endothelium and renders the vessels more susceptible to
the action of angiogenic factors.1,15,16 AV bundles have
also been proposed as an alternative source for sprouting
angiogenesis.7 However, the neoangiogenetic properties
of AV bundles look poorer than those of AV loops, and
the bundle is at higher risk of thrombosis. Moreover, the
same authors who sustained the feasibility of AV bundles
also reported the lack of new tissue formation using this
model.6 On the other hand, the AV loop model is easier
to establish, as it does not require vascular bundle sacri-
fice, and for this reason it has been successfully used
even in difficult clinical conditions.8
In principle, the ideal template for tissue regeneration
should be a biocompatible and biodegradable scaffold,
capable of ensuring optimal interaction with endothelial
cells to promote angiogenesis, since the architecture of
the scaffold and its biochemical characteristics are known
to play a role in modulating the angiogenic activities of
invading cells.17 Among the engineered artificial dermis,
the collagen-GAG template we used has proven to be a
standard tool in reconstructive surgery. Since its intro-
duction in clinical practice as primary coverage for
major burns after necrectomy, its clinical applications
have largely widened to soft tissue deficits after scar
excision, contracture release, excision of tight, painful or
keloid scars, anesthetic scars, and reconstruction after
large excisions (such as in giant naevi, coverage of post-
traumatic defects, flap donor site coverage, resurfacing
of free flaps, and deep loss of tissue after bone and joint
exposure).18
In our model, the collagen-GAG scaffold acts as a
good matrix for new tissue regeneration, allowing the
growth of newly formed soft connective tissue into the
chamber. Indeed, its properties to direct the ingrowth of
soft-connective tissue are well known in the case of der-
mal regeneration, also thanks to the size and number of
its pores.18,19 Further investigations are clearly required
to clarify the structure and ultrastructure of this dermal
Figure 3. Quantification of blood flow by laser Doppler perfusion
imaging. A: Perfusion of the AV loop before closure of the collagen
chamber in two animals. B: Perfusion of the collagen chamber at
day 0 (top) and day 30 (bottom). The asterisks indicate the proxi-
mal and distal regions of the femoral AV bundle outside of the
chambered region. The bottom part of the figure reports the quanti-
fication of the signal intensity in the boxed regions of interest
(ROIs). [Color figure can be viewed in the online issue, which is
available at www.interscience.wiley.com.]
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scaffold and to understand the influence of pore size,
elastic, and biochemical features on neoangiogenesis and
newly formed tissue ingrowth. In this respect, it is worth
mentioning that the collagen-GAG matrix is amenable to
further improvements, including the creation of more ca-
pable chambers, such as boxes or 3D structures, which
Figure 4. Hematoxylin and eosin staining of a representative histological section of paraffin-embedded collagen implant. Inset a: the free
space of the chamber surrounding the AV loop appears infiltrated by an abundant new tissue resembling a granulation tissue. Inset b: the
collagen trabeculae of the collagen chamber are visible and appear infiltrated by a neoformed tissue. Magnification: 310. [Color figure can
be viewed in the online issue, which is available at www.interscience.wiley.com.]
Figure 5. Masson’s trichrom staining of collagen implant. A, B: Histological sections showing closed integration between the collagen ma-
trix and colonizing cells with many large vessels at the periphery and the adventitia of the grafted vein, interspersed inside the granulation
tissue and the collagen matrix. Arrows indicate recognizable newly formed vessels. C, D: High magnification showing the architecture of
the collagen scaffold and new vessels. Magnification: 310. [Color figure can be viewed in the online issue, which is available at www.
interscience.wiley.com.]
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might increase tissue ingrowth and vascularization, as al-
ready suggested.2,6
The results of our study clearly indicate that, in addition
to its dermal substitute template function, the collagen-
GAG scaffold provides a novel template for the engineering
of other tissues and organs, especially by exploiting the
possibility to transfer the template to other tissues by using
its vascular pedicle. Importantly, the observation that mas-
sive soft connective tissue formation and extensive neovas-
cularization occurs in an isolated and transplantable cham-
ber offers the attractive possibility that this chamber might
be used as a bioreactor for the release of growth factors or
drugs. More interestingly, this isolated and vascularized
chamber can also be viewed as a new template for the
expansion and differentiation of cell populations potentially
enriched in precursor or stem cells. In this respect, further
studies including viral gene transfer and bone marrow-
derived cell seeding into this template are in progress.
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